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ABSTRACT 
The increasing comorbid burden of tuberculosis (TB) and diabetes mellitus (OM) worldwide 
requires the management of all stakeholders including pharmacists. This raises the question 
whether current single disease management system fulfils patients' health needs and whether 
pharmacists could effectively playa role in enhancing the joint management of these two 
commonly associated diseases. Pharmacists have begun to provide pharmaceutical care 
through pharmacist-led medication therapy adherence clinics and clinical pharmacy services 
for several diseases and conditions (e.g. OM, asthma) in some public hospitals in Malaysia but 
are yet to be involved in the management of TB. The management of TB has been largely 
delivered through directly observed treatment (OOT) as high level of adherence to treatment 
is vital. However, little is known on how TB patients with OM are being managed and how 
these patients cope with their medication. The aim of this study was to develop a 
pharmaceutical care service for patients with TB and OM. 
The first three phases (preclinical, phase 1 and phase 2) of the UK Medical Research Council 
framework for the development of complex interventions to improve health was applied to 
develop a pharmaceutical care service for patients with both TB and DM in a tertiary hospital 
in Malaysia. First, literature relating to TB and OM was reviewed (preclinical). Second, the 
pharmaceutical care needs of TB and DM patients were explored using semi-structured 
interviews with twenty patients, three phYSicians, three nurses, and a focus-group with four 
pharmacists (phase 1). Third, action research was conducted to assess the feasibility of 
providing a pharmaceutical care service for patients with TB and OM (phase 2). This study 
received ethical approval from the Medical Research and Ethics Committee (MREC), Ministry 
of Health, Malaysia. 
Patients and health care professionals reported several medication-related issues in the phase 
1 study. Patients were most inclined to discuss their concerns about their medication. Patients 
also tended to display different attitudes towards medication-taking, depending on their 
beliefs, the severity of illnesses, perceived efficacy of the treatment, and the severity of 
medication-related problems. The findings also revealed that many of these concerns had not 
been discussed with their physicians. This was also caused by the patients' and physicians' 
tendencies to prioritise the management of TB, and unintentionally neglecting other 
comorbidities especially when patients were primarily managed at the chest clinic. Other 
difficulties identified in comorbid management included delayed initiation of both TB and OM 
treatment, chest physicians' lack of confidence in managing 'difficult' OM in TB patients and 
the burden of attending multiple clinics for patients. Health care professionals believed that 
pharmacist-led medication therapy adherence clinics (MTACs) encouraged the provision of 
patient-centred care, enhanced pharmacist-patient communication, created opportunities for 
inter-professional interactions and could be used as a model to provide pharmaceutical care 
services. Health care professionals urged pharmacists to playa role in the management of TB 
and OM by providing patient education and counselling. 
The phase 2 study revealed that the prevalence of OM in TB patients was 15%. Action research 
allowed the researcher, together with a hospital pharmacist, to identify pharmaceutical care 
needs in TB and OM patients, and fulfilled some of them. Pharmaceutical care issues identified 
included lack of medication adherence, poor management of OM, the need to manage 
adverse drug reactions, and the lack of frequent monitoring of certain monitoring parameters 
for TB, OM and other comorbidities at the chest clinic. Many patients had uncontrolled OM, 
however, many were more likely to be adherent to TB medication than medication of OM 
and/or other conditions. As a follow-up action, pharmacists advised these patients to place 
equal importance to TB and non-TB related management. Additionally, pharmacists also made 
treatment recommendations and referred patients to their chest physicians for further 
management of medication-related problems. Nevertheless, there were barriers that 
impinged the provision of pharmaceutical care service. The barriers include the lack of space 
with privacy to provide education and counselling to patients; the unavailability of medication 
records and other clinical information for comorbidities at the chest clinic; and the lack of time 
to develop inter-professional relationship. Despite the need to address the barriers, the 
provision of pharmaceutical care service to TB and OM patients was feasible as pharmacists 
were able to integrate TB and OM management by identifying, communicating, and resolving 
some medication-related problems. 
ii 
In summary, this study provided the groundwork by conducting phase 1 and phase 2 study 
prior to developing a full-fledged pharmaceutical care service for TB and DM patients. Future 
work can be done to improve the service through critical analysis of the challenges faced in 
the developmental phase with the effectiveness of the service care plan assessed through a 
randomised controlled trial (ReT). 
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GLOSSARY 
Action research It is a form of research that describes, interprets and 
explains social situations while executing a change 
intervention aimed at improvement and involvement. 
Adherence The extent to which the patient's behaviour matches agreed 
recommendations from the prescriber. 
Bomoh Malay traditional healer 
Comorbidities The presence of one or more disorders (or diseases) in 
addition to a primary disease or disorder. 
Complex intervention Complex interventions are usually described as 
interventions that contain several interacting components. 
Euglycaemia Normal level of glucose in the blood. 
Hempedu Tanah/Hempedu Andrographis paniculata. A herb that is used by locals 
Bumi/ Daun Cerita especially for treating DM. 
Medication-related problems Any problem experienced by a patient that may impact on 
their ability to manage or use their medicines effectively. 
Misai Kuching Orthosiphon staminues. A herb that is used by locals for 
treating DM. 
Mohroo Indian salted yoghurt drink with spices. 
Panas Hot. It is a cultural belief that certain food or drink contains 
hot or cold properties. These properties were believed to 
cause certain symptoms (e.g. cough). 
Pharmaceutical care Pharmaceutical care involves the process through which a 
pharmacist cooperates with a patient and other 
professionals in designing, implementing, and monitoring a 
therapeutic plan that will produce specific therapeutic 
outcomes for the patient. 
Sinseh Chinese medicine practitioners 
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CHAPTER 1: INTRODUCTION 
1 
1.1 Introduction to the thesis 
This thesis is about developing a pharmaceutical care service for patients with tuberculosis 
(TB) and diabetes mellitus (OM) in Malaysia. The purpose of this introductory chapter is to 
provide a background to this thesis. It begins with the problem statement followed by an 
explanation of how I became interested in the topic. The chapter concludes with a brief 
overview of the chapters in this thesis. 
1.2 The problem statement 
There has been a growing interest in identifying strategies to reduce the joint burden of TB 
and DM (Harries et aI., 2010; Ottmani et aI., 2010). The significance of these two chronic 
diseases is threefold. 
Firstly, the already high global burden of DM is estimated to rise. The global burden of OM is 
expected to rise from an estimated 180 million prevalent cases currently recorded to a 
predicted 366 million by 2030 (Wild, Roglic, Green, Sicree, & King, 2004). The greatest increase 
is projected for developing countries (Wild, et al., 2004), where TB is highly endemic. 
Secondly, DM has been known to be a risk factor for TB infection (Jeon & Murray, 2008). The 
association and the negative impact of the convergence of TB and DM have been extensively 
reviewed (Dooley & Chaisson, 2009; Ruslami, Aarnoutse, Alisjahbana, van der Ven, & van 
Crevel, 2010). A study conducted in India revealed that the increased prevalence of DM in 
urban areas was associated with a 15% greater smear positive TB incidence in urban than in 
rural areas (Stevenson et aI., 2007). A systematic review of TB and DM showed that DM was 
associated with a three-fold increased risk of TB (Jeon & Murray, 2008). 
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Thirdly, the management of TB is highly challenging when a patient presents with DM as co-
morbidity (Dooley & Chaisson, 2009; Ruslami, Aarnoutse, et aL, 2010). DM has also been 
associated with higher mortality rates in patients with TB and DM compared to TB only 
patients; an increased risk of TB treatment failure or relapse, and diminished 2-month and 6-
month culture conversion rates (Dooley & Chaisson, 2009; Dooley, Tang, Golub, Dorman, & 
Cronin, 2009; Ruslami, Aarnoutse, et aI., 2010). It was also found that TB and OM patients take 
longer to respond to treatment (Nissapatorn et aL, 2005), and are more likely to develop 
multi-drug resistant TB (MOR-TB) (Bashar, Alcabes, Rom, & Condos, 2001). 
Malaysia is one of the top ten countries in Asia which has the highest number of people living 
with type 2 DM (Chan et aI., 2009). In 2006, the prevalence of DM in Malaysia was 11.6% in 
those above 18 years and 14.9% in those above 30 years (Letchuman et aL, 2010). The 
International Diabetes Federation (IOF) has predicted that the number of individuals with DM 
in Malaysia will increase from 1.5 million in 2007 to 2.7 million in 2025 (Chan, et aL, 2009). 
There has been a continuous increase in the number of new TB cases reported in Malaysia 
with 14,908 cases in 1999 (MOH, 2002) to 18,102 cases in 2009 (WHO, 2010a). Due to the 
rising prevalence of OM a parallel increase of TB could be anticipated. 
The treatment of either DM or TB requires a patient to take a large number of medicines 
which has been known to impact medicine adherence (Munro et aL, 2007; Odegard & Gray, 
2008). The directly observed treatment (DOT) for TB that was introduced in 1990s as a means 
of combating non-adherence has been shown to be a good strategy to enforce adherence to 
TB treatment (WHO, 1994b). In Malaysia, patients with conditions such as DM, asthma and 
human immunodeficiency virus (HIV), and patients on methadone and warfarin therapy are 
able to attend a medication therapy adherence clinic (MTAC) run by hospital pharmacists in a 
few public hospitals to assist with medicine adherence (Clinical Pharmacy Practice; Lim & Lim, 
2010; Loganadan et aL, 2010; Loganadan et aL, 2008). To date, pharmacists in Malaysia have 
not been involved in the management ofTB patients, especially in an out-patient setting. 
Although, DOT and MTACs are good strategies in promoting adherence to TB and DM 
treatment respectively, there is a lack of clinical guideline on the co-management of TB and 
3 
OM patients. In addition, little is known about the overall pharmaceutical care needs of 
patients with TB and OM. 
Efforts to develop an intervention that is tailored to patients with TB and OM requires an 
understanding of particular barriers and facilitators in the health care system as well as to 
understand how best to deliver them in the context of patients' complex lives. Whilst there 
have been a number of qualitative investigations on experiences of TB patients (Munro, et aI., 
2007) and OM patients (Campbell et aI., 2003; Mohd Ali, 2009; Vermeire et aI., 2007), most of 
them focused on the consequences of a single disease state and less is known on the 
challenges of dealing with both diseases concurrently. As such, there is a need to investigate 
patients' and health care professionals' experiences in managing TB and OM in order to 
understand the pharmaceutical care issues of these patients prior to the development of a 
pharmaceutical care service. 
4 
1.3 How I became interested in the topic? 
I received undergraduate and postgraduate trainings in pharmacy and clinical pharmacy 
respectively. Prior to beginning my PhD, I worked as a clinical pharmacy lecturer and my 
research interest was in developing pharmaceutical care services. From my own experience, a 
good inter-professional relationship is important not only in developing a new service but also 
in getting support from physicians in order to conduct research within their practice 
environment. My previous experience and exposure had directed me towards this research 
topic in this study. 
When I was doing a masters degree in clinical pharmacy, I was acquainted with a chest 
physician who was involved in teaching clinical aspects of infectious diseases which included 
TB. I remembered this physician in particular because he was open and receptive to 
suggestions and recommendations given by pharmacy students. He had emphasised the 
importance of health care professionals working in collaborative practice. 
I knew pharmaCists were not involved in the management of TB and since I had a pre-
established contact with the chest physician, I thought it would be easier to approach him and 
express my desire of developing a pharmaceutical care service for TB patients. The physician 
concerned was a chest consultant and head of the respiratory department of a tertiary public 
hospital in the northern region of Malaysia. I informed him about my interest and asked his 
permission to conduct a preliminary observational study in his out-patient clinic. 
Upon his approval, I observed how DOT was given at the chest clinic. This helped me to 
familiarise myself with the clinic environment. I reviewed 30 newly diagnosed TB cases 
reported in January 2007. I wanted to find out whether I could identify pharmaceutical care 
issues by reviewing TB patients' medical records. However, I experienced difficulties in 
identifying those issues due to poor documentation of medication history especially for co-
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morbidities in the patients' medical records. More than half of the patients had comorbidities 
(n=16) and DM (n=7) was the most common comorbid condition in TB patients. Nevertheless, 
this preliminary finding intrigued me to investigate the management of comorbidities in TB 
patients. 
At that time, I assumed adherence to TB treatment might not be a problem with DOT in place 
but I wondered how comorbidities of TB patients were managed and whether pharmacists will 
have a role to play. In order to have a homogenous group, I decided to focus on TB patients 
with comorbid DM. 
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1.4 Organisation of the study 
This thesis is divided into seven chapters. The current chapter provided an introduction to the 
thesis. 
Chapter 2 begins with a description about Malaysia, TB and OM in Malaysia and its health care 
system. Subsequently, it discusses the concept of pharmaceutical care and complex 
intervention. Then, it presents the literature review on TB and OM, the role of pharmacists in 
the management of TB and OM and patients' and providers' perspective on medication-
related issues. The chapter ends with the rationale for the study and presents the aim and 
objectives of the study. 
Chapter 3 describes the methodology and methods underpinning the phase 1 study. It 
describes the qualitative methods that were chosen and how validity and reliability can be 
assessed. It illustrates the data collecting process and methods of analysis in detail. 
Chapter 4 presents and discusses the patients' and health care professionals' experiences in 
managing TB and OM; health care professionals' perceptions on pharmacist-led MTAC and the 
potential role of a pharmacist in managing T6 and OM. 
Chapter 5 describes the methodology and methods used in phase 2 study. It provides 
explanation on action research and describes the data collection process and methods of 
analysis in detail. 
Chapter 6 presents and discusses the feasibility of providing a pharmaceutical care service to 
TB and OM patients. It presents the prevalence of OM in TB patients, describes the 
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pharmaceutical care issues of TB and DM patients and discusses the factors hindering the 
provision of service. 
Chapter 7 summarises the overall findings and concludes with the implications for practice, 
policy and research. 
8 
CHAPTER 2: LITERATURE REVIEW 
9 
2.1 Introduction 
This chapter has three important components. Firstly, it provides the background information 
about Malaysia. Secondly, it describes the concept of pharmaceutical care, why 
pharmaceutical care is a complex intervention and how a complex intervention can be carried 
out. Thirdly, it provides a literature review on TB and OM, the role of pharmacists in the 
management ofTB and OM, the patients' and providers' perspectives on managing 
medication-related issues and, a summary of the literature review and the rationale for the 
study. The chapter ends by presenting the aim and objectives of the thesis. 
10 
2.2 Malaysia 
Malaysia is located in Southeast Asia, between 2 and 7 degrees north of the Equator and 
occupies an area of 330,803 square kilometres (Department of statistics Malaysia, 2011). 
Malaysia consists of a federation of 13 states and the Federal Territories of Kuala Lumpur, 
Labuan and Putrajaya. Peninsular Malaysia, is bordered by Thailand in the north and Singapore 
in the south. The South China Sea separates the states of Sabah, Sarawak from Peninsular 
Malaysia. Sabah and Sarawak are bordered by Indonesia. Sarawak also shares a border with 
Brunei. 
In 2010, the Malaysian population was estimated to be around 28.3 million (Department of 
Statistics Malaysia). The population density is approximately 86 persons per square kilometre 
with the annual population growth rate projected to be 2.0% annually. Malaysia has an 
ethnically diverse population consisting of 67% Bumiputeras (Malays and ethnic minorities), 
25% Chinese and 7% Indians. In general, Malaysia is a very young country with 27% of the 
population below the age of 15, 67% between the age of 15 and 64, and 5% of the population 
is 65 years and above (Department of Statistics Malaysia). Over the years, the life expectancy 
at birth of males and females increased to 71 years and 77 years respectively in 2010 
(Department of Statistics Malaysia) from 55 years and 58 years in 1957 (Merican & Yon, 2002). 
Basic immunisation coverage of infants improved to 100% (Merican & Yon, 2002). Bacille 
Calmette Guerin (BCG) vaccination is given to all newborns in Malaysia. 
Islam is the most common religion in Malaysia with the proportion of 61.3 %. Other religions 
embraced are Buddhism (19.8%), Christianity (9.2%) and Hinduism (6.3%) (Department of 
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Statistics Malaysia). The Malay language is the official language in Malaysia. Other spoken 
languages include English, Chinese1 and Tamil. 
1 There are various spoken Chinese dialects which include Mandarin, Hokkien and Cantonese. 
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2.2.1 T8 in Malaysia 
TS is one ofthe ancient infectious diseases which remain a major public health problem till 
today. Despite the availability of effective anti-TS drugs, it has been estimated that TS 
accounts for 1.7 million deaths every year and 9 million new cases worldwide which is more 
than any other time in history (WHO, 2009). Pulmonary TS is the commonest form of TB and 
the symptoms include cough persisting for more than two weeks, cough with sputum which is 
occasionally bloodstained, loss of appetite, loss of weight and fever (Schaaf & Zumla, 2009). 
T8 was the number one cause of death in Malaysia in the 1940s and 1950s (Iyawoo, 2004). 
Prior to the availability of anti-T8 drugs in the late 1950s, patients were isolated in sanatoria 
and were managed by surgical means (Iyawoo, 2004). The Malaysian government launched its 
National T8 control programme (NTP) in 1961 (Iyawoo, 2004). The National TB centre 
functioned as the headquarters of the NTP, and the state general hospitals with their chest 
clinics functioned as the state directorates (Iyawoo, 2004). Every state has its own State TS 
Managerial Team which is responsible for the implementation of the activities of the NTP at 
the state and district levels. In 1995, the national TB directorate has been shifted to the Public 
Health Division of the Ministry of Health (MOH) and is now under the director of disease 
control. The National TS centre is now known as the Institute of Respiratory Medicine (Iyawoo, 
2004). 
The aims of T8 treatment are to reduce morbidity, prevent mortality, prevent relapse, 
decrease transmission and prevent the emergence of MDR-TS (MOH, 2002). The essential first 
line drugs include isoniazid (H), rifampicin (R), pyrazinamide (Z), streptomycin(S) and 
ethambutol (E). A-six-months course of chemotherapy has proven highly effective and reliable. 
These drugs should be able to cure almost all newly diagnosed patients if the treatment 
regimen is prescribed for an adequate period of time and if the patient consumes the 
prescribed medication without fail. The treatment regimens are divided into intensive and 
maintenance phases. During the intensive phase, three or four drugs are given daily for two 
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months. This will lead to rapid sputum conversion and amelioration of clinical symptoms. 
However, during the continuation phase, two or three drugs are usually given intermittently 
for the subsequent four months. The duration of treatment is extended for severe forms of 
extra pulmonary TS and immunocompromised patients. 
Malaysia adopts the Directly observed treatment, short-course (DOTS) strategy, which has 
been recommended by the WHO (MOH, 2002). DOT is one of the key elements of DOTS. As 
such, all anti-TS drugs are administered under supervision whereby patients are directly 
observed by a health personnel or trained person. Each dose of medication taken by the 
patient under supervision is recorded. However, supervision of treatment need not necessarily 
be confined to health care facilities. The other four elements of DOTS include: 
1. The government's commitment to a National TS Control Programme 
2. Case detection through sputum smear microscopy examination of TS suspects in 
general health services 
3. A regular, uninterrupted supply of quality TS medication 
4. A monitoring and reporting system to evaluate treatment outcome for each and every 
patient with proper documentation. 
Although efforts were taken to increase DOTS coverage to 100%, 10-15% of TS cases were 
being managed by private medical practitioners where DOT may not be practiced (lyawoo, 
2004). 
The number of new TS cases rose from 14,908 in 1999 (MOH, 2002) to 18,102 in 2010 (WHO, 
2010a). Despite being a curable disease, 1,600 TS deaths were recorded in 2010 (The Star, 
2011). Although TS is the second highest infectious disease in Malaysia after dengue, it is the 
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main cause of deaths from infectious diseases in 2010 (Tan, 2011). The current notification 
rate of 64 cases for every 100,000 people categorised Malaysia as an 'intermediate TB burden' 
country (Lee, Abd Rahman, Loh, & Vuen, 2010). Among the states in Malaysia, Sabah recorded 
the highest notification rate with 110 cases for every 100,000 people (Lee, et aI., 2010). The 
rise in the notification rate could be linked to many factors such as the increase in population, 
the increase in immigrants, urbanisation, and other risk factors like smoking and the HIV 
epidemic as well as the increase in the number of health facilities that enabled a higher degree 
of detection and diagnosis (Lee, et aI., 2010). 
Under the Millennium Development Goals (MDG) set by the World Health Organisation 
(WHO), the number of TB cases should be reduced by half by 2015 in comparison with 1990. 
The goal for Malaysia would be 31 cases for every 100,000 people by the end of 2015 
compared with 61 cases for every 100,000 people in 1990 (Lee, et aI., 2010). However, the 
current notification rate is higher than what was found in 1990. This trend indicates that 
Malaysia might not achieve the desired target by 2015. Drastic measures need to be 
undertaken in order to reverse the incidence rate. 
The increasing number of HIV patients is another factor for the surge in the number of TB 
cases. Out of 15,192 TB patients who were screened for HIV in 2009, 11% (n=1644) of TB 
patients were HIV positive (WHO, 201Oa). Collaboration between National TB programme and 
HIV programme resulted in the formation of a National Committee for TB-HIV strategic plan 
(MOH, 2010). The government health care facilities provide TB and HIV screening and offer TB-
HIV patients universal access to anti-retroviral treatment for free. 
MDR-TB is a worldwide concern. Globally, the proportion of MDR-TB among new TB cases 
ranges from 0% to 28.3% (WHO, 2010b). In 2009, 7664 TB patients in Malaysia were tested for 
MDR-TB and 55 patients were confirmed to have MDR-TB which is equivalent to 0.7% (WHO, 
2010a). The prevalence of MDR-TB indicates an increasing trend when compared with 0.1% in 
1996 (Iyawoo, 2004). Data on treatment adherence to DOT revealed that in 2008, 3.7 % of 
15 
newly diagnosed TB patients defaulted on TB treatment and 4.7 % were lost to follow-up or 
referred out (MOH, 2010). Poor adherence to treatment may contribute to the increase of 
drug resistance. 
It was found that men make up a larger percentage ofTB patients compared to women with a 
2:1 ratio (Lee, et aI., 2010). It has been reported that many Malaysians are not aware that TB 
has made a comeback and this has resulted in late treatment seeking behaviour (The Star, 
2011). This is a huge concern for public health because people who do not seek treatment 
early are risking others by spreading the disease. Many Malaysians who developed TB visited 
bomohs (traditional Malay healers) and sinsehs (Chinese medicine practitioners) and only 
sought medical treatment when their conditions became worse (The Star, 2011). As such, 
there is a clear need to increase the nation's awareness with regards to TB and its treatment. 
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2.2.2 OM in Malaysia 
OM is a chronic metabolic disorder with hyperglycaemia and other metabolic abnormalities. It 
is due to insulin resistance and/or deficiency as well as increased hepatic glucose output. OM 
can be either type lor type 2. Type 1 OM is an autoimmune disease, whilst type 2 OM is 
associated with older age, obesity, family history of diabetes, previous history of gestational 
diabetes and physical inactivity. Type 2 OM is far more common than type 10M. There is 
currently no known cure for OM but it can be controlled. The aim of OM management is 
directed at reducing the complications of OM. Acute complications of OM include 
hypoglycaemia and hyperglycaemia. The common symptoms include polyuria, polydipsia, 
tiredness and weight loss and other precipitating factors such as infections. Macrovascular and 
microvascular complications are chronic complications. Cardiovascular, cerebrovascular, and 
peripheral vascular diseases are all macrovascular complications. Microvascular complications 
include nephropathy, neuropathy and retinopathy. 
Rapid socio-economic growth, urbanisation, sedentary lifestyle, changes in nutritional habits 
with high intake of carbohydrates and saturated fats, and increased proportion of the 
population who are overweight and obese have all contributed to OM epidemic in Malaysia 
(Ismail et aI., 2002; Letchuman, et aI., 2010; Noor, 2002). The National Health and Morbidity 
Survey (III) showed that the overall national prevalence of OM among Malaysians aged 30 
years and above had increased from 8.3% in 1996 to 14.9% in 2006 (Letchuman, et aI., 2010). 
Forty-eight percent of patients above the age of 30 were not aware that they had OM 
(Letchuman, et aI., 2010). Among those who were previously diagnosed with OM, only 84.3% 
were under treatment (Letchuman, et aI., 2010). Another national study carried out by Rampal 
et al. in 2004 showed that among those receiving treatment for OM, only 25.1% had their 
fasting blood sugar under control (Rampal, 2010). 
There were no Significant difference in the prevalence of OM among males and females in 
Malaysia (Letchuman, et aI., 2010; Rampal, 2010). Among the ethnic group, the Indians had 
17 
the highest prevalence of OM which is at 19.9% for those aged 30 years and above 
(Letchuman, et aL, 2010). Prevalence of OM was also higher among urban population 
compared to the rural population (Letchuman, et aI., 2010). The risk of having OM increases 
with increasing age, positive family history of OM, increasing BMI, and lower levels of 
education (Rampal, 2010). The majority of OM patients with suboptimal glycaemic control had 
inadequate self-management skills and lacked OM-related knowledge (Tan & Magarey, 2008). 
Previous studies in Malaysia indicated a high prevalence of suboptimal glycaemic control and 
that OM complications were common (Chuang, Tsai, Huang, Tai, & The Oiabcare-Asia 1998 
Study Group, 2002; Ismail et aI., 2001; Ismail et aI., 2000; Mafauzy, 2005; Mimi, Teng, & Chia, 
2003). It was found that 4.3% of OM patients had amputations (Letchuman, et aI., 2010). 
Studies that evaluated the prevalence of stroke found that 55% of patients who had stroke 
were OM patients (Hamidon & Raymond, 2003; Wong & Asian Acute Stroke Advisory Panel, 
1999). More than half of the patients (57%) who required dialysis in Malaysia had diabetic 
nephropathy (Lim & Lim, 2006). Late presentation to the hospital and delayed treatment were 
other reasons for complications and poorly controlled OM (Rampal, Loong, Azhar, & Sanjay, 
2010). On the other hand, active screening for OM complications (e.g. screening for 
microalbuminuria and neurology testing) were not routinely practiced by many health care 
providers in Malaysia (Rampal, et aL, 2010). Fifty-five percent of OM patients never had an eye 
examination (Letchuman, et aI., 2010). This indicates a high level of complications among 
patients with OM in Malaysia. 
When it comes to the treatment of OM, 77% of patients were on oral hypoglycaemic agents, 
7% were on insulin alone or in combination with oral hypoglycaemic agents and the rest was 
not on any treatment (letchuman, et aI., 2010). The progressive nature of OM indicates that 
patients will eventually need insulin to reach the targeted blood glucose level. However, the 
lack of insulin usage is a major concern and one of the reasons reported was the fact that 
physicians were prolonging a failing treatment (Letchuman, et aL, 2010). 
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In summary, OM care is far from satisfactory with the majority not achieving targeted blood 
glucose levels and presenting with complications. There is lack of awareness about OM in the 
community, lack of intensification of OM treatment through the use of insulin, lack of 
screening for complications and lack of emphasis on self-management of OM. More efforts 
need to be taken to address these issues. 
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2.3 The health care system in Malaysia 
Health care in Malaysia is provided by the public and private sectors and non-governmental 
organisations (NGOs). Public health services are heavily subsidised by the government. The 
Ministry of Health (MOH) is the major provider of health services and is responsible for the 
health of the population, as stated in the Federal Constitution. Primary care services at health 
clinics are delivered almost free of charge, whereby each patient is charged a nominal fee of 
RM 1 (equivalent to £0.2) for each outpatient visit (Yu, Whynes, & Sach, 2008). From January 
2012, all senior citizens aged 60 years and above are exempted from paying the nominal fee of 
RM1 and they are entitled to receive free outpatient treatment in all government hospitals, 
health clinics and dental clinics (MOH, 2011b). Secondary and tertiary care services provided 
at hospital facilities are also highly subsidised by the government. 
The government provides primary, secondary and tertiary care through various types of health 
facilities. These facilities include hospitals, special medical institutions, national institutes of 
health, dental clinics, health clinics, mobile health and dental clinics and flying doctor stations 
(MOH, 2011a). There are 131 government hospitals (with a total of 33,211 beds) and six 
special medical institutions (with 4,582 beds) (MOH, 20lla). Patients can go to any general 
outpatient services and hospitals for medical emergency and admissions at the public health 
sector. However, access to specialist services is controlled through a national system of 
referral (Yu, et aI., 2008). Specialist services are available at certain hospitals such as national 
referral hospitals in the capital, the state hospitals and selected district hospitals. Referral to 
specialist services will be made if patients cannot be managed at general outpatient facilities. 
Other government agencies like the Ministry of Education, Ministry of Human Resource, 
Ministry of Defence, Ministry of Rural Development and the Ministry of Housing and Local 
Government also complement the role of the MOH (Merican & Yon, 2002; Thomas, Beh, & 
Nordin, 2011). There are eight hospitals (3,690 beds) under the non MOH government 
agencies (MOH, 20lla). The Ministry of Education is responsible for the running of university 
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or teaching hospitals and the training of technical health personnel for the country. The 
Ministry of Human Resources is responsible for the enforcement and regulations in relation to 
the safety and health of industrial workers as well as the estate plantation workers. The 
Ministry of Defence provides health services for its personnel and dependants as well as the 
surrounding local population living within its territory. The Ministry of Housing and Local 
Government is responsible for the licensing and enforcement of some specific health 
legislation in areas under its control. The Ministry of Rural Development was previously 
responsible for the aborigine's health, through its jungle services and a hospital for aborigines 
but recently these services are being provided by the MOH. 
The private health sector is the second major provider of health services which have been on 
the rise, especially in urban areas. Private health providers complement the medical services 
provided by the government (MOH, 20lla). In 2010, there were 217 private hospitals (with a 
total of 13,186 beds), 22 maternity homes, 12 nursing homes, three hospices, 36 ambulatory 
care centres, 6,442 medical clinics and 1,512 dental clinics (MOH, 20lla). 
The increasing demand for high quality health services has contributed to the growth of the 
private health sector. The quality of care at private facilities was perceived to be of high 
quality with reduced waiting time (MOH, 2000). The quick service at a private general 
practitioner's clinic also offers convenient medical services, in particular to the nearby 
population. 
The private sector charges user fees on patients for utilising health services in order to operate 
and maintain their facility. Access to private health services is inevitably limited to the affluent 
population that can afford to pay high user fees as out-of pocket payments or co-payments 
(with coverage of private insurance) (MOH, 2000; Thomas, et aI., 2011). Private health 
insurances provide premiums according to the risk of having illness (Merican & Yon, 2002). 
Patients who have pre-existing diseases may not be selected to the scheme or they may have 
to pay higher premiums (Merican & Yon, 2002). 
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Other providers of health care include the traditional complementary medicine practitioners 
and the NGOs. Traditional complementary medicine in Malaysia includes traditional Malay, 
traditional Chinese and Ayurvedic treatments and is well accepted by both rural and urban 
communities (Merican & Yon, 2002). Currently, guidelines and the passing of the Traditional 
and Complementary Medicine Bill for the various fields in traditional medicine are being 
studied carefully by various organisation in Malaysia (Thomas, et aL, 2011). The NGOs (e.g. 
Malaysian AIDS council) contribute towards the provision of health care on a voluntary basis 
and are not profit oriented. 
Lack of integration between the public and private health sectors is a problem (Merican & Yon, 
2002). At present, patients can go to any health care facilities but their medical records are 
not shared. The private sectors are centred mainly in the urban areas, leading to inequitable 
distribution of health services and resources (Merican & Yon, 2002). In addition, only those 
who could afford to pay higher fees could go to private hospitals. The charges from private 
hospitals on services component range from 15% to 28% of the hospital bills and medication 
whereby 15% of this bill is not declared to patients (Thomas, et aL, 2011). The charges for 
professional fees take up almost 50% of the total bill (Thomas, et aL, 2011). The attractive 
salary in private health sector has triggered the out flow of senior doctors and specialists from 
the public sector to the private sector which led to varied distribution of workforce in public 
and private sectors in Malaysia (Merican & Yon, 2002; Thomas, et aL, 2011). In 2000,46% of 
all doctors in Malaysia were in the private sector and were responsible for 20% of hospital 
beds while the rest of the doctors were in the public sector looking after 80% of the beds 
(Thomas, et al., 2011). When compared with private sector, 71% of hospital admission occurs 
in public sector (MOH, 20lla). The main difference between the private and public hospitals 
with regards to TB care provision is that the treatment of TB is free of charge in public 
hospitals. As for OM, a nominal fee of RM1 is charged for OM treatment for patients under 60 
years of age at any outpatient clinics in the public sector. 
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2.3.1 Pharmacy practice in Malaysia 
Pharmacists in Malaysia practise under two different sets of legal-historical framework (Wong, 
2001). Pharmacists working in government hospitals have complete control over the supply of 
medicines. However, pharmacists at the private sectors especially in community pharmacies 
are yet to have full dispensing rights as medical doctors in the private sectors still dispense 
medicines to their own patients. This doctor-dispensing practice has been allowed since the 
colonial era when Malaysia suffered from an acute shortage of all professionals (Wong, 2001). 
Nevertheless, these practices are more likely to change with the increasing number of 
pharmacists in Malaysia. 
Almost 7000 pharmacists were registered with the Malaysian Pharmacy Board in 2009, giving 
a pharmacist to general population ratio of about 1:6000 (Hasan et aI., 2010). In line with the 
WHO recommendation, the MOH expects to achieve a ratio of 1:2000 (pharmacists to general 
population) by 2020 (Hasan, et aI., 2010). The increase in the number of graduates in 
pharmacy allowed the MOH and Pharmacy Board to implement a new registration process in 
2005, whereby the registration is dependent on a period of mandatory government service 
(Hasan, et aI., 2010). The registration process consists of one year as a provisionally registered 
pharmacist and three years of mandatory service as a fully registered pharmacist in public 
hospitals. However, this led to a surplus of pharmacists in public hospitals and the three years 
of mandatory service has been reduced to one year since October 2011. 
Over the years, the pharmacy practice in Malaysia has shifted its focus from product-oriented 
services to patient-centred services. Pharmacists today work alongside other medical 
professionals in an increasingly cohesive environment and together they play an active role in 
patient care. Pharmacists provide pharmaceutical care services during ward rounds and 
through Medication Therapy Adherence Clinics (MTAC). The aim of MTAC is to optimise 
medication therapy in chronic diseases such as OM, retroviral disease, asthma and chronic 
kidney disease. MTAC services have also been expanded to cover warfarin management, pain 
23 
management, medication management in patients with neurological disorders, psychiatric 
problems and hypertension (MOH, 2009). Pharmacists educate patients on their medications, 
promote adherence to drug therapy and monitor safety and effectiveness of the treatment 
(Rahman, 2010). MTAC was started in 2004 and has grown ever since. In 2009, there were 187 
MTACs in the country (MOH, 2009; Rahman, 2010). MTAC is practised in 150 hospitals and 37 
health clinics and these clinics did follow-up sessions with 23,447 patients in 2009 (Rahman, 
2010). 21.5% from the total 345,903 number of outpatients counselled in hospitals and 
health clinics were done through the MTAC services (MOH, 2009). Despite the growing 
number of these clinics, little is known about the perceptions of pharmacists and other health 
care professionals regarding the service. Feedback from the healthcare professionals as well as 
from patients may help to improve the provision of service. 
Besides MTAC, specialised clinical pharmacy services such as clinical pharmacokinetics 
services, the nutritional support services, and cytotoxic drug reconstitution services have 
provided the opportunity to individualise treatment based on patient needs. These services 
are provided for inpatients. 
The increasing number of pharmacists in Malaysia encouraged the development of new 
pharmacy services in the public health sector. Pharmacists are already being placed in health 
clinics (Rahman, 2010) and pharmacists are also beginning to do home visits to monitor 
adherence to treatment (Merican, 2010). Technology and telecommunications have been 
integrated through innovative and creative ideas by the pharmaceutical services at the MOH 
to further improve drug delivery system. Some of the new services include the Integrated Drug 
Dispensing System, Drive through Pharmacy, 'Short Message Services (SMS) and Take' as well 
as the appointment card system (Merican, 2010). These new services have enabled patients to 
collect repeat medications at their own convenience. The Integrated Drug Dispensing System 
allows patients to collect their medications at any government hospital or clinic of their choice 
and this system enable patients to save time and travel expenses. The drive through pharmacy 
system was introduced in two hospitals in Malaysia whereby patients can drive directly to the 
dedicated counter and collect their medicines without having to wait. Other innovative 
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approaches taken include the Home Delivery service which enables patients to receive their 
repeat medication through post at a minimal charge. In addition, these services will help to 
reduce the waiting time at public hospitals. However, these services are limited and yet to be 
fully established in all hospitals in Malaysia. 
Many pharmacists also practice in the private sector which include the community pharmacies 
(chain pharmacies and independent pharmacies), pharmaceutical industry as well as in 
academic institutions. Community pharmacists in Malaysia are yet to have the full control over 
the supply of medicines as general practitioners are legally allowed to dispense medicines in 
their clinics. This doctor-dispensing practice has been allowed since the colonial era due to a 
shortage of health care professionals. Pharmacists have been seeking full dispensing rights and 
this issue has not been resolved till now. However, the growing number of pharmacists may 
lead to positive changes in the future. Besides dispensing medication, community pharmacists 
provide other services such as patient education and counselling, blood glucose monitoring, 
and finger prick testing of blood glucose and cholesterol. 
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2.4 Pharmaceutical care: a philosophy for pharmacy practice 
Hepler and Strand (1990) formulated the most widely used definition of pharmaceutical care: 
'Pharmaceutical care is the responsible provision of drug therapy for the purpose of achieving 
definite outcomes that improve a patient's quality of life'. The outcomes are cure of a disease; 
elimination or reduction of a patient's symptoms; arresting or slowing a disease process; or 
preventing a disease or symptoms (Hepler & Strand, 1990). Barber (2001) argued that the 
outcome measures refer to the patient's clinical condition whereby the goals are stated in 
terms of the disease. It was felt that this original definition of pharmaceutical care was not 
adequately conceived which led to the development of many other definitions (Barber, 2001). 
In 1998, Strand, Cipolle and Morley approached the topic from a humanistic perspective and 
proposed the following definition: 'Pharmaceutical care is a practice in which the practitioner 
takes responsibility for a patient's drug-related needs and is held accountable for this 
commitment' (Cipolle, Strand, & Morley, 1998). In other words, pharmacists should practice in 
a patient-centred manner whereby pharmacists' decisions should be made based upon the 
wants and needs of the patients, who may have specific drug-related needs. 
The European understanding of pharmaceutical care is basically the professional care for the 
individual patient in a pharmacy (van Mil, Schulz, & Tromp, 2004). It is the way pharmacists 
coach individual patients about their medication. The concept also includes the responsibilities 
of pharmacists, medication surveillance, counselling and the evaluation of all the outcomes of 
care. 
Despite the various definitions, pharmaceutical care is generally regarded as a philosophy for 
pharmacy practice in many countries across the globe (van Mil, et aI., 2004). Not only the 
definitions of pharmaceutical care differ, the terminologies used to describe pharmacy 
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services that embrace the concept of pharmaceutical care vary. For example, in the United 
States, the term medication therapy management services refers to a strategy to incorporate 
the philosophy of pharmaceutical care into everyday pharmacy practice for a defined patient 
population or patients with certain diagnoses (McGivney et aL, 2007; Pellegrino, Martin, 
Tilton, & Touchette, 2009). In Malaysia, pharmacists provide pharmaceutical care services 
through MTACs for various disease in some public hospitals (Gnanasan, Wong, Mohd Ali, Ting, 
& Anderson, 2010; Lim & Lim, 2010; Loganadan, et aL, 2010; Loganadan, et aL, 2008). Besides 
MTAC, pharmaceutical care is also an embedded concept in many other clinical pharmacy 
services that are being provided in hospitals and community pharmacies in Malaysia. 
27 
2.4.1 Development of a pharmaceutical care service 
The expansion of pharmaceutical care services in various disease management settings calls 
for more pharmaceutical care research to be conducted. Pharmaceutical care research falls 
under the umbrella of health services research. Research in this area is context specific as it 
depends on the local health care system. 
It has been reported that it is vital to first conduct a need assessment study as the first phase 
in developing a pharmaceutical care service (van Mil, 2004). Needs assessment is a basic 
research which tries to identify the types of care required in a given patient in terms of 
pharmaceuticals which will eventually lead to the development of a proposal for a 
pharmaceutical care intervention. Impact assessment is the second phase of the research 
which tries to investigate whether the provision of pharmaceutical care improves the patients' 
clinical, humanistic and economic outcome (van Mil, 2004). However, most pharmaceutical 
care studies focus mainly on the second phase of the research in determining whether the 
pharmaceutical care intervention leads to the expected outcomes with a lack of consideration 
or explanation given to the mechanisms by which those outcomes are mediated. For example, 
the impact of a pharmaceutical care intervention in improving patients' health lies on the 
assumption that the intervention worked as planned; that the pharmacists were comfortable 
with their new roles; that patients welcomed the service and that the necessary collaboration 
with other health care professionals had taken place. In reality, there could be many barriers 
that hinder the provision of service. As such, there is a need to understand the components 
that are most likely to affect the provision of pharmaceutical care prior to finalising the design 
of the pharmaceutical care service or in evaluating the outcome of the service. 
This shows that pharmaceutical care is actually a 'complex intervention' as there are various 
factors contributing to the success of the delivery and it is difficult to measure specific 
outcomes (MRC, 2000; Tulip & Campbell, 2001). A systematic review showed that it is difficult 
to replicate and evaluate pharmaceutical care research as there are various interconnecting 
28 
factors or components that need to be considered (Kennie, Schuster, & Einarson, 1998). For 
example, some components of pharmaceutical care may involve the need to improve 
therapeutic outcomes while other components may work through psycho-social or 
behavioural modifications in an individual patient through patient education and counselling 
(Wong, 2004). In addition, some components have an organisational nature whereby inter-
professional communication between pharmacists, physicians and other health care 
professionals is important in the delivery of pharmaceutical care (Wong, 2004). All these 
factors reveal the multifaceted nature of a pharmaceutical care intervention. 
The UK Medical Research Council (MRC) has defined 'complex interventions in health care' as 
"interventions comprising separate elements which seem essential to the proper functioning 
of the intervention although the active ingredient is difficult to specify" (MRC, 2000). In fact, 
not only the number of elements in the intervention package are complex, there are other 
dimensions of complexity which include the range of possible outcomes, the behavioural 
differences of those delivering and receiving the intervention and the variability in the target 
population (Craig et aI., 2008). For example, the active ingredients of pharmaceutical care 
could consists of many elements such as the pharmacist's personality and expertise, whose 
skills, patient characteristics and behaviours, inter-professional relationships and 
organisational culture (Tulip & Campbell, 2001). These factors highlight the complex nature of 
a pharmaceutical care service and research in pharmaceutical care should consider these 
elements (Tulip & Campbell, 2001). 
The MRC has designed a framework for the development and evaluation of RCTs for complex 
intervention to improve health care services which is applicable to pharmacy practice (MRC, 
2000; Watson, 2006). The framework provides a flexible guide for devising complex 
interventions (see Figure 2-1). In 2006, the MRC reported that the process of development and 
evaluation of complex intervention may not follow a linear sequence as suggested in 2000 
(Craig, et aI., 2008) which resulted in alteration of the model to a cyclical design. However, the 
content was more or less the same and it is still applicable. 
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Other models such as the Reach, Effectiveness, Adoption, Implementation and Maintenance 
(RE-AIM) framework has also been suggested to be applied for designing, implementing and 
evaluating practice-based interventions and complex interventions (Planas, 2008). The RE-
AlM framework suggests that all interventions need to be designed and evaluated in terms of 
their Reach to the intended target population, Effectiveness or efficacy, Adoption by target 
settings or institutions, Implementation with consistent delivery and Maintenance of 
intervention effects in individuals and settings over time. The Multiphase Optimisation 
Strategy (MOST) framework (Collins, Murphy, Nair, & Strecher, 2005), National Institute for 
Health and Clinical Excellence (NICE) public health guidance on behavioural change (National 
Institute for Health and Clinical Excellence (NICE), 2007) and research steps for public health 
interventions (de Zoysa, Habicht, Pelto, & Martines, 1998) are examples of other frameworks 
that are tailored for behavioural and public health interventions. 
Although both MRC and the RE-AIM framework appear to be more relevant for developing 
complex interventions, the MRC framework has been widely used in health care services 
research (Bradley, Wiles, Kinmonth, Mant, & Gantley, 1999; Byrne et aI., 2006; Murchie, 
Hannaford, Wyke, Nicolson, & Campbell, 2007) and has been suggested to be applied in 
pharmaceutical care interventions (Tulip & Campbell, 2001; Watson, 2006; Wong, 2004). 
Therefore, for this study the MRC framework was thought to be the most feasible with regards 
to its generic approach than other specific evaluation guidelines. In this study, stepwise 
implementation of the development of a pharmaceutical care service for TB and OM patients 
is guided by the MRC framework (see Figure 2-1) because of its applicability towards 
pharmacy practice research (Montgomery, Kalvemark-Sporrong, Henning, Tully, & Asa Kettis-
Lindblad, 2007; Wong, 2004). 
As RCTs can be expensive and time-consuming, preliminary development work is important to 
identify the components of RCT intervention, the mechanism that will influence the 
intervention and the feasibility of the protocol before embarking on a RCT (Horne. R., 
Weinman, Barber, Elliott, & Morgan, 2005; MRC, 2000). This PhD project, which is explorative 
in nature, therefore serves as a preliminary development work by applying the first three 
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phases of the MRC framework prior to designing and evaluating a full -fledged pharmaceutical 
care service for TB and DM patients that could be evaluated through a RCT in the future. 
Theory 
Explore relevant 
theory to ensure 
best choice of 
intervention and 
hypothesis and 
to predict major 
confounders and 
strategic design 
issues 
Pre-clinical 
Modelling 
Identify the 
components of 
the intervention, 
and the 
underlying 
mechanisms by 
which they will 
influence 
outcomes to 
provide 
evidence that 
you can predict 
how they relate 
to and interact 
with each other 
Phase I 
Exploratory 
Trial 
Describe the 
constant and 
variable 
components of a 
replicable 
intervention AND 
a feasible 
protocol for 
comparing the 
intervention to 
an appropriate 
alternative 
Phase II 
Definitive 
RCT 
Compare a fully 
defined 
intervention to 
an appropriate 
alternative using 
a protocol that is 
theoretically 
defensible, 
reproducible and 
adequately 
controlled in a 
study with 
appropriate 
statistical power 
Phase III 
Continuum of increasin evidence 
Long-term 
implementation 
Determine 
whether others 
can reliably 
replicate your 
intervention and 
results in 
uncontrolled 
settings over the 
long term 
Phase IV 
Figure 2-1 The MRC framework for the development and evaluation of RCTs for complex 
interventions to improve health (MRC, 2000) 
There are five stages in MRC Framework (see Figure 2-1). 
Pre-clinical (Theory) 
The first step of the MRC framework emphasises the importance of identifying existing 
evidence by carrying out a literature review and establishing a theoretical basis for an 
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intervention (Craig, et aI., 2008; MRC, 2000). 'Pharmaceutical care', as explained in section 2.4 
was chosen as the theoretical basis for this study and a literature review on TB and OM was 
conducted (see section 2.5) in order to gather relevant background information. 
Phase I (Modelling) 
The second step of the framework requires an understanding of a particular intervention and 
its possible effects. This phase is called modelling. Modelling allows the identification of 
different components of an intervention, their interactions, and their effect in the outcome. 
For example, in order to deliver a pharmaceutical care service, pharmacists need to 
understand people, their experiences, their social relationship, their culture and belief systems 
(Oupotey & de Oliveria, 2009). Many research techniques such as qualitative testing through 
interviews and focus group, surveys, computer simulations, economic modelling, and 
observational studies can be used for the purpose of modelling. With regards to this study, 
qualitative methodology was employed to explore patients' and providers' experiences in 
managing TB and OM (see chapter 3). 
Phase II (Exploratory trial) 
Exploratory trials are used to evaluate whether the evidence gathered in the previous phases 
is effective in achieving the desired outcome. This includes the implementation of testing 
procedures to assess the feasibility of the intervention, the estimation of the likely recruitment 
and retention rates of the research subjects and the calculation of an appropriate sample size 
(Craig, et aI., 2008). In this study, the feasibility of providing a pharmaceutical care service for 
TB and OM patients was investigated. Furthermore, the prevalence of OM in TB patients was 
determined to estimate the likely recruitment of patients (see chapter 5). 
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Phase III (Definitive RCT) 
This phase relates to the conduct of a definitive RCT of the intervention. Phase III trials should 
have adequate statistical power, adequate randomisation and blinding (where feasible), 
appropriate outcome measures and informed consent of participants. All aspect of phase III 
trial should be tested in the exploratory trial (phase II) prior to their inclusion in the RCT. This 
phase is beyond the scope of this PhO project. However, future work will concentrate on 
evaluating the effectiveness of the pharmaceutical care service through a RCT. 
Phase IV (Long-term implementation) 
The final stage of a complex intervention is the implementation stage by getting the evidence 
into routine practice or policy. Surveillance, monitoring an long-term follow-ups are needed to 
determine whether short term changes that were seen in a RCT persist and whether benefits 
that was previously recommended were sustained (Craig, et aI., 2008; MRC, 2000). 
The following section represents the preclinical phase of the MRC framework as it presents the 
review of literature on TB and OM; the role of pharmacists in the management of TB and OM; 
and patients' and providers' perspectives on the management of TB, OM and comorbid 
conditions with regards to medication-related issues. 
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2.5 The convergence of TB and DM epidemic 
2.5.1 Association of TB and OM 
A link between TB and OM has long been recognised. Richard Morton's Phtisiologia: or a 
treatise on consumption which was published in 1694, stated that an association between TB 
and OM was suggested even in Roman times (Dixon, 2007). An Indian physician Susruta was 
aware about the association in 600CE and Avicenna reported that phthisis frequently 
complicated OM (Guptan & Shah, 2000). Early studies have shown that patients with OM had 
threefold to fourfold increased risk of developing TB (Boucot, Dillon, Cooper, Meier, & 
Richardson, 1952; Root, 1934). In 1934, Root revealed that "in the latter half of the 19th 
century the diabetic patient appeared doomed to die of pulmonary TB if he succeeded in 
escaping coma" (Root, 1934). Bouchardat commented "at autopsy every case of diabetes had 
tubercles in the lungs" (Younger & Hadley, 1971). 
Before the advent of insulin, TB was the most common cause of death in OM patients 
(Himsworth, 1938; Skavlem, Castle, & Moore, 1942). Case series in 1930s showed that insulin 
was used as an aid in the treatment of TB (Day, 1940; Ellman, 1932; Heaton, 1932 ; 
Himsworth, 1938). Insulin was used to help TB patients gain weight and build up their natural 
resistance to fight illness (Heaton, 1932 ). Similarly, insulin was a must in TS patients with OM 
(Sanyai, 1959; Himsworth, 1938; Skavlem, et aI., 1942). An expert clinic was established half a 
century ago for "tuberculous diabetics" in Birmingham, UK and successfully reduced the 
mortality rate (Luntz, 1954). 
However, the availability of treatment for both diseases in the second half of the 20th century 
led to separate management of diseases and the association between TB and OM was not 
much of a concern. Nevertheless in the last decades, the soaring OM epidemic globally has 
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called for a renewed interest in understanding the link between TB and OM (Ruslami, 
Aarnoutse, et aL, 2010). The importance of addressing the risk factors of TB including OM in 
order to reduce the growing burden of TB has been highlighted (Lonnroth, Jaramillo, Williams, 
Dye, & Raviglione, 2009). The high prevalence of OM in developing countries is a major 
concern because these are the countries that harbour TB the most (Harries, et aL, 2010). 
Many studies have shown that 5-30% of TB patients present with OM (Alisjahbana, van Crevel, 
& Sahiratmadja, 2006; Feleke, Abdulkadir, & Aderaye, 1999; Pablos-Mendez, Blustein, & 
Knirsch, 1997; Ponce-De-Leon, Garcia-Garcia, Garcia-Sancho, Gomez-Perez, & Valdespino-
Gomez, 2004; Singla et aL, 2006; Wang, Lee, & Hsueh, 2005). A meta-analysis that was 
conducted in 2008 revealed that OM patients were 3 times more likely to contract TB 
compared to people without OM (Jeon & Murray, 2008). Studies from Ethiopia (Feleke, et aI., 
1999) and Tanzania (Swai, McLarty, & Mugusi, 1990) showed that patients with type 1 OM had 
a threefold to fivefold higher risk of contracting TB than patients with type 2 OM. 
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2.5.1.1 The global burden of T8 and OM 
Socio-economic and lifestyle changes in the developing countries have led to an upsurge of 
type 2 OM. The total number of people with OM worldwide is projected to rise from 285 
million in 2010 to 439 million in 2030 (IOF, 2009). It has been estimated that 70% of patients 
with OM in 2030 will live in TB-endemic countries (Harries, et aL, 2010). Although it has been 
predicted that the incidence of TB in most parts of the world will stabilise or drop in the 
coming decades, the rising prevalence of OM will contribute to the TB epidemic. India, China, 
and Indonesia will be the most affected due to the rising prevalence rates for OM (Ruslami, 
Aarnoutse, et aL, 2010). It was estimated that new TS cases attributable to OM will increase 
from 11.4% to 14.1% in 2030 in the top ten countries with the highest burden of OM (Ruslami, 
Aarnoutse, et aL, 2010). 
OM appears to be a more important risk factor at the population level as compared to HIV, 
although HIV is the strongest risk factor for TS at an individual level. It was estimated that OM 
contributed to 14.8 % of pulmonary TB cases in India, while HIV contributed to 3.4% of 
pulmonary TB cases (Stevenson, et aI., 2007). A study in California showed that the estimated 
risk of TB attributable to OM in Hispanic people was 25% and it was equivalent to that of HIV 
(Pablos-Mendez, et aL, 1997). 
A Tanzanian study showed that among 34 TB and OM patients, 73% of OM was newly 
diagnosed (Mugusi, Swai, Alberti, & McLarty, 1990). Similarly, an Indonesian study showed 
that among 94 TB and OM patients, 61% of OM was newly diagnosed (Alisjahbana et aL, 2007). 
This indicates the importance of screening for OM in TB patients. 
The chance of detecting TB in OM patients will depend on the incidence of TB in a particular 
country (Ruslami, Aarnoutse, et aI., 2010). It is equally important to diagnose OM at early 
stage, as OM is a time-dependent risk factor for TB (Ruslami, Aarnoutse, et aL, 2010). It has 
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been documented that long duration of DM and poor glucose control may increase the risk of 
TB (Banyai, 1959; Swai, et aI., 1990). 
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2.5.1.2 Effect of DM on therapeutic outcomes of T8 
It has been reported that TB patients with DM were usually 10-20 years older than those 
without DM and have a higher body weight before the initiation of treatment, and even more 
after treatment (Ruslami, Aarnoutse, et aI., 2010). A study from West Africa showed that 23% 
ofTB patients with DM were obese as compared to 3% of patients without DM (Salde et aI., 
2006). In Indonesia, 53% of TB patients with DM weighed more than 50kg before the initiation 
of TB treatment as compared to 16.5% in patients without DM (Alisjahbana, et aI., 2007). 
Patients with TS and DM might have lower plasma concentrations of anti-TB drugs, 
contributing to higher rates of treatment failure (Ridzon et aI., 1998; Sahai et aI., 1997; Weiner 
et aI., 2005). A pharmacokinetic study that was conducted in Indonesia showed that exposure 
to rifampicin (AUCO-6h) was 50% lower in heavier TB patients with DM compared to patients 
without OM during the continuation phase of treatment (Nijland et aI., 2006). This finding is a 
concern because low concentrations of anti-TS drugs can cause treatment failure or 
resistance. Therefore, TB and OM patients with higher body weight may need dosage 
modifications of anti-TB drugs. 
DM patients with MDR-TB are at risk for poor outcomes (Bashar, et aI., 2001). Besides, the 
presence of DM may potentiate the adverse effects of anti- TB drugs, especially renal 
dysfunction and peripheral neuropathy (The Francis J. Curry National Tuberculosis Center, 
2009). Pyridoxine should be given with isoniazid during TB treatment in DM patients to 
prevent peripheral neuropathy (American Thoracic Society, Centers for Diseases Control and 
Prevention, & Infectious Diseases SOciety of America, 2003). Serum creatinine and potassium 
levels in patients with MOR·TB should be monitored more frequently, often weekly for the 
first month and then at least monthly thereafter (WHO, 2006a).lt has been recommended 
that OM must be managed closely throughout the treatment of drug-resistant TB and TB care 
providers should be in close communication with the physician who manages the patients' DM 
(WHO, 2oo6a). 
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In terms of therapy, patients with TB and OM were approximately eight times more likely to 
be culture positive after six months of standard therapy compared with TB only patients 
(Alisjahbana, et aI., 2007). A Malaysian study reported that patients with OM were more often 
treated longer than 6 months, but the bacteriological outcome was not reported (Nissapatorn, 
et aI., 2005). The median time for culture conversion after two months of TB treatment was 
longer in OM than TB only patients (Dooley, et aI., 2009; Restrepo et aI., 2008; Singla, et aI., 
2006). 
OM can also cause changes in oral absorption, decreased protein binding of drugs, renal 
insufficiency or fatty liver with impaired drug clearance (Gwilt, Nahhas, & Tracewell, 1991). 
Although, the effect of OM on TB drug concentrations are yet to be thoroughly investigated, it 
has been recommended that therapeutic drug monitoring should be considered if poor 
response to treatment is observed in patients with TB and DM (Peloquin, 2002; Yew, 2001). 
Studies have also indicated that DM increases the risk of death in patients with TB (Dooley, et 
aI., 2009; Wang et aI., 2009). 
In summary, DM affects therapeutic outcome of TB, delays sputum conversion, increases the 
risk for MDR-TB and mortality. 
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2.5.2 The pharmacological issues in the management of T8 and OM 
Like all infections, TB infections could worsen OM control. Although TB can cause glucose 
intolerance and might predispose patients to OM, the drugs used to treat TB might also 
worsen glycaemic control in patients with OM. 
The standard treatment regimen for drug-susceptible TB has not changed in decades. 
Isoniazid, rifampicin, and pyrazinamide, are still the key anti-TB drugs. The most important 
drugs for OM are classified as insulin secretogogue (sulphonylureas and metiglinides), 
biguanide (metformin), thiazolidinediones (TZO) and insulin. Sulphonylureas and TZOs are 
metabolised by cytochrome P450 enzymes in the liver. 
Rifampicin is a very potent inducer of cytochrome P450 enzymes (Burman, Gallicano, & 
Peloquin, 2001; Niemi, Backman, Fromm, Neuvonen, & Kivisto, 2003; Venkatesan, 1992). 
Induction of these enzymes can accelerate the metabolism of a number of drugs given 
together with rifampicin and reduce the therapeutic effect. Treatment with rifampicin can 
cause direct or indirect hyperglycaemia with oral hypoglycaemic drugs (Atkin, Masson, 
Bodmer, Walker, & White, 1992; Niemi, Backman, Fromm, Neuvonen, & Kivisto, 2001). Plasma 
levels of several drugs for OM (tolbutamide, glibenclamide, gliclazide, glimepride, glipizide, 
repaglinide, nateglinide, rosiglitazone, pioglitazone) were significantly lower when CD-
administered with rifampicin (Ruslami, Aarnoutse, et aI., 2010). However, oral hypoglycaemic 
agents are not contraindicated during the treatment of both TB and drug-resistant TB but 
patients may require higher doses. Insulin requirements might increase when rifampicin is 
administered in patients with type 1 OM (Hatorp, Hansen, & Thomsen, 2003). Rifampicin also 
caused early-phase hyperglycaemia with associated hyperinsulinemia even in non-OM patients 
(Takasu et aI., 1982 ; Waterhouse, Wilson, White, & Chowdhury, 2005). Due to rifampicin's 
direct and indirect effects on glycaemic control, careful monitoring with appropriate dose 
adjustment of OM medications is crucial in patients with TB and OM. It has been 
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recommended that blood glucose levels should be monitored after the initiation and 
discontinuation of rifampicin in patients using oral hypoglycaemic agents (Ruslami, Aarnoutse, 
et aL, 2010). It takes about one week to reach full induction of drug-metabolising enzymes 
upon the initiation of rifampicin treatment and it takes about two weeks for the induction to 
dissipate upon the discontinuation of rifampicin (Niemi, et aL, 2003). 
Isoniazid is an inhibitor of some of the enzymes that are induced by rifampicin. However the 
inductive effect of rifampicin overshadows the inhibitory effect of isoniazid on the same 
enzyme, so the overall effect of isoniazid plus rifampicin may decrease the concentrations of 
other drugs (Venkatesan, 1992). The effect of rifampicin and isoniazid on metabolism of insulin 
is unknown. However, insulin might not be affected as it is mostly degraded in the liver by 
hydrolYSis of disulphide connections between the A and B chains through the action of insulin 
degrading enzymes (Duckworth, Bennett, & Hamel, 1998). 
Metformin is not metabolised by rifampicin and might be a good alternative to 
sulphonylureas. Metformin is a first choice drug for type 2 OM (Nathan et aL, 2006) as it has 
several mechanisms to control hyperglycaemia and does not lead to hypoglycaemia 
(Campbell, White, & Saulie, 1996). It is relatively cheap, widely available and associated with 
less weight increase than other oral anti-diabetic drugs. However, the disadvantage of 
metformin when it is given together with anti-TB drugs is that up to 30% of patients may 
experience gastrointestinal side effects (Campbell, et aI., 1996), which may lead to non-
adherence and poor treatment outcome. 
It has also been argued that better glycaemic control in TB and OM patients can only be 
achieved with intensive insulin treatment regimens and patients on oral hypoglycaemic agents 
should be converted to insulin (Rao, 1999). Marked weight loss, adversity of aging, longer 
duration of diabetes, higher insulin and calorie needs in TB patients are all important 
indications for withholding oral hypoglycaemic agents in TB patients. Insulin has anabolic 
action, lowers pill burden, improves appetite and promotes weight gain. Biguanides are 
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contraindicated in hepatic disease, and therefore may not be suitable for tuberculosis patients 
since hepatotoxicity is a common adverse reaction of anti TB drugs. High doses of biguanides 
promote weight loss and might not be suitable in TB patients. 
A study from India, showed that almost 90% of patients achieved fair to good glycaemic 
control with the use of insulin in TB and DM patients (Kotokey, Bhattaharya, Das, Azad, & De, 
2007). Conversely, another study from India reported that TB and DM patients were treated 
with oral hypoglycaemic agents and dosage adjustment was made based on fasting blood 
sugar levels, while insulin injections were only given upon completing TB treatment 
(Balasubramaniam et aI., 2007). The authors stated that although insulin injections should be 
recommended for TB and DM patients, as a policy, these patients were treated only with oral 
hypoglycaemic agents. However, it was unclear why insulin injections were allowed to be 
initiated after completing TB treatment and not during the course of TB treatment. The study 
showed that it was not easy to control DM although TB and DM patients responded to TB 
treatment through DOT. 
In December 2009, a national web-based seminar on TB and DM was conducted in the United 
States (The Francis J. Curry National Tuberculosis Center, 2009). Richard Brostrom, a Public 
Health Medical Director and TB controller in the Commonwealth of the Northern Mariane 
Islands (CNMI) provided his recommendations with regards to DM management in TB patients 
in the seminar. The following is the excerpt from the seminar's transcript: 
I think we would rely on common sense, which is that optimising glucose 
control would seem very likely to promote more rapid resolution of the TB 
infection. And so I would tend to approach this patient like we've approached 
patients with let's say gestational diabetes, where you really want to try to 
achieve euglycaemia for the benefit of the fetus, here we're trying to achieve 
eug/ycaemia for the benefit of killing the microbe. And so I would suggest that 
adding met/ormin, while an absolute wonderful and first line drug for the 
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treatment of early diabetes, would not give you the bang for the buck that you 
need. If he's running blood sugars in the 300 to 400s his HbA1c is going to be 
11, let's say, and that's really going to accelerate the progression of his TB 
disease. So I think almost certainly one would recommend initiating insulin for 
this gentleman. Now there is a school of thought that says, 'Oh, difficult 
patients will never start insulin.' And there certainly is a subset of patients that 
I have for whom I just can't get through to them. However, the overwhelming 
majority of our patients, once they understood, once they experience it, once 
it's been done with the help of a skilled diabetes educator, can succeed with 
insulin therapy. And there are multiple modalities of insulin. There is once a 
day, long-acting. There are insulins that can be used around mealtime. One 
could work with gentleman over time to achieve more optimal glucose control 
(The Francis J. Curry National Tuberculosis Center, 2009) 
Richard Brostrom highlighted the importance of insulin to achieve tight glycaemic control in TB 
patients with OM. So far, the Brazilian Thoracic Association has considered replacing oral 
hypoglycaemic agents with insulin during TB treatment to keep fasting blood glucose below 
160mg/dl (8.89 mmol/I) (Conde et aL, 2009). 
Recent population pharmacokinetic studies have shown the importance of individualised 
dosing of isoniazid, pyrazinamide, and rifampicin (Ronald, Richard, & Gumbo, 2009). Isoniazid 
serum clearance differs depending on the patient's number of N-acetyltransferase 2 gene *4 
(NAT2*4) alleles (Ronald, et aL, 2009). The relationship between gene dose and serum 
clearance (AUC: MIC ratio) provide an example of how dosing can be adjusted for different 
patient genotypes (Ronald, et aI., 2009). Pyrazinamide serum clearance has been shown to 
increase in patients with higher body weight (Ronald, et aL, 2009). In order to maximise 
efficacy and minimise toxicity of pyrazinamide, it is important to individualise dosing based on 
each patient's weight (Ronald, et aI., 2009). Rifampicin's volume of distribution, clearance, and 
absorption has wide between-patient and within-patient variability (Ronald, et aI., 2009). 
Rifampicin's action is concentration-dependent and the recommended dose of rifampicin is 
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10mg/kg body weight (Blumberg et aI., 2003), which might be at the lower end of the dose-
response curve. Higher daily doses are probably more effective and reduce treatment duration 
(Mitchison, 2000). In practice, most guidelines advise 4S0mg/day for patients below 50kg and 
600mg/day for patients above SOkg. Since patients with OM are usually heavier and gain more 
weight during TB treatment, it has been recommended that dose adjustment must be made, 
especially in the later phase oftreatment (Ruslami et aI., 2010). 
Microbial pharmacokinetic-pharmacodynamic (PK-PO) indexes and targets to optimize 
microbial killing and minimize resistance have been identified for rifampin, isoniazid, 
pyrazinamide, and the fluoroquinolones. These PK-PO indexes suggest that different doses and 
dosing schedules than those currently recommended could optimize therapy and perhaps 
shorten the duration of TB treatment (Ronald, et aI., 2009). Since OM has been associated 
with significantly worse patient outcomes, treatment for TB and OM patients need to be 
improved due to the PK-PD variability by providing individualised treatment (Hall II, Leff, & 
Gumbo, 2009). It has been recommended that pharmacists should utilise their skills in 
pharmacogenomics and pharmacokinetics to individualise TB treatment (Ronald, et aI., 2009). 
In short, conversion to insulin and individualised TB treatment are a recognised 
pharmacological need for TB and OM patients. 
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2.5.2.1 The recent expert recommendations and research priorities 
In order to develop a policy document on TB and OM, the International Union Against 
Tuberculosis and Lung Disease (IUATLD), World Diabetes Foundation (WDF) and the WHO Stop 
TB Department started off a series of consultation in January 2009 (Ottmani, et aL, 2010). 
Based on these consultations, the experts recommended that additional literature review 
were needed to address many unanswered questions in the area ofTB and OM (Harries, Billo, 
& Kapur, 2009; Harries, et aI., 2010; Ottmani, et aL, 2010). Previous studies that were 
published between 1965 and 2009 were reported to have limitations as many studies were 
health facility-based case-control studies using medical chart diagnoses of OM which could be 
subjected to confounding and most studies were conducted in developed countries (Harries, 
et aI., 2010). 
As such additional systematic review and meta-analysis was conducted from May to August 
2009 by experts from the Harvard School of Public Health to address key questions such as 
screening for TB and OM, TB chemoprophylaxis and the impact of OM on the management of 
TB (Harries, et aI., 2010; Ottmani, et aI., 2010). Subsequently, an expert meeting was held in 
November 2009 at IUATLD, Paris, France to discuss the findings; to determine whether there 
was sufficient evidence to make policy recommendations about joint management of TB and 
OM; and to address research gaps and develop a research agenda for TB and OM. The meeting 
ended with the following four main recommendations and four main priority areas for 
research (Ottmani, et aL, 2010): 
1. Collaboration between TB and OM care and control initiatives 
The health ministries, technical agenCies, funding agencies and donors should 
recognise the link between TB and OM and encourage closer collaboration between 
the National TB programmes and stakeholders involved in national OM prevention and 
care. 
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2. Screening for active T8 among OM patients 
In high TB burden countries, OM patients should be routinely asked about TB 
symptoms and recent exposure to TB as part of regular clinical check-ups. For 
example, OM patients with persistent cough for more than two weeks should be 
screened for TB. 
3. Screening for OM among T8 patients 
People with newly diagnosed TB should be screened for OM especially in countries 
with medium to high prevalence of OM. 
4. Management of T8 and OM comorbldlty 
Treatment and monitoring of TB and OM patients should be optimised as 
recommended in national guidelines and/or international best practice. Cross-referrals 
of TB and OM cases should be ensured and integrated approaches for diagnosis, 
management and prevention should be explored. T8 health workers should deliver 
OM health education, behaviour modification messages and interventions as part of 
the routine health education. 
Harries et al. (2010) identified four key priority areas for research which include: 1) the need 
to screen OM patients for active TB and vice versa, 2) the impact of OM and non-OM 
hyperglycaemia on T8 treatment outcome and mortalities, 3) the implementation and 
evaluation of the T8 OaTS strategy model for managing and monitoring OM, and 4) the 
development of better point-of-care diagnostic and monitoring tests, including the 
measurements of glycosylated haemoglobin (HbAIC) for OM patients. 
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In December 2009, Richard Brostrom shared his experience in managing TB and DM patients 
in CNMI in a web-based seminar (The Francis J. Curry National Tuberculosis Center, 2009). He 
provided four steps to integrate TB and DM care which he named as the 'Saipan standards' 
(The Francis J. Curry National Tuberculosis Center, 2009). The four steps include: 1. Diagnose 
DM in TB patients; 2. Adjust TB treatment in DM patients; 3. Help manage DM during TB 
treatment and; 4. Prevent TB in DM patients. These standards aim to assist TB care providers 
to prevent, identify, evaluate and manage patients with TB and DM (Brostrom, 2010). 
Huge projects are being conducted in China and India to create the awareness of the link 
between TB and DM (World Diabetes Foundation, 2010, 2011). The projects aim to: 1) train TB 
health care workers in diagnosing and managing DM through capacity building workshops and, 
2) screen TB patients for DM. These projects started in 2009 and will be completed in 2012. 
Protocols and guidelines on treatment for patients with TB and DM will be developed based 
on the findings of these projects (World Diabetes Foundation, 2010, 2011). 
Recently, IUATLD and WHO have developed a collaborative framework which aims to guide 
national programmes, clinicians and others engaged in care of patients and prevention and 
control of TB and DM on how to establish a coordinated response to both diseases, at 
organisational and clinical levels (WHO, 2011). 
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2.5.3 Role of pharmacists 
2.5.3.1 Pharmacists' role in T8 management 
In 1993, WHO declared TB as a 'global emergency' (WHO, 1994a) and promoted the DOTS 
strategy to manage TB (WHO, 1994b). Kanyok (1997) urged pharmacists to promote 
adherence by getting involved in DOTS programme. Prior to the introduction of DOTS, three 
studies reported pharmacists' role in the management of TB (Coleman, 1983; Dayton, 1978; 
Taylor, 1992). 
Coleman (1983) described the role of clinical pharmacist as a primary care provider in a TB 
clinic. The role of the clinical pharmacist include obtaining the medical and drug history; 
explaining the pathophysiology and epidemiology of tuberculosis to the patients; monitoring 
side effects and managing problems during follow-up visits with physical assessment 
techniques and laboratory tests (Coleman, 1983). Dayton (1978) explained the role of a 
pharmacist in improving adherence to anti-TB treatment in a rural TB out-patient clinic. The 
pharmacist was responsible for maintenance of patient records, patient consultation, onsite 
drug preparation and dispensing, and teaching responsibilities (Dayton, 1978). There was 
increased pharmacist-physician interaction as the pharmacist had the opportunity to 
contribute drug-related information (Dayton, 1978). 
However, except for Kanyok (1997), there was a lack of studies on the contribution of 
pharmacists in TB management after the introduction of DOTS. Nurses began to playa major 
role as DOT providers and pharmacists' expertise were somehow underused. Even the recent 
study by Clark et al. (2007) was conducted in TB patients who were not on DOT. less is known 
about pharmacists' role in a DOTS setting especially in the clinics or hospitals. 
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Mismanagement of MDR-TB by using too few drugs or less effective second-line drugs and 
failure in educating patients on the importance of adherence have been cited to be the 
reasons for the emergence of extensively-drug resistance TB (XDR-TB) (Mitrzyk, 2008). The 
WHO and the United States Centers for Disease Control and Prevention (CDC) have identified 
XDR-TB as a serious public health threat and are calling for increased efforts in managing TB 
(Gandhi et aI., 2010; Mitrzyk, 2008). It has been suggested that pharmacists should playa key 
role in the prevention and treatment ofTB by promoting adherence, assessing patients for risk 
factors for resistant disease, providing information about disease control and prevention, and 
monitoring for effectiveness, adverse effects, and drug interactions (Mitrzyk, 2008; Mkele, 
2010). Clark et al. (2007) demonstrated that patients' adherence to TB treatment improved 
when a pharmacist provided patient education on medication used and addresses patients' 
pharmaceutical care issues. The study also identified the pharmaceutical care needs and issues 
of first-time TB and MDR-TB patients. 
After decades of managing TB via DOTS, the WHO launched the 'Stop TB strategy' in 200G in 
response to a number of challenges (e.g. MDR-TB, TB-HIV epidemic, weak health systems, and 
lack of engagement of private providers) that have not been fully resolved through DOTS (Stop 
TB Partnership, 2006; WHO, 200Gb). This strategy called for the engagement of all 
stakeholders including pharmacists within public and private sectors (Stop TB Partnership, 
2006; WHO, 200Gb). Private pharmacies are often the first point of contact when people with 
early unspecific symptoms of TB like cough and fever seek help from the health services. As 
such, community pharmacists can play an important role in the early detection and refer 
patients for TB screening. 
The Indian Pharmaceutical Association has integrated private pharmacies with DOTS 
programme. Community pharmacists who participated in the TB Fact Card project in Mumbai, 
India played important roles such as providing TB information, referring patients for diagnOSiS, 
providing DOTS medicines boxes, administering anti-TB treatment, and in following up on 
patiens who defaulted treatment by phone calls ("DOTS TB Pharmacist Project-Public-private 
Initiative in Mumbai; FIP, 20lla; Gharat, Bell, Ambe, & Bell, 2007). 
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Recently, the WHO and FIP have signed a joint statement which was launched at the World 
Pharmacy Congress in Hyderabad in September 2011 on the role of pharmacists in the 
management ofTB (FIP, 2011b). This WHO/FIP Joint Statement emphasised the need for 
engaging pharmacists in TB care and control. It calls on TB programmes and pharmacy 
associations to engage pharmacists and utilise their expertise to: 1) increase awareness of TB, 
and refer people with TB symptoms to facilities with quality diagnosis and treatment; 2) 
provide patient-centered treatment supervision to promote adherence and help prevent 
multidrug-resistant TB; 3) promote the rational use of anti-TB medicines through procuring 
and dispensing quality-assured medicines and fixed-dose combinations recommended by 
WHO; and by prohibiting the sale of anti-TB medicines over the counter, or without 
prescription; and 4) support health-care providers to rationalise and strengthen their TB 
management practices (FIP, 2011b). 
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2.5.3.2 Pharmacists' role in OM management 
There is a growing body of literature supporting the roles of pharmacist in DM care. Studies 
conducted in various settings around the globe have shown that pharmacists' interventions 
improved HbA1C values and other clinical outcomes in DM patients (AI Mazroui et aI., 2009; 
Anaya et aI., 2008; Armor, Britton, Dennis, & Letassy, 2010; Choe et aI., 2005; Clifford, Davis, 
Batty, & Davis, 2005; Davis, Clifford, Davis, & Batty, 2005; Fornos, Floro Andre's, Carlos 
Andre's, Mercedes Guerra, & Egea, 2006; Kiel & McCord, 2005; Lim & Lim, 2010; Loganadan, 
et aI., 2010; Loganadan, et aI., 2008; Machado, 2007; Nowak, Singh, Clarke, Campbell, & Jaber, 
2002; Scott, Boyd, Stephan, Augustine, & Reardon, 2006; Turnacilar, Sancar, Apikoglu-Rabus, 
Hursitoglu, & Izzettin, 2009; Wubben & Vivian, 2008). Some studies have also reported 
improvements in both clinical and economic outcome (Cranor, Bunting, & Christensen, 2003; 
Cranor & Christensen, 2003). 
A systematic review on the effects of pharmacists' interventions showed that pharmacists 
managed to build strong relationship with DM patients and were regarded to be a reliable 
source of information (Wubben & Vivian, 2008). The review showed that pharmacists ensured 
continuity of care by having on-going relationships with other health care professionals and 
served as a 'bridge' between these health care professionals and the patients. In addition, 
pharmacists provided recommendations to patients and their health care professionals to 
optimise therapeutic outcomes. Another review of pharmacist contribution to DM care in the 
United States indicated that pharmacists working as educators, consultants or clinicians in 
partnership with other health care professionals or working in a collaborative-practice model 
were able to contribute to improved patient outcomes (Armor, et aI., 2010). Pharmacists 
played important roles by following-up patients between physician visits, utilising their clinical 
expertise to monitor and manage DM medication plans, and educating patients on disease, 
lifestyle and adherence (Smith, 2009). 
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A study conducted in a hospital outpatient clinic in United Arab Emirates indicated that a 
comprehensive pharmaceutical care programme (consisting of patient education and advice 
on medication adherence, metabolic control and life style) delivered by a clinical pharmacist 
over a 12-month period significantly improved glycaemic control and health-related quality of 
life (AI Mazroui, et aI., 2009). A 12-month randomised controlled trial of pharmaceutical care 
in community-based DM patients revealed that regular face to face and telephone interviews 
with an experienced clinical pharmacist improved HbA1c and reduced blood pressure (Davis, 
et aI., 2005). Davis et aL (2005) suggested that pharmaceutical care strategies can be easy to 
implement and time-efficient when telephones and emails are used to facilitate 
communications (Davis, et aI., 2005). 
Pharmacist-coordinated DM management programme has been shown to be effective in 
improving clinical markers and adherence (Kiel & McCord, 2005). Similarly, Malaysian studies 
have also shown that pharmacist-led MTAC for DM patients were successful in improving 
adherence and glycaemic control (lim & lim, 2010; Loganadan, et aI., 2010; Loganadan, et aI., 
2008). Another study reported that provision of pharmaceutical care service through 
pharmacist-led clinics significantly reduced the risk of cerebrovascular accidents and coronary 
heart disease in DM patients (Lowey et aI., 2007). 
In summary, it has been suggested that pharmacists can be involved in the direct care of 
patients with DM by screening, encouraging self-management and education, monitoring for 
preventive care and comorbid conditions, providing expertise on medication management and 
forming collaborative relationships with other health care providers (Brooks & Prevost, 2007). 
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2.5.4 Patients' and providers' perspectives on medication-related issues 
One of the important components in the provision of pharmaceutical care is to understand 
patients' needs and experiences (van Mil, 2004). Most pharmaceutical care studies do not 
report medication-related issues from the patients' perspectives. Patients' perspectives of 
their diseases may differ from those of health professionals. Qualitative studies provide rich 
descriptions and insights that are valuable in understanding these factors (The PloS Medicine 
Editors, 2007). For example, Gordon and colleagues explored medication-related problems in 
patients with cardiovascular disease (Gordon, Smith, & Dhillon, 2007). They found that 
patients were: 1) concerned about adverse effects of medication and its management, 2) 
having different views with regards to the use of medicines, 3) concerned about declining 
ability to use their medicines due to cognitive, physical and sensory problems, 4) lacking 
information or understanding about the use of medicines, and 5) having problems attributed 
to access to, and organisation of services. 
Stack (2009) suggested that it is important to identify patients' perspectives on specific co-
morbid conditions. However, qualitative studies that explored patients' and providers' 
experiences and perspectives on managing both T6 and DM treatment are lacking. As such, 
individual qualitative studies on T6 and DM treatment as well as studies on people's 
experiences in managing multiple medicines due to comorbidities are presented in the 
following sections. 
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2.5.4.1 Patients' and providers' experiences in managing TB treatment 
A systematic review of qualitative studies on patients' adherence to TB treatment identified 
eight factors that was considered to be important by patients, caregivers and health care 
providers (Munro, et aI., 2007). These factors include: 1) organisation of treatment and care; 
2) interpretations of illness and wellness; 3) the financial burden of treatment; 4) knowledge, 
attitudes, and beliefs about treatment; 5) law and immigration; 6) personal characteristics and 
adherence behaviour; 7) side effects; and 8) family, community and household support. 
Patients' adherence to treatment was believed to be influenced by the interplay of these 
factors. 
Medication issues were one of the themes identified in a qualitative study that explored 
factors affecting quality of life of TB patients (Marra, Marra, Cox, Palepu, & Fitzgerald, 2004). 
Patients reported that adverse effects of medication (e.g. gastrointestinal disturbances and 
itchiness), large size of tablets and the high number of medicines were bothersome (Marra, et 
aI., 2004). Similarly, other qualitative studies have also reported that patients who 
experienced or anticipated adverse effects of medications tended to default TB treatment 
(Munro, et aI., 2007; Noyes & Papay, 2007) and that patients expressed difficulties in 
consuming multiple medication (Hansel, Wu, Chang, & Diette, 2004; Marra, et aI., 2004; 
Munro, et aI., 2007). In fact, patients have expressed their desire to reduce the amount of 
medicines or decrease the duration of therapy (Hansel, et aI., 2004). 
Studies have shown that patients stop taking their treatment if they do not believe in the 
efficacy of the treatment (Munro, et aI., 2007; Noyes & Papay, 2007). One study found that 
adherence appeared to be better during the initial acute phase of the illness, when the 
patients were more symptomatic and they defaulted TB treatment as soon as their symptoms 
improved (Naidoo, Dick, & Cooper, 2009). Patients could also be non-adherent if they were 
taking other traditional medicines and perceived there to be negative consequences if these 
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were taken concurrently with TB medication (Munro, et aL, 2007). Naidoo et aL (2009) 
showed that patients also stopped TB treatment after visiting traditional healers. 
Many health care providers stated that patients found DOT intrusive and an imposition on 
lifestyle (Hansel, et aL, 2004). Furthermore, responsibilities in the home may be given priority 
over treatment adherence (Munro, et aL, 2007). Patients appeared to have less choice or 
flexibility concerning their treatment as they had to give up part of their working day to attend 
and had to wait to receive and be observed taking their drugs (Munro, et aL, 2007; Noyes & 
Po pay, 2007). Noyes & Popay (2007) highlighted that there is a need for locally tailored, 
patient centred programmes rather than a single world-wide intervention like DOT. Self-
supervision was found to be the preferred option by most people (Noyes & Po pay, 2007). 
The quality of health care the participants received is another factor that influenced 
adherence (Naidoo, et aL, 2009). Noyes & Po pay (2007) highlighted the crucial need for more 
effective exchange of expertise and knowledge between patient and the DOT provider. They 
cited that the 'experiential knowledge' from TB patients should inform the medical practice. 
For example, patient reported issues like "the hunger induced by getting better, different 'lay' 
understandings about the nature of 'cure', the debilitating effects of TB and TB medication, 
and the 'meaning' of the side effects of medicines" should be taken into account (Noyes & 
Popay, 2007). 
Family support, including financial assistance, collecting medication, and emotional support, 
were found to be very important to ensure patient adherence to treatment (Munro, et aL, 
2007). TB patients who experienced family instability or social isolation were less likely to 
comply with medical treatment (Naidoo, et aL, 2009). 
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In summary, adverse effects of medications, multiple medicines, treatment beliefs and 
concerns, inconveniences caused by DOT, poor patient-provider communication and lack of 
family support were found to be the factors affecting TB treatment. 
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2.5.4.2 Patients' and providers' experiences in managing OM treatment 
AI-Qazaz and colleagues from Malaysia explored OM patients' knowledge about the disease 
and its medication. It was reported that patients lacked knowledge on adverse effects of OM 
medication and had not received sufficient information from their physicians. Forgetting to 
take medication and modification of treatment regimen were also reported (AI-Qazaz, Hassali, 
Shafie, Syed Sulaiman, & Sundram, 2011). Another qualitative study from Malaysia also 
showed that many patients lacked awareness about OM and its treatment (Mohd Ali, 2009). 
Many patients were unaware that they had OM until complications sets in (Mohd Ali, 2009). 
Concurring with AI-Qazaz et al. (2011), patients reported that they were not given adequate 
information and wanted to know more about their disease (Mohd Ali, 2009). Pharmacists who 
participated in the study reported that some patients had erroneous beliefs such as OM can be 
cured and that they could eat anything if they took their insulin (Mohd Ali, 2009). It was also 
reported that patients' education level was another factor that contributed to their 
understanding about the disease and its management (Mohd Ali, 2009). Multiple medication 
taking was felt to be problematic for patients with comorbidities especially when multiple 
dosing was involved (Mohd Ali, 2009). 
A qualitative meta-analysis on obstacles to adherence in type 2 OM patients revealed that the 
factors affecting adherence were less related to the health care system and more to patients' 
knowledge about OM, beliefs and attitudes, and their relationship with health care 
professionals (Vermeire, et aI., 2007). It has been reported that patient-provider 
communication was one of the factors that affected adherence to OM treatment regimens 
(Matthews, Peden, & Rowles, 2009). Matthews et al. (2009) reported that providers did not 
acknowledge the importance of their patients' autonomy and did not encourage active 
participation in disease management. Many patients denied that their OM symptoms were 
serious and admitted that they would consider their condition to be serious and would be 
more likely to adhere to treatment if the symptoms worsened (Matthews, et aI., 2009). 
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Lawton and colleagues explored perceptions and experiences of taking oral hypoglycaemic 
agents among people of Pakistani and Indian origin (Lawton, Peel, Parry, & Douglas, 2008). 
The study found ambivalent views about oral hypoglycaemic agents. Despite believing the 
importance of oral hypoglycaemic agents, some patients reduced their tablet intake without 
consulting their physicians. The patients felt that the drugs worked by providing relief of 
symptoms and that it was detrimental to take the medication for a long period as well as in 
combination with other medication (Lawton, et aI., 2008). 
A synthesis of qualitative research in lay experiences of DM and DM care showed that patients 
employ 'strategic non-compliance' by monitoring and observing symptoms and manipulate 
dietary and medication regimens in order to live a normal life rather than limiting social and 
work activities in order to adhere to medical advice (Campbell, et aI., 2003). In other words, 
DM patients self-manage by making modification to their medication regimen and lifestyle 
according to the severity of illness. 
In summary, qualitative studies have shown that many OM patients: lacked knowledge about 
their disease and its treatment; believed that their disease was not serious in the absence of 
complications; modified treatment regimens; had difficulties in complying with dietary 
recommendation; were burdened with multiple medicines; and had not raised some of their 
medication-related concerns with their physicians. 
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2.5.4.3 Patients' and providers' experiences of managing comorbidities 
and its treatment 
As there were no studies conducted in patients with TB and DM, this section provides a 
general review on patients' and providers' experiences in managing comorbidities. 
Studies have shown that patients with comorbidities had a higher risk of dying, a poorer 
functional status or quality of life (Fortin, Bravo, Hudon, Lapointe, Almirall, et aL, 2006), 
psychological distress (Fortin, Bravo, Hudon, Lapointe, Dubois, et aI., 2006), longer hospital 
stay and a higher cost of care (Fortin, Soubhi, Hudon, Bayliss, & Akker M, 2007; Gijsen et aL, 
2001). 
It has been widely reported that patients with comorbidities prioritise their health conditions 
and its treatment (Bayliss, Steiner, Fernald, Crane, & Main, 2003; Beverly, Wray, Chiu, & 
Weinger, 2011; Elliott, Ross-Degnan, Adans, Safran, & Soumerai, 2007; Jowsey et aL, 2009; 
Stack, 2009). Some health issues could be neglected or compromised when patients prioritise 
health conditions by selectively attending to the management of those conditions based on 
perceived severity or importance (Bayliss, et aL, 2003; Beverly, et aL, 2011; Jowsey, et aL, 
2009). Some patients found management of all their conditions to be challenging and in some 
cases financial barriers led to prioritisation of treatment (Beverly, et aL, 2011). On the other 
hand, Elliot et aL (2007) reported that people prioritised their medicines based on their 
experiences of side effects, cost, beliefs on treatment necessity and concerns about medicines 
(Elliott, et aL, 2007). 
Stack (2009) explored the way patients with comorbid OM perceived and managed multiple 
medicines and their multiple conditions. Some of the findings revealed that patients wanted to 
avoid additional medicines; compared between medications and alternative methods of 
treatment; believed medicine taking and lifestyle management were different issues; were 
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concerned about adverse effects; and expressed a range of emotional responses to multiple 
medicine taking. Other studies have also shown that patients were reluctant to take 
medication and preferred to reduce the number of medications (Elliott, et aI., 2007; 
Townsend, Hunt, & Wyke, 2003). Studies have shown prevalent cultural belief that medication 
should be minimised (Britten, 1994; Townsend, et aL, 2003). 
Another study showed that comorbidities reduced patients' ability to act on risk factors; 
complicated the process of detecting the early symptoms of deterioration of each condition, 
and complicated their capacity to manage multiple medication (Jowsey, et aI., 2009). The 
study reported that patients found managing medication for their numerous conditions to be 
complicated, time-consuming, inconvenient and confuSing. Another study found that some 
patients felt that they had insufficient knowledge about drug interactions and side-effects 
(Jowsey, et aL, 2009). Bayliss and colleagues reported that some people expressed difficulties 
in managing comorbidities, especially when each disease had a different management and 
some believed that medicines for one condition would worsen the symptoms of other 
conditions (Bayliss, et aI., 2003). 
Given the challenges of managing comorbidities, it has been suggested that future practices 
should move away from single disease orientation and move toward strategies that meet the 
needs of people with comorbid conditions and strengthen their capacity to self-manage 
(Fortin, et aL, 2007; Jowsey, et aL, 2009). Specialised education and services that cater to the 
needs of people with clusters of comorbidities need to be developed (Gijsen, et aL, 2001; 
Jowsey, et aL, 2009). Jowsey et aL (2009) called for more research to address specific 
combinations of diseases that are known to be comorbid and highly prevalent. In addition, 
there is a need for optimal coordination among health care professionals (Gijsen, et aL, 2001). 
Increased understanding of comorbidites among health care professionals and increased 
communication between specialities are vital to improve coordination of care (Fortin, et aL, 
2007). 
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Piette & Kerr (2006) highlighted that there is a need to know more about how physicians 
prioritise DM management goals relative to the management of comorbidities, how health 
systems affect these choices, and the ways in which patients' multiple providers either share 
goals or coordinate care. Less is known about how DM patients rate the importance of their 
diabetes-specific self-management behaviours, treatments, and outcomes when compared 
with other comorbid conditions (Piette & Kerr, 2006). As comorbid conditions and their 
treatments often interact, it is vital that treatment be coordinated by a single provider or a 
team of providers with an understanding of the patient's many challenges (Piette & Kerr, 
2006). It has been suggested that care managers and clinical pharmacists can assist in 
coordinating activities within a patient's complex medical care regimen (Piette & Kerr, 2006). 
In summary, studies on patients and providers perspectives in managing comorbidities 
revealed that patients prioritised treatment; wanted to reduce the number of medicines and 
had many challenges in managing multiple diseases and its treatment. Coordination of care is 
vital in order to manage people with comorbidities. 
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2.6 Summary of the literature review 
• Malaysia 
o The increasing prevalence of OM and the continuous surge in the number of 
TB cases reported in Malaysia is a huge concern. 
• Pharmaceutical care research 
o Pharmaceutical care is a complex intervention and the MRC framework 
provides a guideline for developing complex interventions. 
• Association of TB and OM 
o OM triples the risk of developing TB, increases mortality and severity of TB, 
and slows the response to effective TB treatment. 
• The pharmacological issues in the management of TB and OM 
o TB and its treatment can worsen OM control. Rifampin interacts negatively 
with commonly used oral hypoglycaemic drugs like sulfonlyureas and 
thiazolidinediones. Blood levels of these drugs are lower when rifampin is 
being used and can affect OM control. It is important to monitor blood glucose 
and adjust OM medication while on rifampin. OM patients also have a higher 
incidence of peripheral neuropathy while taking isoniazid. 
o TB and OM patients consume multiple medicines which may have an impact 
on adherence. 
• Role of pharmacists 
o Pharmacists have been urged to participate in the management of TB. 
o Pharmacists have played important roles in the management of OM and 
improved clinical outcomes. 
o Pharmacists in Malaysia are providing pharmaceutical care service through 
MTAC and other clinical pharmacy services. 
• Patients' and providers' perspectives on medication-related issues 
o There is a need to understand the problems faced by people with specific 
combination of comorbid conditions like TB and OM. 
o Qualitative studies have provided various insights on patients' experiences in 
managing TB, OM and comorbid conditions but less is known about the 
experiences of people with TB and OM. 
o There is a need to integrate the management of comorbid condition. 
• More research is currently needed in the area of TB and OM. 
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2.7 Rationale for study 
The gaps in the literature with regards to the scarcity of research in TB and OM, the call for 
integrated management for comorbid conditions, and the lack of involvement of pharmacists 
in the management of TB resulted in the idea of developing a pharmaceutical care service for 
patients with TB and OM. It is envisaged that this study could contribute to the body of 
knowledge in relation to 1) patients' and providers' experiences and perceptions in managing 
TB and OM, 2) identification of medication-related problems in patients with TB and OM and 
3) the role of pharmacist in the management of TB and OM. 
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2.8 Research aim and objectives 
This study aimed to develop a pharmaceutical care service for patients with TB and DM. The 
specific objectives of the study were divided into two phases. 
Phase 1: 
i. To identify the pharmaceutical care needs of patients with TB and OM in Malaysia. 
ii. To explore health care professionals' views on the existing pharmacist-led 
medication therapy adherence clinic and the potential role of pharmacists in the 
joint management of TB and OM. 
Phase 2: 
i. To investigate the feasibility of providing a pharmaceutical care service for 
patients with TB and OM. 
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CHAPTER 3: METHODOLOGY AND METHODS (PHASE 1) 
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3.1 Introduction 
This chapter describes how the phase 1 study was carried out. It presents the research 
methodology, describes the data collection methods, explains how the data was analysed and 
discusses how the validity and reliability of the phase 1 findings detailed in this thesis can be 
assessed. 
3.2 Objectives 
The objectives of the phase 1 study were: 
i. To identify the pharmaceutical care needs of patients with TB and OM in Malaysia. 
ii. To explore health care professionals' views on the existing pharmacist-led medication 
therapy adherence clinic and the potential role of pharmacists in the joint 
management of TB and OM. 
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3.3 The methodology of Phase 1 study 
This section explains how the methodology for this study was derived from the research 
questions. In order to explore the pharmaceutical care needs of TS and OM patients, it is 
important to understand the experience of both patients and health care professionals in 
managing TS and OM and whether pharmacists have a role to play. Therefore, three research 
questions were identified as the starting point of this phase 1 study. 
• What are the experiences of patients and healthcare professionals in 
managing TS and OM? 
• How do health care professionals perceive the existing pharmacist-led MTAC 
service? 
• How can pharmacists playa role in the management of TB and OM? 
As there was no prior information about medicine taking experiences of patients with both TB 
and OM and lack of reported evidence on health care professionals' perceptions on 
pharmacist-led MTAC service in Malaysia, there was the need to explore these issues. Hence, a 
qualitative research approach was chosen. 
The next section describes the nature of qualitative research. 
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3.4 Qualitative research 
Qualitative methods are gaining recognition in health care research and by policy-makers too 
as they provide detailed and contextual explanation to a complex phenomenon. Qualitative 
research investigates how and why things happen rather than quantifying them (Murphy, 
Dingwall, Greatbatch, Parker, & Watson, 1998; Pope & Mays, 2006). It allows in-depth 
exploration of issues pertaining to individuals' experiences (Bowling, 1997) and how and why 
similar events are conceived in a different way by other stakeholders (Murphy, et aI., 1998; 
Sofaer, 1999). This strategy is helpful in the exploratory stages of a research project as it forms 
the base for subsequent explanatory research. 
Qualitative research allows the adoption of a flexible framework for data collection. Therefore, 
rather than being fixed at the start, the study design can be modified as the research 
progresses in response to the researcher's understanding of the issues (Lincoln & Guba, 1985). 
This is a key attribute of qualitative research because the researcher does not usually have a 
complete understanding of the issues under investigation. Furthermore, the aim is to learn 
from every step and as the understanding increases, the study design can be modified 
(Dahlgren, Emmelin, & Winkvist, 2004). 
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3.5 Data collection and sampling methods 
In qualitative research, interview is one of the most important data collection tools (Morse & 
Field, 1995). It is a very effective way of accessing people's perceptions, meanings, and 
constructions of reality (Morse & Field, 1995). It is a complex social process and there are 
many different types of interviews. Interviews can be structured, semi-structured and 
unstructured (Minichiello, Aroni, & Timewell, 1995). 
Interviews can be conducted on a one-to-one or group basis. The latter include techniques 
such as group interviews, community interviews and focus groups. Focus group discussions 
allow a small group of people to discuss a subject of common interest with the guidance of a 
moderator or facilitator. The facilitator plays an important role to control the scope of the 
discussion and to make sure that everybody gets the chance to voice their opinions on the 
subject matter (Krueger & Casey, 2000). Focus group are not the same as group interviews as 
it utilises group dynamics to access peoples' concerns, group norms and knowledge (Kitzinger, 
1994, 1995; Krueger & Casey, 2000). Group members influence each other by responding to 
ideas and comments of others. Focus group discussions produces large amount of data within 
a short period (Krueger & Casey, 2000). 
Interviews can be administered face-to-face, over the telephone an on-line. However, face-to-
face interviews are good for establishing rapport and also for capturing the body language of 
the participants. 
The actual data generated by interviews are words. Interviews are generally audio-recorded 
and then transcribed verbatim to produce transcripts for analysis but they can also be video 
recorded to capture non-verbal communication. 
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3.5.1 Selection of interview type for this study 
This study employs semi-structured interviews. Face-to-face interviews were conducted with 
patients and health care professionals from the respective TB and DM setting. This interview 
method was chosen because some of the aspects to be addressed were already identified 
from the literature and also to ensure that key issues pertaining to the research question were 
covered with all participants. 
On the other hand, focus group discussions were used to gather information from pharmacists 
in order to utilise group dynamics. The other reason is, pharmacists in this context are not 
involved in the care of TB and therefore, they were not subjected to the same questions raised 
in the semi-structured interviews. Different sets of questions were posed to pharmacists in the 
focus group discussions, to facilitate the expression of ideas and encourage pharmacists' to 
voice their perspectives within a homogenous group (Pope & Mays, 2006). To avoid hierarchy 
within the health care professionals affecting the data, focus group discussions were not 
carried out with all the health providers (Pope & Mays, 2006). For example, nurses might not 
share their opinion freely in the presence of a physician hence, one-to-one interviews with 
physicians and nurses were conducted. 
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3.6 Qualitative Sampling 
Qualitative research does not require large or statistically representative samples as the norm 
for quantitative research. Qualitative samples are generally small and the 'richness' of the data 
relevant to address a specific problem is more important than the number of participants 
recruited into a study. Nevertheless, effective sampling strategy is equally important in 
qualitative research. 
In this study, purposive, convenience and snowball sampling strategies were used. Purposive 
sampling was used to select adult patients with TB and DM from all the three main ethnic 
groups (Malay, Chinese, Indian) in Malaysia. Convenience sampling was used to recruit the 
physicians and nurses. Snowball sampling was used to recruit pharmacists for the focus group 
discussion. The researcher contacted the chief pharmacist of the hospital and requested him 
to introduce pharmacists especially those who led the MTACs to participate in this study. 
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3.7 Interview Guide 
Two interview guides and one focus group guide (see Appendix 5 and 6) were developed to 
lead the interview and discussion process. Topics that were covered in the interview guide for 
patients include the experiences of living with TB and OM, adherence to medications and 
medication-related problems. The topics for physicians and nurses included experiences in 
managing patients with TB and OM, potential role of pharmacists, DOT and health system 
barriers. The topics for the focus group were experiences in managing MTAC and the potential 
role of pharmacist in managing TB and OM. The interview guide was developed following a 
literature search. 
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3.8 Process and Procedures 
3.8.1 Ethical Approval 
Prior to the commencement of the interviews, ethical approval was sought. The phase 1 study 
was registered with the Malaysian National Medical Research Register. All the required 
documents were submitted to the ethical committee of the Ministry of Health, Malaysia. 
Ethical approval was obtained (reference number: NMRR-08-10-1165) two months after 
submission (see appendix 2). 
3.8.2 Recruitment setting 
The study was mainly conducted at a tertiary public hospital in the northern region of 
Malaysia. Patients were recruited for semi-structured interviews from the Hospital's Chest 
clinic as well as from three other district hospitals from the state. Initially, it was not intended 
to recruit patients from the district hospitals but coincidently, the first few interviews 
conducted in the Hospital's Chest clinic were all with Chinese patients. The nurses suggested 
the researcher follow the health care professionals (TB health care team) to district hospitals 
in order to have higher chances of interviewing Malay and Indian patients. Hence, the 
researcher joined the health care professionals' weekly visits to the district hospitals. It also 
provided an opportunity to observe how DOT was done in those settings. 
Physicians, nurses and pharmacists who participated in the study were recruited from one 
tertiary public hospital. Physicians and nurses were first recruited from the chest clinic. 
Pharmacists were recruited from the pharmacy department. Upon completing interviews with 
the physician and nurses from the chest clinic and a focus group discussion with the 
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pharmacists, it was felt that more information was needed to clarify some issues and 
therefore, a physician and a nurse from the endocrine clinic were recruited. 
3.8.3 Participant identification and recruitment 
Patients with TB and OM could be identified from patient medical charts and registers as well 
as from their attending doctors and nurses. The nurses said that they were in a better position 
to identify potential patients with TB and OM due to their daily interaction with TB patients 
who attend the clinic for DOT. They informed the researcher that although patients could be 
identified from the registers, not all patients were having their DOT at the hospital's chest 
clinic as they can have DOT at any government health clinics close to their homes. Such 
patients only visit the hospital's chest clinic during their follow-up. As such, the researcher 
relied on the nurses in identifying the patients for this study. As for the patients at the district 
hospitals, the researcher contacted and informed the nurses prior to the visit in order to 
enable them to identify and refer potential patients. 
The patient inclusion criteria for this study are listed below and those who matched the 
criteria were invited to participate in the interview. 
Inclusion criteria: 
• Adult patients ( 18 years and above) with clinically diagnosed TB and OM 
(For safety reasons, only those who had been on TB treatment for more than 2 
months were recruited) 
• English, Malay or Tamil language speaking patients 
• Patients prescribed with both TB and OM medications 
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Exclusion criteria: 
• TB only patients 
• TB and OM patients who were terminally ill or unable to provide written informed 
consent 
The patient information sheet (see Appendix 3) was provided to patients identified as suitable 
participants for the study. Patient recruitment and interviews continued until new themes 
ceased to emerge. This was achieved after interviewing 20 patients. 
On the other hand, it was not possible to expect saturation of themes to be reached with the 
limited number of health care professionals within the context of this study. Therefore, health 
care professionals who were believed to be able to produce 'rich' information were 
approached and recruited for in-depth interviews. The details of how they were recruited 
were already explained in section 3.8.2. 
3.8.4 Interview setting 
Patients were interviewed at the chest clinics. It was held in a quiet location (e.g. empty 
nurse's room, counselling room) that was suitable for an interview within the clinic setting. 
Health care professionals were interviewed in their respective rooms or offices in the hospital. 
One focus group discussion was conducted with a group of pharmacists in the pharmacy 
department. 
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3.8.5 Interview process 
Patients were given options to be interviewed alone or in the presence of their family 
members. The purpose of the study and process of the interview were explained to all 
patients. Patient's permission to audio record the interview was obtained. They were also 
reminded that they were able to withdraw their participation with no resulting consequences 
at any point of the process and that they only need to answer questions that they feel 
comfortable to answer. This process was aimed to provide a non-threatening environment 
which encouraged patients to tell their own story. Demographic data including gender, age, 
ethnicity, and occupation were also collected from each patient. 
The researcher is a trilingual and is able to speak in English, Malay and Tamil languages. All 
Chinese and Malay patients chose to communicate in Malay which is the national language. 
Indian patients were comfortable to be interviewed either in Tamil or English. Among health 
care professionals, the nurses from the Chest clinic spoke in Malay while the rest preferred 
English. The focus group discussion was conducted in English. 
3.9 Data collection and data management 
Data collection began in April 2008 and continued till July 2008. All the interviews were 
conducted by the researcher. However, the focus group discussion was facilitated by the 
researchers main supervisor who was in Malaysia at that time. The researcher made the 
arrangement for the focus group discussion and played the role of a note taker. Refreshments 
were provided after the focus group session. 
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3.9.1 Interview and focus group data 
All interviews and focus group discussion were audio recorded using a digital interview 
recorder. The recorded materials were downloaded to a personal computer. The recordings 
were played via Windows media player and it facilitated the transcribing process. 
3.9.2 Field notes 
The researchers field notes were documented in individual patients' data collecting form. 
Field notes were documented after each interview session. These notes were useful during the 
data analysis as it helped the researcher to recollect the events that took place during the 
interview. The field notes were reviewed with the interview transcripts to help recall and 
clarify a particular event. 
3.9.3 Transcription 
Audio-recordings were transcribed verbatim. In order to ensure the study was rigorous and 
trustworthy, the audio-recorded and written verbatim versions of the interviews were 
assessed for accuracy and completeness of data by three Malaysian pharmacists who were 
pursuing a doctoral degree in pharmacy and were familiar with the local languages. For 
example, interviews that were conducted in Tamil were verified by a Tamil speaking 
pharmacist and interviews that were conducted in Malay were verified by the other 
pharmacists. 
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3.9.4 Translation 
In order to ensure consistency (Twinn, 1997), all non- English transcripts were translated to 
English by the researcher. As there was only a single translator in this study, the translation 
was consistent and reliable (Twinn, 1997), but it took a huge amount of time to do it. It takes 
nearly two hours to translate one transcribed page (Squires, 2008). However, translation was 
needed because one ofthe researcher's supervisor is British and does not speak Malay and 
Tamil and the other two supervisors do not speak Tamil. Factors which affect the quality of the 
translation include the linguistic competence of the translator and the translator's knowledge 
of the people under study (Birbili, 2000). As mentioned earlier, the researcher is trilingual and 
is familiar with the local people. 
However, it must be acknowledged that there is the potential for modification of the data 
through mistranslation, partial omission or oversimplification which is unavoidable during 
translations (Escott & Walley, 2005; Wong & Poon, 2010). Such modification could be 
intentional or unintentional, but the reliability of translation to reflect the participants' 
intended response will influence the validity of the data (Escott & Walley, 2005). Although, all 
the transcripts were translated to English for verification purpose, the data was analysed in 
the original language. Furthermore, it was easier to cross check certain data with the audio 
recordings, especially when there was a need to consider the voice modulations of the 
participants in certain circumstances. This helped to reduce the misinterpretations. In this 
study, the translation was meant to capture the meaning of the statements, rather than giving 
a literal translation (Esposito, 2001). For example, one Indian participant mentioned that 'he 
had no appetite' and if those words were to be literally translated as he said it in Tamil, it 
would be 'my tongue died'. 
During the data analysis, the selected themes and sub-themes were translated to English 
again. The retranslated themes were checked against the earlier version of the translated 
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transcripts. Although only the selected themes were translated, repeating the translation 
process helped the researcher to check whether there were any discrepancies between the 
first and second translations, thus avoiding misinterpretations. 
Comparing the first and the second version of the translation showed that better translation in 
terms of preserving the actual meaning was produced in the second version. Thus, it is better 
to translate selected themes rather than translating the whole transcript. In fact, it has been 
recommended that verbatim transcription and data analysis can be done in the original 
language and only the emergent concepts and categories (themes and sub-themes) needed 
translations to English (Chen & Boore, 2009). 
Some researchers may raise the issue of back translating translated interviews as a way to 
validate the translation (Chen & Boore, 2009; Maneesriwongul & Dixon, 2004). Chen & Boore 
suggest that another translator should take the English version and back translates the 
concept and categories from English to the original language. Subsequently, they suggest the 
involvement of an expert panel committee in reaching final agreement on the translation in 
order to gain conceptual equivalence and the words used by native speakers (Chen & Boore, 
2009). However, it has been argued that back translations can incur additional time and costs 
to the study (Squires, 2008). It was also argued that back translation does not necessarily 
ensure the trustworthiness of the results and therefore, a qualified bilingual individual 
competent in the qualitative researcher's diSCipline can easily validate the conceptual 
equivalence of the translation (Squires, 2008). Therefore, back translation was not done in 
this study. To ensure accurate translation from Malays to English, assistance was procured 
from the researcher's supervisor. The researcher revisited and retranslated some of the 
excerpts until agreement was reached between the researcher and the researcher's 
supervisor. Similarly, a Tamil speaking PhD student (pharmacist) assisted the process of 
verifying the translations from Tamil to English. Consensus validation was the finalisation pOint 
with the supervisor and the PhD student for all the translations. 
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3.10 Data analysis 
Thematic analysis was used to analyse these interview data, informed by a constant 
comparison approach (Boyatzis, 1998; Braun & Clarke, 2006). It involves identifying, analysing, 
and reporting patterns or themes within data (Boyatzis, 1998; Braun & Clarke, 2006). The 
transcripts were read repeatedly while listening to the audio recording and emerging topics 
were coded and constantly compared and contrasted with other transcripts (Braun & Clarke, 
2006). 
The data was analysed with the aid of the qualitative computer software NVivo (version 8). 
This software allows handling of large amounts of data and enables useful comparisons to be 
carried out (Bazeley, 2007). It facilitates constant comparison between interpretations and 
illustrative statements from the original transcript (Bazeley, 2007). The documents containing 
the transcripts and field notes were imported from Microsoft Word into NVivo for analysis. 
The documents can then be opened in NVivo and coded for analysis (Bazeley, 2007). 
Data analysis began with the themes that have guided the research design. These themes are 
called 'nodes' in NVivo (Bazeley, 2007). These themes can be anticipated or emergent. NVivo 
stores tree type of nodes: free nodes, tree nodes and case nodes (Bazeley, 2007). The free 
nodes are stand alone nodes and usually the analysis begins by identifying the free nodes 
(Bazeley, 2007). Free nodes can later be moved to tree nodes and vice versa. Tree nodes are 
organised into hierarchy and can be used to show the relation between nodes. Case nodes are 
used to organise coding according to cases. Tree nodes and free nodes were used in this study. 
Coding is a process of which a researcher identifies and labels text that relates to a node 
(Bazeley, 2007; Miles & Huberman, 1994). The transcripts were read line by line and key nodes 
were identified (Miles & Huberman, 1994). The identified nodes were used to develop a 
coding framework for coding the data. The coding process involved reading, linking and 
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connecting texts to the represented nodes. Newly identified nodes were added to the coding 
framework. Coding is an iterative process whereby previously coded texts were revisited and 
checked whether the assignment of the data to specific nodes were correct or could be moved 
to other nodes. At times the same texts were coded with different nodes, as they embraced 
different meanings. 
Tree nodes were arranged into parent nodes (themes) and child nodes (sub-themes) which 
showed the hierarchical organisation (Bazeley, 2007). This process continued until all 
transcripts had been analysed and the coding was compared until no new themes emerged 
especially in patients' interviews. The number of interviews with health care professionals was 
limited by recruitment and saturation could not be assessed. 
The next section explores the concept of reliability and validity. 
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3.11 Reliability and validity of data and methods 
Qualitative research is often subject to validity and reliability criticism. The weaknesses of 
qualitative research are the potential for bias and the lack of generalisability due to smaller 
samples which are selected through non-random means. Nevertheless, unbiased, in depth, 
valid, reliable, credible and rigorous data can be produced if the research was carried out 
appropriately (Anderson, 2010). The claims made in qualitative research needs to be 
supported by convincing evidence (Murphy, et aI., 1998). 
3.11.1 Validity 
The validity of research findings refers to the extent to which the findings are true 
representations of the phenomena (Anderson, 2010; Smith, 2002). Validity can be 
demonstrated by a number of strategies including triangulation, use of contradictory 
evidence, respondent validation, and constant comparison (Anderson, 2010). 
Triangulation is using two or more methods to study the same event. This enables the 
researcher to compare different perspectives of the same event or experience and build a 
more comprehensive understanding of the subject matter. If both sources confirm the same 
findings, then the research is thought to be valid (Smith, 2005). In this study, some of the 
issues were triangulated using different strategy of inquiry (e.g. focus group and interviews) 
and sources (e.g. medical records) in order to substantiate the findings. 
Respondent validation allows participants to read through the data and analyses and provide 
feedback on the researcher's interpretations oftheir responses. It is also a suitable method of 
checking for inconsistencies, challenges the researcher's assumptions, and provides them with 
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an opportunity to revisit their data (Anderson, 2010). First, this strategy was not feasible due 
to the low literacy level of some patients and the fact that the researcher was not able to see 
the patients again. Respondent validation was conducted using a different approach in this 
study. The findings of the study were presented in an oral presentation session (see Chapter 5) 
to the health care professionals after completing the study. The session provided an 
opportunity for the health care professionals to check for consistencies and provided further 
information on certain issues. Additional issues were raised during the question and answer 
session which was held after the presentation and that led the researcher to revisit the 
transcripts and field notes to confirm some of the issues. 
The use of constant comparison means the data from one participant was compared to 
another participant to generate a complete understanding rather than presenting a single 
view. In this study, constant comparison method helped to identify both the emergent and the 
unanticipated themes. 
Qualitative study relies on those who conduct the research and therefore, the 
acknowledgement of what they bring into the research is important as it influence what they 
see and how they analyse their data (Charmaz, 2006). Validity can be compromised if 
participants do not feel free or comfortable to express their thoughts or opinions (Smith, 
2002). Although, the necessary steps had been taken to make sure the interviewees were 
comfortable to talk about their experience, some unavoidable factors could have affected the 
validity of the data. 
Being a novice, the validity of the study could have been compromised due to lack of 
interviewing skills especially at the beginning stage of the study. There were some cues that 
were not grasped during the initial interviews in which further probing could have led to a 
deeper understanding about the phenomena. However, the researcher was only able to 
reflect on it after gaining a deeper understanding on the nuances of qualitative research which 
happened at the later stages of the PhD project. 
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For example, it was observed that health care professionals especially physicians responded in 
a clinical way. Although this might not affect the validity of the study, the fact that the identity 
of the researcher (pharmacist) was known could have affected the way the health care 
professionals responded to the questions. 
On the other hand, the majority of the patients informed the researcher that they had not met 
a pharmacist before which means that they do not know the role of a pharmacist. 
Nevertheless, these patients knew that they were talking to someone who is equivalent to a 
doctor as the researcher was wearing a white coat and that might have impacted the data to a 
certain extent. Patients might have provided answers which are socially acceptable and 
avoided actions or behaviours that could be negatively judged. Again, their account are not 
considered invalid but the potential influence of the context should be considered (Murphy, et 
al.,1998). 
language barrier was another aspect that could have compromised the validity of this study. 
Some of the Chinese patients had difficulties in articulating their views in Malay language 
resulting in short replies. They would have been able to provide detailed explanation if they 
were interviewed by a Chinese speaking interviewer. 
This study was conducted in a clinic environment and that could have also affected the way 
patients responded in the interview. Participants would have been more comfortable and 
relaxed if they were interviewed in their choice of place (e.g. patient's home). It was decided 
not to conduct the interview in patients' homes for health and safety precautions. 
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3.11.2 Reliability 
The reliability of a study refers to the reproducibility and stability of the findings. Internal 
reliability relates to consistency of application of themes to the data and can be addressed by 
the use of inter-rater reliability checks. Different researchers' applications of the themes can 
be compared and adjustments made if and where necessary. This can be time consuming, 
labour intensive and it can be facilitated by the use of NVivo. 
In order to check the reliability of the data analysis in this study, sections of the coded 
transcript was presented to my supervisors to establish agreements on the codes assigned to 
each section of the data. 
The data within each code were also assessed to confirm that the code represented the data. 
The summary of all interviews and discussion were presented to the researcher's supervisors 
in order to allow them to get a complete understanding of the study. Consensus validation 
was used to confirm themes and the matching of the transcribed quotes with the themes and 
sub-themes derived from the analysis. 
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3.12 Ethical issues 
It is important to make sure that the study was conducted in an ethical manner whereby the 
participants' identities were protected. The section below discusses the three important 
aspects (anonymity, confidentiality and informed consent) (Goodwin, Mays, & Pope, 2006) of 
research ethics in qualitative research. 
3.12.1 Anonymity 
The identities of all participants were removed and pseudonyms were assigned. The settings 
from which the participants were recruited were not reported as health care professionals 
stood a higher chance of being recognised based on their professions and due to the limited 
number of health care professionals in the clinic. 
3.12.2 Confidentiality 
Participants' contact details were not obtained during the data collecting process. The audio-
recorded data and transcripts were saved in a password protected personal computer. 
Patients' name and health care professionals' demographic data that might reveal the 
participants identity were removed before the data analysis and will not be included in any 
publications. 
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3.12.3 Informed Consent 
Written informed consent (see Appendix 4) for participating and audio recording of the 
interviews and discussions was obtained from each patient and health care professional prior 
to the start of any research activity. 
The findings and discussion of phase 1 study are presented in Chapter 4. 
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CHAPTER 4: EXPLORING THE PHARMACEUTICAL CARE NEEDS 
OF T8 AND OM PATIENTS (PHASE 1) 
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4.1 Introduction 
The findings of the phase 1 study are presented in two sections in this chapter. Firstly, 
patients' and health care professionals' experiences of managing TB and OM are explained. 
Secondly, health care professionals' views on the expanding role of pharmacists are 
presented. The chapter concludes with the discussion of key findings. 
4.2 Participants characteristics 
In total, 20 patients, three physicians and three nurses were interviewed. Four pharmacists 
participated in a focus group discussion. The characteristics of patients are shown in Table 4-1. 
Detailed characteristics of patients are provided in Appendix 8. The mean age of patients with 
TB and OM was 57 years (range 42-78 years). The majority of patients were male (n=18). There 
were seven Malay, eight Chinese and five Indian patients. All Malay and Chinese patients 
preferred to be interviewed in Malay, four Indian patients were interviewed in Tamil and one 
Indian patient preferred English. All patients were diagnosed with pulmonary TB and three of 
them had a relapse of pulmonary TB. One out of the three participants who relapsed 
developed MDR-TB and was isolated in a TB ward. Fourteen patients had history of chronic 
OM preceding the diagnosis of TB and six were newly diagnosed with OM while on TB 
treatment. Eight patients reported to have other concurrent health problems such as 
hypertension, hyperlipidemia, osteoarthritis, cholelithiasis, diabetic foot, and pneumonia. Five 
patients had history of cataract surgery. 
Out of six health care professionals who participated in the interviews two physicians (a 
consultant and a specialist) and two nurses were attached to the chest clinic whilst the rest (a 
consultant and a nurse) were from the endocrine clinic. The two nurses from the chest clinic 
had more than six years of working experience and the nurse from the endocrine clinic had 
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eight years of working experience. As for the pharmacists who participated in the focus group 
discussion, two were running the MTAC for DM patients; one was running the MTAC for 
human immunodeficiency virus (HIV) patients whilst the fourth pharmacist was responsible in 
providing pharmaceutical care services to in-patients at the respiratory wards, which includes 
TS patients. Pharmacists had four to five years of working experiences. Demographic data for 
the health care professionals are not presented to protect their identities due to the small 
number of participants. All names used below are pseUdonyms. 
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Table 4-1 Characteristics of TB and OM patients (n=20) 
Patient characteristics Number of patients 
Age-, mean ± SO (range) 
40-59 
60-79 
Gender 
Male 
Female 
Ethnlclty 
Malay 
Chinese 
Indian 
History of OM 
Newly diagnosed OMb 
Previously diagnosed OM (range 1-30 years) 
Classification of TB 
Newly diagnosed pulmonary TB 
Relapsed pulmonary TBc 
Other concurrent health problemsd 
Social history 
Ever smoked 
Alcohol consumer 
Marital status 
Single 
Married 
Occupational status 
Employed 
Unemployed 
Retired 
57.3 ± 9.2 years (42-78 years) 
13 
7 
18 
2 
7 
8 
5 
6 
14 
17 
3 
8 
8 
2 
o 
20 
8 
6 
6 
"This is age (mean and standard deviation) and range of age rather than number of patients 
bOM was diagnosed at the chest clinic 
cOne of the patient who had a relapse of pulmonary TB also had MDR-TB 
dOther concurrent health problems include hypertension, hyperlipidemia, osteoarthritis, cholelithiasis, 
diabetic foot, and pneumonia 
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4.3 Patients' and health care professionals' experiences in managing T8 
and OM 
As the focus of this study was to explore the pharmaceutical care issues of TB and OM, issues 
related to the treatment ofTB and OM were regarded to be relevant. Concerns about 
medication and issues related to the management of TB and OM were the two major themes 
identified in this study. Summary of themes and subthemes are presented in Table 4-2. 
Table 4-2 Themes and subthemes related to the experiences of managing TB and OM 
Themes Subthemes 
Concerns about 
medication 
Management of TB and 
OM 
Adverse effects of medication 
Burden of multiple medication 
Concerns about drug interactions 
Medication confusion 
Necessity and efficacy of medication 
Longer duration of TB treatment in DM patients 
Delayed initiation of TB and OM treatment 
Poor record keeping 
Patient-physician communication barrier 
The ambiguity of OM management in TB patients 
DOT and the burden of attending multiple clinics 
Self-management and incorporation of traditional remedies 
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4.3.1 Concerns about medication 
Concerns about medication relate to the adverse effects of medication; the burden of 
consuming multiple medicines; concerns about drug interactions; medication confusion; and 
the necessity and efficacy of medication. 
4.3.1.1 Adverse effects of medication 
One physician believed that nausea and vomiting was the only medication-related problem 
observed in patients with TB and OM that was different from TB only patients. 
The only problem ... I notice that if I see patients with OM with TB, they tend to 
have a bit more of nauseatic symptom ... (Rahmat, physician, chest clinic) 
Rahmat also reported the measures that he took to manage patients who vomited during TB 
treatment. The option of prescribing TB treatment at night (before bedtime) was considered in 
order to reduce the occurrence of nausea and vomiting. 
So all these patients with OM and TB, when they are vomiting, normally I 
admit them to the ward. They must hold on with TB and diabetes treatment 
side effects ... a few patients what I do is that because they have lot of nausea, 
vomiting, I give them their TB treatment at night... so, they sleep off with the 
tablet so they don't have much nausea vomiting at night (Rahmat, physician, 
chest clinic) 
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Similar to physicians, nausea and vomiting was the most common complaint and was reported 
by eight patients. Patients also speculated about the reasons they felt to be the causes for 
nausea and vomiting. Many said that the vomiting was more severe when they took 
medication on an empty stomach. While others thought strong medication odour and 
concomitant use of TB and DM medication were causing the problem. For example: 
... cause when / take the medicines for my diabetes, it disturbs the TB 
medicines, very fast, /'1/ feel like vomiting (Choo, 53 years, Chinese male 
patient) 
Patients also mentioned their strategies to alleviate nausea and vomiting. For example, they 
avoided taking TB medication and DM medication simultaneously, taking food before 
consuming TB or DM medication. One patient adjusted the dosage of DM medication to 
prevent vomiting without first consulting his physician. 
Doctor asked me to take two tablets of gliclazide but now I'm only taking one. I 
feel like vomiting, feel ill. Since I'm experiencing it, / can't follow doctor's 
instruction. (Ejass, 64 years, Malay male patient) 
However, unlike physicians, patients discussed their experiences with a range of additional 
adverse effects of medication. Five patients experienced painful toes and ankles. One patient 
described the episode: 
When I take my TB medicines, my leg hurts, it's similar to how I used to have 
pain for gout, if you get it, it's very difficult, toes till here (ankle) will ache, 
happens a lot in the morning (Chao, 53 years, Chinese male patient) 
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Four other patients reported visual disturbances. Other adverse effects that were reported by 
patients include swelling of the limbs, itchiness, palpitation, drowsiness and fatigue. 
Some patients talked about developing other problems that they perceived to be related to 
multiple medicines taking such as losing appetite, feeling depressed and lethargy. 
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4.3.1.2 Burden of multiple medication 
Having to consume a high number of medicines was considered burdensome for many 
patients. One patient reported that he took about 21 tablets a day, which included treatment 
for TB, OM and other presenting comorbidities. Four patients said that they had some 
reservations or fear of taking a large quantity of TB medication at the initial stage of the 
treatment but found it to be tolerable after some time. Another patient reported that it was 
easier to take OM medication since the number of medication was lesser when compared with 
TB medication. 
Insya/lah (God willing), I can take the OM medicines, twice a day only and the 
medicines are not a lot but if you compare with TB medicines, 13 pills, that's a 
lot, even just looking at it, it's frightening. I am really scared of taking 
medicines, but what can I do. (Nusa, 53 years, Malay male) 
Some feared that multiple medicines can lead to other health problems. For example: 
I'm afraid. If I have to take so many medicines, definitely I'll be scared ... 1 might 
end up with other problems. (Yuen, 64 years, Chinese male patient) 
Many expressed difficulties of consuming mUltiple medicines on an empty stomach. 
When I had to come (for DOT), I had to fast. When I take the medicines in 
empty stomach, I a/ways vomit. (Badrul, 55 years, Malay male patient) 
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Conversely, some patients expressed that they did not find mUltiple medication taking a 
problem as they have "got used to it" or they did not have any option as they had to take the 
medication to improve their well-being. 
One physician affirmed that the recent availability of fixed-dose combinations of TB 
medication in Malaysia would be able to reduce the burden of multiple medicines. 
But now we got the fixed-dose combination ... We are already starting in 
patients now with TB ... So patients need to take four to five tablets a day. Last 
time they take twelve tablets a day. (Rahmat, physician, chest clinic) 
On the other hand, another physician mentioned that despite the availability of fixed- dose 
combinations, not all patients were privileged to get the fixed-dose combination due to the 
higher cost, and reiterated the burden of multiple medicines. 
We manage to bring the [ixed- dose combination in ... it is not very popular ... we 
are not giving to everybody ... so the pill loads ... is always a problem. (Chong, 
physician, chest clinic) 
According to the same physician, only certain patients who have problems tolerating multiple 
medicines were given the fixed-dose combination of TB medication. 
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4.3.1.3 Concerns about drug interactions 
Some patients were concerned about drug interactions when multiple medicines were 
consumed. For instance: 
When I take the medicines for diabetes, it disturbs the TB medicines. Very fast, 
I'll feel like vomiting. (Zaman, 50 years, Malay male) 
Some believed that drug interactions may cause other health problems. For instance, one 
patient perceived that the pain-killer that he used to take became ineffective after he started 
taking TB medication. 
Last time, when it is painful, I go to the pharmacy to buy the small pill, in two 
hours it will be okay. Now after taking the TB medication, there is no effect ... I 
even had to take two pills. (Choo, 53 years, Chinese male patient) 
When health care professionals were asked about whether they experienced any drug 
interactions in TB and OM management, a physician said 'I'm not aware of any drug 
interactions in TB and DM'. Similar account was given by another physician . 
... what differences from diabetes TB patient to other TB patients? Well, I don't 
know whether they are different in the developing side effects or drug 
interactions ... not sure about that ... (Chong, physician, chest clinic) 
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4.3.1.4 Medication confusion 
Despite receiving labelled medication, most of the patients do not know the name of their 
medication. However, they were able to describe their medication based on the shape and 
colour with limited knowledge on indications of the medication. 
I'm not sure what is it jor, I just take them (Ooi, 63 years, Chinese male 
patient) 
The diabetic medicine is elongated in shape and it is white in colour and 
another one is white round tablet. There is another one jor cholesterol which is 
a heart shape tablet (Ramamany, 56 years, Indian jemale patient) 
Since there are many medicines that have the similar colour and shapes, patients reported 
that they were confused with some of the medication (e.g. glibenclamide and perindopril have 
similar colour and shape). Although some may know medicines by name, confusion arose due 
to the strength of the medicines. A higher number was equated with a stronger medicine for 
which the patient believed a smaller amount should be taken. One patient said that he was 
confused when a different prescription for OM was issued but he did not voice or discuss his 
concerns with his physician. 
I was recently prescribed with g/iclazide and metjormin. Prior to g/iclazide, I 
was taking glibenc/amide. I don't know why the dosage oj g/ic/azide was BOmg 
when the g/ibenclamide was 5mg. I think the physician had made a mistake, so 
I only take one tablet instead of two (Ejass, 64 years, Malay male patient) 
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Researcher's reflection 
I felt that it was important to clarify that gliclazide and glibenclamide are two different drugs 
and therefore the doses are not equivalent. I spoke to the patient after completing the 
interview. He said that he did not realise that the medication were different and that he now 
understood and would start taking his medication as prescribed by the physician. 
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4.3.1.5 Necessity and efficacy of medication 
Despite all the challenges with having to take medication, patients talked about the 
importance of medication especially TB medication in curing their disease. They expressed the 
efficacy ofTB medication which was based on the improvement in their health condition. They 
gained appetite and some felt energised. They also reported that they started to trust TB 
medication due to the fast recovery. 
When I was first diagnosed with TB, I just don't feel like doing anything. I feel 
very lazy. But now after taking the medicines, I'm feeling much better. (Sharon, 
42 years, Chinese female patient) 
Oh yes, I take my medication daily. I'm excited now. I can eat. There's no blood 
anymore. I'm so relieved. {Nusa, 53 years, Malay male patient} 
Pavithran talked about how his physician linked the necessity of taking OM medication to 
avoid the relapse of TB. 
Doctor said lot of improvement {chest x-ray} ... He told me to continue my TB 
medication. Then he said "Diabetic one, you must strictly take, you leave it you 
will get back to TB". (Pavithran, 49 years, Indian male patient) 
When health care professionals were asked whether patients tended to prioritise their 
treatment given the presence of other comorbidities, one physician reported that he did not 
know what patients prioritise but the message that TB can be cured had been stressed. 
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I don't actually know what they prioritise. But I think we already told them that 
TB is curable and TB is infectious ... so we stress that they should be taking 
medicines regularly and should be compliant to the medication. And we 
mentioned that whatever disease that they already have, TB is also very 
important because it is curable. But what the patient prioritise, I'm not so sure. 
(Rahmat, physician, chest clinic) 
Patients talked about the necessity of TB medication in greater depth as compared to OM 
medication. Although, they reported that they took their OM medication regularly, they did 
not disclose how they felt after taking OM medication in detail as compared to how they 
described the improvement in their health after taking TB medication. 
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4.3.2 Management of TB and OM 
4.3.2.1 Longer duration of T8 treatment in OM patients 
Physicians reported that because TB and OM patients presented with more cavities in their 
lungs as compared to TB only patients, the former group had to undergo a longer duration of 
TB treatment. Unlike patients with TB alone who mostly required six months treatment, those 
with TB and OM were reported to need an additional three months . 
... my patients are always taking the same TB dose and everything. Only thing I 
notice about TB and diabetes is that I give them longer treatment. Nine 
months ... Prognosis if you ask me is good. Only thing patients with TB and OM, 
OM patients tend to have very bad x-rays when they come and see me. They 
have got lots of cavities ... (Rahmat, physician, chest clinic) 
Most of the patients did not express any difficulties with regards to longer duration of 
treatment. However, some patients informed that they did not know that they had to take 
their medication for nine months. Some patients took comfort with their improving health 
condition and that motivated some of them to continue their treatment. 
On the other hand, those who had a relapse of TB believed that they were unlucky and had no 
other choice rather than repeating the treatment process. 
It's my bad luck, I've got it (TB) again for the third time. (Ooi, 63 years, 
Chinese male patient) 
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Some believed that consuming medication for a long duration will be detrimental for health. 
As one mentioned: 
If you take medicines for a long period, you may fall ill. (Goh, 51 years, Chinese 
male patient) 
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4.3.2.2 Delayed initiation of T8 and OM treatment 
Late treatment-seeking behaviour was reported to be a major obstacle for early initiation of 
TB treatment. A physician reported how he regularly observed patients presenting with 
severe stages of TB. He also believed that the awareness to seek early treatment is lacking . 
... 1 go to the district hospital every month and I can see four to six new cases. 
Probably half of them are at very severe stage ... they have high tolerance in 
their symptoms ... they seek other sort of treatment before they come to us and 
those who smoke they usually cough with or without infection. So they think it 
is part of their smoker culprits and that don't seem to alert them that much ... 
they have been in their house, coughing for months, come with very bad 
destroyed lungs, even young population I think education playa very 
important role ... the awareness definitely not good enough. (Chong, physician, 
chest clinic) 
T8 and OM patients in this study confirmed that they were diagnosed with TB at the hospital 
after coughing for a long period oftime. They also mentioned that they first sought treatment 
for cough from private clinics or pharmacies. 
When I first had TB, I coughed, coughed blood, real fresh blood ... after one 
week I went (private clinic), he (doctor) said 'panas' (hot), he gave medicines, 
but it never went off, only then I went to see the doctor in the health clinic, x-
ray, he said I had TB. (Nusa, 53 years, Malay male patient) 
When the same patient was asked of why he did not present to the hospital despite coughing 
blood. He replied: 
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Oh you know, f thought it will disappear on its own. f thought the pain will be 
gone in a day or two. I am still young. (Nusa, 53 years, Malay male patient) 
Another patient revealed how he prioritised family affairs than seeking early treatment. 
Never mind, that's what I thought. After a few days I can go, because my son is 
about to get married. f would like to wait until the big day is over. f can always 
go and check. I was just worried that I may not make it for the wedding if I go 
to the hospital so as long as I could tolerate it, why must I check first. (Yuen, 64 
years, Chinese male patient) 
Many patients reported that OM was diagnosed only when they presented to the hospital for 
some other problems. For example: 
I didn't know. I only knew when my leg was injured. I do not have any 
sensation on the other leg. Since I injured my leg, I came for a check-up. They 
told me that this whole area (pointing to his leg) was gone. Then, they 
amputated my leg. (Jeyaraj, 52 years, Indian male patient) 
Four patients reported that they discovered that they had OM when they went for their eye 
check-up or surgery. Another four patients were diagnosed with OM when they were screened 
at the chest clinic following the diagnosis of TB. Therefore, many did not know that they had 
OM until it was detected at the later stages. 
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Some patients lived in denial and doubted the diagnosis of TB. For example, Veeramuthu did 
not inform his family members regarding the diagnosis of TB, although he had been on TB 
treatment for 2 weeks. 
I yet to tell anybody at home ... I have not brought anyone for check-up. (Veeramuthu, 
50 years, Indian male patient) 
Prior to the diagnosis, he had been coughing for more than a month. He kept saying that he 
could not understand how he developed TB. He said that he had quit smoking 5 years ago and 
he was still doubtful whether the diagnosis of TB was correct or not. Therefore, he was 
reluctant to inform his family members. Denial about the disease could also lead to delayed 
initiation of treatment in affected family members. 
Nurses also reported that Malay and Indian patients tended to be more secretive about their 
disease and do not refer family members for screening. 
But when it comes to some of the Malay and Indian community, there are 
many incidences where patients do not give correct contact address and they 
also don't refer their family members for screening. In fact they tend to hide 
them ... Even when the whole family is infected, there will be some who will be 
quiet and silent about it. (Ros, nurse, chest clinic) 
Nurses reported that Chinese patients were generally more vigilant and took extra precautions 
to make sure that all family members were screened for TB. 
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The Chinese are very afraid of TB, so they are extremely careful ... sometimes 
when there is one family member who developed TB, we usually tell them that 
close family members should be screened, at times 20 or 30 people will come 
for screening, even those who do not stay together will come ... they are very 
scared. But the Malays and Indians are not like that. The Malays, they will go 
and see the 'bomoh' (Malay traditional healer) based on their own beliefs. 
(Rohana, nurse, chest clinic) 
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4.3.2.3 Poor record keeping 
Poor medical and medication history taking and poor record keeping were observed. Three 
patients had previous history of cataract surgery but they did not inform their physicians 
treating their TB as they were not asked about it. However, one patient reported that he had 
informed his physician that he had had an eye surgery before the initiation of TB treatment 
but he was prescribed with ethambutol and he was on treatment for one month. It was only 
when the eye physician came to know about it, the recommendation to stop ethambutol was 
made through a letter to the respiratory physician. 
I informed the doctor that I had an eye operation ... Even that day, the doctor 
told me that this medicine (ethambutol) can cause eye problem. But the 
medicine was given to me. Then one day, I went for an eye check-up and the 
doctor said 'Don't take this medicine, you can't take this medicine'. So he 
wrate to the doctor over here ... Only then the medicine was stopped. Even after 
stopping it, it took me nearly one week to get my vision improved (Yuen, 64 
years, Chinese male patient) 
Similarly, two patients informed that they had history of gout but it was not documented in 
their medical records. 
Researcher's reflection 
As I also viewed patient's medical record prior to the interview, I realised that medical and 
medication history was incomplete. I managed to gather further information about medication 
especially for comorbidities during the interview session. 
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4.3.2.4 Patient-physician communication barrier 
When physicians were asked whether patients complain about their medication, one physician 
reported that patients prefer to communicate their problems to the nurses. Physicians 
believed that patients communicate better to nurses since they provide DOT and also due to 
time limitation during medical consultation. 
They don't complain to me. Probably they complain to my nurses but not to 
me. Because the treatment is given by the nurses ... To them probably I suppose 
they complain. They never tell me anything probably we do not have much 
time to talk to the patients. We see them in appointment. They probably might 
tell the nurses about all the side effects. (Rahmat, physician, chest clinic) 
Nurses explained that although they advise patients to tell their health problems when they 
visit their physician, patients tended to complain about their problems to them rather than 
informing their physicians. 
Before seeing the doctor they will tell us. 'Nurse, I feel itchy, I feel this and 
that'. We tell them to tell the doctor whatever they feel, but after seeing the 
doctor, they come back and tell us again. Sometimes we ask them why they 
did not tell the doctor? That's the problem, patients prefer to tell us. (Ros, 
nurse, chest clinic) 
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4.3.2.5 The ambiguity of OM management in T8 patients 
Two physicians from the chest clinic were asked whether they treat OM in TB patients. It 
seemed that physicians managed OM based on the criteria of 'simple' OM or 'difficult' OM. 
Both had similar notions that they were capable of treating 'simple' diabetes or in other words 
manage 'non-insulin' patients. 
We try not to treat the diabetes here as we are not the real experts. There are 
experts out there, and if it is simple diabetes which can be easily controlled 
sugar, then probably we will treat here. Otherwise, people with diabetes 
especially with complications like chronic kidney disease or some other 
problem, we will refer them. (Chong, physician, chest clinic) 
Diabetes can be treated by me. It shouldn't be a problem. Unless they have 
difficult kind of diabetes and need insulin therapy and then I refer them to the 
endocrine clinic. If their diabetes can be given in oral therapy, then I treat them 
in my clinic. (Rahmat, physician, chest clinic) 
It was felt that more information about the management of OM in TB patients could be 
obtained if the health care professionals from the endocrine clinic could provide their point of 
view. Therefore, the idea to interview health care professionals from the endocrine clinic 
came after completing the interviews with patients and healthcare professionals from the 
chest clinic. Nevertheless, the physician from the endocrine clinic also mentioned that OM can 
be treated by the chest physicians and were only referred to them when it was 'difficult'. 
However she was unsure about the types of assessment that patients with TB and OM receive 
when they were not treated by the endocrine physicians. 
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They (TB and DM patients) should get the same thing ... because sometimes, the 
chest physicians themselves can treat diabetes, and sometimes unless it is very 
difficult then they will call us. At the time, usually when we see, we will send 
for assessment, to assess the leg, check the renal profile ... that has been our 
practice. But other physicians attending to these patients, I can't say ... Well, if 
it is not a difficult diabetes, they may remain on the same oral hypoglycaemic 
agents that they are on, if they are difficult then we will put them on insulin. 
(Adi/ah, physician, endocrine clinic) 
Being unclear about the meaning of 'simple' and 'difficult' OM, further questions were posed 
to Adilah. 
Interviewer: How do you differentiate between simple and difficult because 
the physicians from the Chest clinic used that as well? 
Adilah: Yes, it depends on the HbAlc. Most of the time, if their starting HbAlc 
is more than 9, usually there will be a need of at least two oral hypoglycaemic 
agents with insulin on board ... it's just that if they are already on maximum 
oral hypoglycaemic agents and the HbAlc is still not well control, still not 
achieving targets, we would introduce insulin therapy. The aim is to reduce 
HbAlc to less than 7. So if they are already a diabetic and they have TB, the 
chances are the glucose control will deteriorate, so it makes more logic to add 
insulin. 
The importance of HbAlc in order to differentiate 'simple' and 'difficult' OM relates to the 
importance of having the data in patients' medical records at the TB clinic. Based on the 
preliminary findings, minimal documentation of medication history as well as laboratory 
findings was seen. It was indeed unknown how physicians interpret 'simple' and 'difficult' OM 
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if the HbA1C was not recorded. This issue was also raised during the interviews with the 
physicians from the Chest clinic. 
We are doing HbAlc if the patient is only following-up here. We do HbA1C at 
least 3 to 4 months once ... lf it's not done then probably it's done in the clinic 
where they follow-up. (Rahmat, physician, chest clinic) 
The issue of non-documentation or absence of non-TB related data was also mentioned by 
another physician from the chest clinic. Chong informed that relevant information for non-TB 
drugs might not be available at the Chest clinic. 
If you are here, you can get the information for TB, we have all the records 
here. But the others, we don't keep the records here. (Chong, physician, chest 
clinic) 
Issues regarding insulin were discussed with the endocrine physician. 
Interviewer: Is it true that only the physicians from the endocrine department 
can prescribe insulin? 
Adilah: Under the general specialties, they can let other doctors to prescribe as 
well. Yeah we cannot handle too many patients. 
Interviewer: Is it better to put them on insulin? 
Adilah: Our patients are very resistant ... but if they get TB and they are little bit 
concerned about their health, then it might be easier to convert them to 
insulin. 
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4.3.2.6 DOT and the burden of attending multiple clinics 
Discussions regarding the management of TB via DOT revealed that almost all health care 
professionals felt that DOT was a good strategy to ensure adherence to TB medication. 
DOTS is good for many things ... When they come and see the doctors or 
nurses, they can get the medicines everyday for compliance and at the 
sometime also the nurses can ask the patients for side effects of the drugs too 
and the third thing this can also prevent MDR- TB in this patients. 50 in general, 
if you ask me definitely it is good for the patients. (Rahmat, physician, chest 
clinic) 
As for me, I can see patient taking medicine every day, make sure they take 
medicine every day, it's good, if they don't take medicine for one day we can 
trace and we prevent the disease from spreading ... (Ros, nurse, chest clinic) 
Unlike health care professionals, not all patients were in favour of DOT. Some patients 
expressed that they will be able to self-supervise their treatment. The following quotes 
express how strongly patients feel about the necessity of TB medication and how they would 
like to negotiate with the health care professionals to allow self-supervision of TB treatment. 
Because I asked. Earlier when I asked, they say cannot, they say that I'll throw 
my medicines. But I take my medicines daily. I won't forget, because I know 
how it is after I take the medicines ... I want to ask the doctor, at least give me 
(TB medication) every three or four days. It will be easier for me. (Long, 63 
years, Chinese male patient) 
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Even though I'm poor, my life is very important, so definitely I'll take my 
medicines. I won't lie, some may just collect the medicine, not to eat but to 
keep. I would like to discuss and see. I'll say my life, I'll take care of it. I'll 
definitely take my TB medication. It is like God giving me to take. If I don't 
take, I'll die. (Tim, 78 years, Chinese male patient) 
Few patients reported that it was important to visit the clinic daily for DOT due to the complex 
treatment regimen. One patient said: 
I feel that this is a very effective method. Because the medication is a lot. Even 
if I take it at home, it is difficult for us to follow the prescription (Zainal, 50 
years, Malay male patient) 
Another patient stressed that DOT provided the opportunity to get better care. 
Doctors must check weekly and let us know, doctors must get to know what is 
going on and we want to discuss with doctors too (Yuen, 64 years, Chinese 
male patient) 
The same patient also expressed willingness to travel to the general hospital for DOT although 
there was a health clinic closer to his home. This was due to the impression that nurses at the 
general hospital were better trained and were more knowledgeable about multiple diseases 
compared to nurses in health clinics, which meant that more information could be obtained 
from the general hospital nurses. 
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They (nurse at health clinic) also provide DOT in the health clinic, but sometime 
the missy (nurse) can't answer, she doesn't know anything, if there's a lot of 
disease, she can't take care of all. (Yuen, 64 years, Chinese male patient) 
Vuen also viewed DOT as an avenue that provides peer support through meeting other 
patients. 
It is much better to come over to GH (general hospital) ... to meet other friends 
(TB patients), we have to take good care, we get to see others getting better 
(Yuen, 64 years, Chinese male patient) 
Health care professionals preferred patients to have DOT at the clinic. However, patients will 
be assessed whether they were suitable candidates for DOT. 
I prefer that they take their medicines everyday in the clinic... I feel if they take 
in their house, somebody responsible must be there to see the patients taking 
their medicines every day. Unless those who are ill and they can't come to the 
clinic everyday (Rahmat, physician, chest clinic) 
We try to ensure DOTS for everybody but sometimes it's not quite possible if 
they are crippled by disease or ... (Chong, physician, chest clinic) 
Some patients accepted DOT although there were some strong resentments projected. For 
example: 
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I do not have any problem with that (DOT) because I'm self-employed. But I 
feel like being punished because I have to come every day. I'm not a small kid 
anymore. I'm a grown-up (Najip, 54 years, Malay male patient) 
Nevertheless, some health care professionals and patients also reported that DOT was felt to 
be inconvenient as patients have to visit the clinic everyday and it also involves the 
participation of other family members. 
I think DOT is a good way to control TB but again it's not very convenient or 
patient friendly kind of treatment. Patients have to come to clinic every day. 
Get the family involved to bring them (Chong, physician, chest clinic) 
Although it was agreed that DOT could be troublesome to some patients, one physician 
reported that patients were given the flexibility to choose their appointment time. 
We are flexible of the patient's time to make sure that patient can come every 
day for DOT and the time is up to them to decide (Rahmat, physician, chest 
clinic) 
Nevertheless, health care professionals also acknowledged the burden of having to attend 
multiple clinics due to comorbidities. One physician reported that patients have long waiting 
time in other clinics as compared to chest clinic. 
The only barrier is ... for TB it is not a problem because TB patients they come to 
my clinic everyday and they don't have to wait. They get the treatment and 
they go home straightaway. 50 there's no waiting time, there's no wasting 
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time there for the patients. Only problem is that when they come to other 
clinics, they have to wait for a long period. They may have to take their 
diabetic medicines in medical clinics or cardia medicines in cardia clinic. There 
they have to wait very long. 50 the barrier is the long waiting time. That's all ... 
Long waiting time to see the doctor and long waiting time to get the 
medication in the pharmacy. (Rahmat, physician, chest clinic) 
Our clinic days do not coincide, sometimes they have to come on different 
days. (Adilah, physician, endocrine clinic) 
Nurses also reported that patients complained about having to make various visits to different 
clinics on different days. 
You know they have to come so many times, if they can make it on the same 
day, like in the morning they come to chest clinic and in the evening they go to 
cardia clinic or something, then they will only have to come once which will be 
easier for them but unfortunately clinic days are different. (Ros, nurse, chest 
clinic) 
From my own observation, patients came for their DOT and then went back home to take their 
food before consuming their OM medication. Some of them expressed that they experienced 
giddiness which could have been due to hypoglycaemia. Some patients had to walk back home 
after their DOT or follow-up visits. Nurses reported that some patients complained that it was 
difficult to come for daily DOT as they could not afford to pay for the transportation. 
Sometimes there are patients who will tell, (Nurse no money' ... to come by 
taxi it will cost RM 30 and they can't afford it. (Rohana, nurse, chest clinic) 
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4.3.2.7 Self-management and incorporation of traditional remedies 
Unlike TB, OM management depended on self-management. Some patients reported that they 
sometimes forget to take their OM medication especially at night. Health care professionals 
reported that non-adherence to OM medication were commonly seen. 
Some patients still don't like to take drugs, they are not regular, we have 
patients that they will come and tell us that they take their medicines for 3 to 4 
days, they feel better then they off it... But there are quite a number of 
patients, that we do know that they are not taking their medicines on regular 
basis, or not compliant to injections, you know from three they might drop the 
injections to two and try to get away with it, so HbAIC control is very difficult 
especially patients who are not well motivated (Adilah, phYSician, endocrine 
clinic) 
A nurse reported that patients feared insulin injections and preferred insulin pens as 
compared to conventional needle and syringes. 
Most of the patients at the beginning, they are reluctant to take insulin, 
because they have the fear oh every day I must inject, they got this fear, they 
prefer taking tablets, even though there are many tablets they don't mind. 
Some will get used to injections ... but some still so reluctant... they will complain 
to us that problem this problem, even when there is no problem they will 
complain that they cannot use the needle ... There will be a reason for them to 
make the doctor stop the insulin ... but now / think few patients ... we switch to 
pen, they are okay with it, because it is easy to carry, it is already there ... just 
take and then inject. Whereas the needle and the syringe, the old fashion type, 
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they have to keep it clean, you know all that basic procedure ... (Manjit Kaur, 
nurse, endocrine clinic) 
One patient reported how he requested for changing insulin to oral hypoglycaemic agents 
after a bad experience with the use of insulin. 
I used to take insulin injections. There was once the needle broke. I told them 
(doctors) that I dare not take insulin any longer. 50 they replaced it with pills. 
(Veeramuthu, 50 years, Indian male patient) 
None of the patients interviewed reported owning a self-monitoring glucometer. The majority 
of patients indicated that their blood sugar was only checked during their follow-up visits at 
the OM clinic. Two patients reported that they have checked their blood sugar at the 
community pharmacy. For example: 
Interviewer: Do you check your sugar regularly? 
Mydin: Not really. But I take my medicines regularly. At times, I check in the 
pharmacy. If I pay them RM5, they will check for me (Mydin, 72 years, Indian 
male patient) 
When patients were asked whether they knew their current blood sugar level, some reported 
that they don't know, some said that their sugar level was lower than what it was when they 
were first diagnosed with OM but the blood sugar level was still uncontrolled and only two 
patients reported that their blood sugar level was normal during their last check-up. 
I think that time, slightly high about 16 ... Now I don't know (Pavithron, 49 
years, Indian male patient) 
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Last time it was 12 to 13, recently it was about 9 plus (Hakim, 55 years, Malay 
male patient) 
When I first checked, it was 19, I think now it is about 4 or 5 (Jeyaraj, 52 years, 
Indian male patient) 
Some patients talked about the fluctuating nature of their blood sugar levels based on food 
intake and exercise. 
Those days the sugar level fluctuates because I used to eat a lot and it will be 
high, if I eat less then it will be low, so it goes up and down, it was never quite 
the same, so it all depends on what I eat, when I eat more the sugar goes up 
so I have to be careful with what I eat (Long, 63 years, Chinese male patient) 
Now it is about 9 or more, previously it was more than 12. Then once I started 
exercise and worked hard, it went really low and the doctor said that I don't 
have diabetes any longer ... but later I got it again (Chao, 53 years, Chinese 
male patient) 
Some reported that they had changed their diet and began to exercise. 
I exercise and control my food. Morning, I take oats, afternoon I take brown 
rice and at night, I take oats (Sharon, 42 years, Chinese female patient) 
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Some patients said that they abstained themselves from eating certain food items (e.g 
chicken, pork, eggs, potatoes) that they believed could worsen either their TB or DM. When 
patients were asked about their diet, many reported that they reduced their intake of rice. 
Some patients claimed that they only ate rice in the afternoon and had a light diet at night. 
When they were asked of what they meant about light diet, some said that they ate noodles 
or burgers. For example: 
Now I don't take much rice. Even if I take, I anly take it once a day ... At night, I 
eat chicken burger. (Badrul, 55 years, Malay male patient) 
A physician explained that patients have difficulties in sticking to diabetic diet 
recommendation. 
I think the major factor especially in our local cantext here is food, our high 
carbahydrate diet is very difficult for our diabetes patients, asking them to 
change the lifestyle, reducing their food intake, carbohydrate intake is very 
difficult. (Adilah, physician, endocrine clinic) 
Some patients tried to self-medicate themselves by trying herbal or traditional remedies prior 
to being diagnosed with TB. 
I look at my body, I'm not eating like before, the Chinese people will say that it 
is due to 'heat', try Chinese medicine first (Yuen, 64 years, Chinese male 
patient) 
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Some patients believed that cough was caused by 'heat'. The term 'heat' is commonly used 
among Malaysian people regardless of their ethnic background. 'Heat' or 'hot' is assumed to 
be a condition that was caused by either the environment (hot weather) or the types of food 
that was consumed. Certain food was believed to have 'hot' or 'cold' properties. The example 
below shows, how another patient regarded that the cough was due to drinking something 
which had 'cold' properties and in order to reverse the condition he was recommended to 
consume beer which was believed to contain the 'hot' property. 
I cough a lot at night. One day, I took 'mohroo' (Indian yogurt drink). Since I 
like it so much, I took 4 to 5 glasses. Due to that, my friend told me that I will 
keep on coughing and suggested that I should take Tiger (beer) to make myself 
warm and I will be able to sleep. 50 I took it and the coughing was less 
(Veeramuthu, 50 years, Indian male patient) 
Many patients stated that they had been using traditional or herbal remedies mainly for 
treating OM. Patients who perceived the benefit of using traditional or herbal remedies 
continued their practice. Mostly Malay patients reported consuming herbs like Misai Kucing 
(Orthosiphon stamineus) and Daun Cerita/Hempedu Tanah/Hempedu Bumi (Andrographis 
paniculata) to treat DM. 
For diabetes, I drink Hempedu Tanah. That bitter Hempedu Tanah, I soak the 
leaves, drink weekly once ... no bone pains, no tiredness, numbness, well, it 
might work for some but not for all. (Hakim, 55 years, Malay male patient) 
Only two patients spoke about using traditional or herbal medicines for TB. One patient 
explained that he boils the leaves that are used to wrap Malay 'ketupat' (rice cake) and he 
drinks the water in order to treat TB. Another patient said that he took Chinese Medicines 
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when he started TB treatment but has stopped taking it as he was unsure of its effectiveness. 
He informed that he did not know the name of the medicine. 
When I had TB, I had to take. It is in a powder form, I'm not sure of the colour. I 
just consume the powder once daily (Yuen, 64 years, Chinese male patient) 
Similarly, some patients reported that they had stopped using traditional or herbal remedies 
as they were unsure of the benefits or believed that it could not be trusted. 
I don't take Chinese Medicine anymore. Earlier I did try for diabetes. But I only 
drank a bit, I don't know can or cannot, but I can't trust the Chinese Medicine. 
This medicines (hospital medicines), yes I trust, but the one from the sinseh 
(Chinese Medical Hall Practitioners) I can't trust and the one on the streets, 
you can't take it, because it is dusty (Long, 63 years, Chinese male patient) 
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4.4 Health care professionals' perspectives on the expanding role of 
pharmacist 
The role of pharmacists in Malaysia is expanding with the introduction of new services such as 
MTAC. This section describes the views of the health care professionals on the existing 
pharmacist-led MTAC and followed by opinions on the potential role of pharmacist in the 
management of TS and DM. Themes and subthemes are presented in Table 4-3. 
Table 4-3 Themes and subthemes regarding MTAC and the potential role of pharmacist 
Themes Subthemes 
Perspectives on pharmacist-led MTAC Provision of pharmaceutical care 
Pharmacist-physician interaction 
Accessibility and timely delivery of service 
Enhanced pharmacist-patient communication 
Satisfaction 
Potential role of pharmacist in Educate and counsel patients 
managing TB and OM 
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4.4.1 Views on pharmacist-led medication therapy adherence clinic 
4.4.1.1 Provision of pharmaceutical care 
When pharmacists were asked about what they actually do in MTAC, they responded that they 
provided pharmaceutical care service and the main goal was to promote adherence to 
treatment. They described their activity that begins with a thorough medication history taking. 
What we da is, we do a detailed patient medication history so that we know 
exactly how they are taking their medicines and not just following the 
prescriptions ... First we see how they are taking it, why they are not taking it 
and problems with the medicines. (Elvin, pharmacist) 
Subsequently, they also described about having structured patient education and counselling 
programmes that they have developed for OM and HIV patients. The programme is delivered 
in 8 visits for OM patients and 10 visits for HIV patients. 
They see us for eight visits. When they come here (MTAC), we will teach them 
something about diabetes, hypertension, cholesterol and all the essential 
things, which we have developed the syllabus, so that they can actually learn 
while they wait ... After four visits, we actually do revision and counter checking 
that patients know what they are taking. So after they complete these eight 
visits, hopefully their adherence will be better and their knowledge will be 
better and hopefully it translates to better results in HbAlc. (Elvin, pharmacist) 
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We have education kit to educate patients about HIV, what are the side 
effects, we have the drug chart, so the patient can show us which mediaction 
that their taking, whether the patient can identify what they are 
taking ... (Ruhaila, pharmacist) 
Pharmacists also explained that they had to address patients' medication-related concerns. 
They always hear what other people say ... they get confused and scared. For 
example, one patient said 'Perindopril is bad for kidneys. I've got kidney 
problem, I've microalbuminurea, so should I be taking this?' So we have to 
keep on explaining this sort of things. Because doctors don't explain this kind 
of things, so it's a bit hard for us. (Mei Ling, pharmacist) 
Another pharmacist reported how she managed patients with low literacy level and patients 
with visual impairment. 
Some patients, they can't read and we have to draw for them sun, moon ... and 
then the problem is some of them progress to retinopathy and some become 
blind ... I did have patients who were blind and on three types of insulin, mostly 
pens ... So I drew certain shapes like round, moon and triangle and make sure it 
is something that the patients can touch and I stick it on a sticker cardboard 
and then stick it on the insulin pen and the box as well. (Mei Ling, pharmacist) 
When pharmacists were asked about the amount time spent in consultation, they replied that 
it ranges from ten to thirty minutes with longer sessions at the first visit and shorter sessions 
during follow-ups. 
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4.4.1.2 Pharmacist-physician interaction 
Pharmacists believed that they have gained more knowledge, experience and confidence 
through practice and interactions with physicians. At the early stages of the MTAC 
programme, pharmacists did not have a separate counselling area or room. At this point, they 
used to share the clinic session with the physician. Although the lack of space was found to be 
a limiting factor, it provided the pharmacists an opportunity to observe how physicians 
communicate, counsel and do medication history taking. 
Sometimes I observe how the doctors talk to patients, how they talk to the 
patient about their medication ... (Ruhaila, pharmacist) 
Almost all pharmacists echoed that they "learnt a lot from doctors". Being in the same setting 
with the physician provided the pharmacists with a unique inside look at how physician-
patient interaction happened. Not only did the pharmacist learn from the physician, they also 
found areas where they could improve counselling for patients. In addition to picking up skills 
from the physician, a further benefit from this setup was pharmacists taking opportunities to 
improve patient adherence by filling in the gaps that occurred during physician-patient 
interaction. 
It was also found to be convenient for the pharmacists and phYSicians to work as a team in 
making decision on patient's drug therapy. For example: 
Double check of drugs. Here our pharmacist will tell the doctor, 'This patient is 
already on this and that' ... The doctor will say 'Ok ... I'll cancel it or ok /'1/ add 
this'. 50 you see, they take away a big part of the doctor's role. So the doctor 
can see the patients for the other things and ... don't have to waste time 
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asking them these questions ... He (doctor) can concentrate on something else 
to ask the patients. (Manjit Kaur, nurse, endocrine clinic) 
Despite the fact that these pharmacists are now 'independent' (having their own 
clinic/counselling area), the exposure and 'training' happened while they were sharing a clinic 
with physicians. 
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4.4.1.3 Accessibility and timely delivery of service 
Most MTACs are strategically located next to the physicians' clinics and provided patients the 
convenience to access and consult the pharmacists. The main contribution of MTAC was the 
timely delivery of service that focused on effective utilisation of patients' waiting time. 
Patients were referred to pharmacists while they waited for their physicians' appointments 
and consequently patients waiting time was managed effectively. As one pharmacist 
mentioned: 
We will see the patients before they see the doctor to assess the patients' 
adherence, compliance, especially for the follow-up counselling. (Ruhaila, 
pharmacist) 
Another pharmacist reported that they would usually go to the clinic earlier than the doctors 
to see patients and at times patients were referred to them. 
We will go earlier than the doctor to the clinic and sometimes if there is too 
many patients and we can't really cover and see all the patients and those 
patients that the doctor thinks need to see the pharmacists first, then they will 
send them out for us. (Me; Ling, pharmacist) 
In addition, pharmacists were able to make immediate clinical recommendations and 
document pharmaceutical care issues in the patients' medical records before the patients 
were seen by their physicians. This helped the physician to take further action. The MTAC 
strategy of counselling patients while they waited to see the physicians was highly 
commended by health care professionals as patients do not have to spend additional waiting 
time at the outpatient pharmacy to consult the pharmacist there. However, it should be noted 
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that in most out-patient pharmacy settings, due to the high number of patients, pharmacist do 
not have the time to counsel patients in detail. 
Although they have pharmacists to do counselling (at the pharmacy), is this 
available for the patients at this time? Patients have to wait they have to go 
back to work ... and those are hours they don't get paid, 50 when they are here 
(MTAC) while waiting to see the doctor, they see the pharmacist, then 
everything is done. (Manjit Kaur, nurse, endocrine clinic) 
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4.4.1.4 Enhanced pharmacist-patient communication 
Enhanced pharmacist-patient communication was linked with a separate consultation area, a 
longer consultation period and regular follow-up counselling sessions. Pharmacists believed 
that pharmacist-patient communication was better as they had more time with the patients, 
and hence more in-depth information been gathered. In addition, pharmacists believed that 
patients felt more comfortable to share their thoughts and experience with the pharmacists 
when compared to their physicians. As one pharmacist narrated: 
Probably they don't tell the doctor, but they tell us a lot these days. (Elvin, 
pharmacist) 
Pharmacists reported that prior to having a separate counselling area of their own they used 
to counsel the patients in the physician's clinic for more than a year. It was viewed that such 
setting inhibited the patients from communicating openly. During the consultation with the 
physicians patients were seen to be rather quiet. It was thought that some patients feared 
that they might be reprimanded by the physicians if they were found to be non-adherent. For 
example: 
Actually our patients are more open to us. They can tell us whatever they have, 
I mean those problems and when they skip their medication or not comply or 
anything, they will actually tell us ... Because they scared if they tell the doctor 
they will get scolded, so everything they will tell us. And sometimes when we 
are short of room, we will sit together with the doctor and the patients will just 
keep quiet without saying anything, then when we go outside, they will start 
talking. (Mei Ling, pharmacist) 
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But one thing, if pharmacist sits with the doctor in the same room, patients 
don't seem to talk much. Compared to if pharmacist sits in their room, its 
better, the patients tells us more ... (RuhaiJa, pharmacist) 
The provision of structured patient education and regular follow-up counselling sessions by 
pharmacists were seen to be effective in building a good pharmacist-patient relationship. As 
one said: 
We actually have more in-depth information because we spend more 
time ... because they see us every month, become some sort of friends. (Elvin, 
pharmacist) 
Enhanced pharmacist-patient communication was observed when the pharmacists began their 
service in a separate clinic. Patients also showed a higher level of honesty in revealing issues 
related to adherence and that enabled pharmacists to provide more tailor made counselling 
for each patient. 
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4.4.1.5 Satisfaction 
Pharmacists narrated their experiences of running the MTACs with enthusiasm and 
satisfaction as they felt that their contributions were valued by patients and other health care 
team members. 
I think the doctors appreciate what we did so far. (Ruhailo, pharmacist) 
Some 0/ the patients have commented that phormacists are concerned about 
them and therefore they take more responsibility towards their problem. 
(Adilah, physician, endocrine clinic) 
Pharmacists were also seen to be able to contribute to disease management by reinforcing 
education. 
Yeah, I think it definitely improves patient care when we have the pharmacists 
here ... the pharmacists themselves can explain about the disease if we have 
not explain to the patients, diabetic education is reinforce at every step of the 
way ... when we see the pharmacists, besides having the adherence to the 
medication is reinforced, the diabetic education as a whole gets reinforced. 
(Adilah, physician, endocrine clinic) 
The extended role of pharmacists in conducting the MTACs was well received in improving 
medication adherence. Both Adilah and Manjit Kaur reported that patients had informed them 
that they were satisfied with the service provided by the pharmacists. Patients were seen to 
be more adherent to their treatment. For example: 
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Some of the patients have commented that they would like to come back to 
the clinic. Few minutes when they (patients) are with them (pharmacists), I 
think they appreciate that and compliance is better and follow up is better, 
they do not default compared to other clinic. (Adilah, physician, endocrine 
clinic) 
After a few counselling sessions, I mean previously, the first time we saw them, 
their sense of compliance may be 20 or 30% but by the second visit most of 
them almost 100% compliant. So , think counselling is very important. (Mei 
Ling, pharmacist) 
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4.4.2 Potential roles of pharmacists in the management of T8 and OM 
4.4.2.1 Educate and counsel patient 
Health care professionals believed that pharmacists could playa role in promoting adherence 
to TB treatment by providing patient education and counselling . 
... we can inform the patient the importance of taking TB drug because some of 
them are not taking TB drugs properly even with DOT because some of them 
in the clinic, they give one week one week supply ... some of them do not know 
the importance of TB drug or they just come to collect the medication and go 
back. Maybe the pharmacists have to educate about TB drugs ... Because we do 
have HIV patients with TB but then they defaulted TB treatment and died 
because of TB. (Ruhaila, pharmacist) 
They con start of by educating patients about drugs, and then the compliance, 
side effects (Rahmat, physician, chest clinic) 
Although TB education is delivered by the nurses, pharmacists are expected to be able to 
provide education and counselling related to comorbidities management and resolve 
medication-related issues. 
I think they should be involved. Only thing is that, like I said if it is just TB alone, 
shouldn't be a problem. My people can actually educate the patients ... If they 
have other problem, I think the pharmacists are very important. Comorbidities, 
drug interactions and side effects (Rahmat, physician, chest clinic) 
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Nurses felt that they were capable to manage TB but they lacked the knowledge in providing 
information regarding medication for comorbidities. 
Information about drugs, like the diabetes medicines ... We are not so 
knowledgeable you know, sometimes when the patients enquire we are not 
that sure. We ask the doctor, when we know we tell them, sometimes we are 
scared that we may give the wrong information. (Ros, nurse, chest clinic) 
Because some patients are taking so many medicines, for hypertension, 
diabetes, heart case. Sometimes when the patients ask, we do not know about 
the other medicines. For TB, it is ok, we have the charts to refer to, but the 
others we do not know much. (Rohana, nurse, chest clinic) 
When pharmacists were asked whether they have ever counselled TB patients who have 
comorbid conditions, some described their experiences of managing TB patients with 
comorbid DM and HIV. 
Mei Ling: We do have a few, patients who were admitted in the ward, then 
when doctors check, it seems that they have this TB, then they will maximize 
their treatment and everything and then the patients will be sent to the chest 
clinic. 
Interviewer: So the chest clinic will look after them rather than the endocrine 
Mei Ling: Yes 
Interviewer: Ok. And same for HIV or? 
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Ruhaila: For me I'll see more cases of HIV with TB ... I think pharmacist if they 
want to do something with TB patients, it's because of the toxicity of the TB 
drug is a lot, can cause hepatitis. This is something that we can start or do 
something, monitor the side effects, educate patient, drug interactions 
because TB drugs got interactions with some other drug also. 
Interviewer: Do they interact with the HIV drug? 
Ruhaila: Yes, they do. Ok like rifampicin, pyazinamide, ethambutol and 
isoniazid can cause hepatotoxicity, if you give together with nevirapine, which 
can also cause hepatitis it can worsen the liver function, so it's contraindicated 
to be given together. So we have to give the efavirenz. But since rifampicin is 
cytochrome P450 inducer, we actually have to cut the efavirenz, instead 0/. .. we 
have to give ... 
Interviewer: Quite complex 
Ruhaila: Hmmm ... yeah and then of course with the protein inhibitors, they 
have interactions as well, so if the patients are having TB, PI group is 
contraindicated as well. Or if we have to give the PI, then we have to increase 
the dose ... something like that. 
Interviewer: So it's quite complicated. And I think pharmacists will be a good 
person for this, yeah 
Ruhaila: Yeah and I think pharmacists should do that. 
Interviewer: So the diabetes people with TB, do they have problem with 
adherence because they have multiple medicines? 
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Mei Ling: But from those patients that I've seen in the ward, when they are 
first diagnosed with TB, very uncontrolled blood sugar, we will go for insulin 
first and once the control is very wen they switch back to oral. 
When pharmacists were asked about how pharmacists could contribute in the management of 
T8 and OM, pharmacists proposed the MTAC model. 
Ruhaila: As for me, I know that we can help from what we have done earlier. 
50 I think we can do something like MTAc... The pharmacist will be there to 
promote adherence, provide education and ... 
Interviewer: 50, how do you propose this MTAC to be carried out? 
Mei Ling: We can do it monthly 
Ruhaila: Monthly visit is suitable, they will want to see you ... lf we see the 
patient every week, it's tough and time consuming. 50 every month we can see 
the progress 
Interviewer: But TB patients come to clinic every day, it's a different dynamic 
isn't it? 
Cheng: Probably we can have a meeting once a week, something like that. 
Because they are coming every day they can a/ways drop by to see us. We can 
talk to the doctors and inform that pharmacists could help like that. 
Pharmacists believed that MTAC could be a good model that could be adapted for the 
pharmaceutical care management of T8 and OM. 
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4.5 Discussion 
This exploratory study has unveiled a number of pharmaceutical care issues related to TB and 
OM from the patients' and health care professionals' perspectives. It has also provided some 
insights into the perceptions held by health care professionals with regards to pharmacist-led 
MTAC clinics and the potential role of pharmacist in the management of TB and OM. The 
following discusses the key findings of this study. 
Nausea and vomiting were the most commonly reported adverse effects that bothered TB and 
OM patients. Although, nausea and vomiting have been reported to be common adverse 
effects of TB treatment, a physician in this study confirmed that a higher incidence of nausea 
and vomiting were seen in TB and OM patients when compared to TB only patients. OM 
patients are more likely to have gastroparesis (delayed stomach emptying) that could induce 
nausea and vomiting (Park. M. I. & Camilleri, 2006). Metformin is also known to cause 
gastrointestinal problems (Bolen et aI., 2007; Campbell, et aI., 1996). As such, TB and OM 
patients might be at increased risk of developing nausea and vomiting due to the complex 
interplay between the underlying pathological condition and the combined adverse effects of 
both TB and OM treatment. 
Besides nausea and vomiting, patients reported several other adverse effects (e.g. visual 
disturbances, painful toes and ankles) that may have not caught the attention of the 
physicians. This was evident when one of the physicians regarded nausea and vomiting to be 
the only problem associated with TB and OM while another physician reported that he was 
not aware of any adverse effects that was commonly seen in TB and OM patients. While some 
TB and OM patients may not have any specific adverse effects they may have some additional 
problems that may increase the risk of them developing adverse effects to medication. For 
example, complications in OM patients such as retinopathy could also potentiate the risk of 
developing adverse effects. A number of patients in this study had history of cataract surgery 
which might have been attributed to OM. Although all TB patients need to have their visual 
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acuity checked prior to the administration of ethambutol, failure to ask about the history of 
cataract surgery and the failure to document past medical history in patients' medical record 
may put the patients at risk of developing preventable adverse effect. This was obvious when 
one of the patients in this study with a history of cataract surgery reported blurring of vision 
due to ethambutol. This problem was detected by the patient's eye physician and 
recommendation to stop ethambutol was made. Patients may not disclose their past medical 
and medication history if they were not asked about it. Another patient in this study reported 
that he developed symptom that was similar to gout when he started TB treatment. However, 
he was not asked about his past medical history and he did not disclose his problem to his 
physician. This patient's gout could have been precipitated with the use of pyrazinamide. 
Therefore, health care professionals will need to be extra vigilant when it comes to managing 
TB patients with comorbidities. There is a recognised need for a thorough medication review. 
The patients who experienced adverse effects of medication in this study learnt to cope with 
the medication or attempted to alleviate the adverse effects particularly nausea and vomiting 
by not taking their TB and OM medication together or administering medication with some 
food. One physician reported scheduling TB treatment to be administered at night to reduce 
the severity of nausea and vomiting. likewise, another study conducted with HIV patients 
reported that patients eventually learnt to adjust their medication regimen in response to 
adverse effects like nausea and vomiting and developed strategies for alleviating the problem 
on their own or in consultation with their doctor, such as taking the medication at night 
(Remien et aI., 2003). It is clear that patients need to be reassured to continue with their 
treatment and suggestions to reduce the severity of adverse effects are a necessity. 
Besides having to take multiple medicines for TB, patients in this study were also on multiple 
medicines for OM and other comorbidities. Although fixed-dose combinations of T8 
medication may solve some of the burden of multiple medicines, they were not widely 
prescribed in the hospitals studied during the study period. The burden of consuming multiple 
medicines remains a major challenge to concomitant treatment. Concurring with the findings 
of this study, others had reported that patients have difficulties in consuming multiple 
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medicines on an empty stomach (Gebremariam, Bjune, & Frich, 2010; Hansel, et aI., 2004; 
Marra, et aI., 2004) and some were afraid of taking mUltiple medicines as some patients 
associated a high number of medicines with potential harm to the body and a higher risk of 
not tolerating the drugs (Gebremariam, et aI., 2010; Townsend, et aI., 2003). 
Despite receiving medication with their names labelled on their packages, the majority of 
patients in this study were unable to name their medication. However, they were able to 
describe their medication based on shape and colour. A national survey on the use of 
medicines by Malaysian customer revealed that more than half of the respondents were 
unable to identify their medicines trade or generic name (Pharmaceutical Services Division., 
2009). Low health literacy level and language barriers could also be a hindrance for patients to 
confidently discuss their concerns about medication with their physicians. Patients may feel 
inferior in terms of their knowledge and may not express their concern. The reason patients 
do not discuss issues with their physicians included embarrassment, assuming that the topic 
was less important, lack of trust and lack of time (Mohd Ali, 2009; Piette, Heisler, & Wagner, 
2004). It is highly recommended that physicians spend more time discussing medication 
concerns with patients. 
A number of patients in this study had not disclosed some of the adverse effects experienced, 
the use of traditional or herbal remedies and some of their past medical and medication 
histories to their physicians. There is a need for increased awareness among health care 
professionals to enquire about alternative practices used by patients according to their 
cultural background (consumption of traditional/herbal remedies) and the potential drug 
interactions or complications that may arise due to these practices. A study on the use of 
complementary and alternative medicine among patients with chronic diseases at outpatient 
clinics in Malaysia revealed that more than 60% of patients were using some form of 
complementary medicines and more than half of them were using them for OM (Hasan, 
Ahmed, Bukhari, & Wei Loon, 2009). It is important for health care professionals to ensure 
medication safety and recognise potential drug-herb interaction. 
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A synthesis of qualitative studies on medicine taking revealed that patients do not take their 
medication as prescribed because of concerns about the medication IPound et aL, 2005). 
Some patients in this study self-modified treatment regimens without informing their 
physicians. Previous studies have shown that people make decisions that they believe to be 
rational, based on their values, beliefs, and knowledge about medicines, their conditions; and 
the need to perform daily activities IBenson & Britten, 2002; Gordon, et aL, 2007; Pound, et 
aI., 2005; Stack, 2009).Thus, health care professionals were recommended to find out patient's 
perception towards medication, that is, whether medication taking is uncomplicated or they 
have fears about it IBritten, 1994). Although other studies have cited that patients usually 
wish to discuss disease and personal therapy experiences with their physician and emphasise 
their intention to actively participate in the treatment process IRohrbacher, Marx, Schaufler, & 
Schneider, 2009), only a few patients in this study emphasised the need to discuss medication-
related issues with their physician. Similarly, physicians reported that patients do not usually 
complain about their medication-related problems to them and believed that they would have 
probably complained to the nurses as they provided DOT. On the other hand, patients might 
have felt that physicians knew better about their treatment and might not have raised their 
concerns unless they were asked about it. Some patients have been described as 
demonstrating a 'passive' expectation that health care professionals should be responsible for 
decisions about medication (Lawton, et aL, 2008). Physicians are highly regarded and patient-
physician relationships are generally based on the faith that patients have in their physicians 
and that the physicians know what is the best treatment for their patients. Within this 
continuum, either patients may limit themselves from expressing some of their medication-
related problems or physicians may underestimate the patients' ability to communicate in 
greater depth with them. 
Furthermore, patients in this study see their physicians by appointments and the out-patient 
clinic is usually crowded. Longer consultation period is required in order to provide patient 
centred-care (Beisecker & Beisecker, 1990). Lack of physician-patient communication due to 
time scarcity is often blamed to be the barrier to patient care. In order to provide more time 
per patient, more health care workers and team-based approaches are needed IDunn, 2003). 
Although, patients were found to communicate better with nurses, there are possibilities of 
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patients' medication-related problems not being recognised by the nurses due to knowledge 
gaps. As such, pharmacist should be considered as part of the team to resolve medication-
related problems. In fact, this study also provided evidence that pharmacist-led MTAC 
provided patients an opportunity to communicate their medication-related concerns more 
effectively due to longer consultation period and continuity of care. 
Despite experiencing adverse drug reactions and having concerns about consuming mUltiple 
medication, most patients in this study appeared to be motivated to continue taking their 
medication especially TB medication. Almost all patients reported feeling better after taking 
their TB medication and this had encouraged them to adhere to the treatment. This finding is 
consistent with other research, which suggests that patients' adherence to medication is 
positively associated with the patient's beliefs about the benefits of taking the drugs (Benson 
& Britten, 2002; Gebremariam, et aI., 2010; Munro, et aI., 2007; Naidoo, et aI., 2009; Noyes & 
Popay, 2007). Other studies have also shown how patients' adherence was compromised due 
to the believe that TB is incurable, or the treatment was not working, or preference for 
alternative treatment such as traditional medicine (Edginton, Sekatane, & Goldstein, 2002; 
Gebremariam, et aI., 2010; liefooghe, Baliddawa, Kipruto, Vermeire, & De Munynck, 1997; 
Munro, et aI., 2007; Noyes & Po pay, 2007; Rowe et aI., 2005). The present study showed that 
patients who perceived the benefit of traditional medicines or remedies continued taking 
them in conjunction with TB and OM treatment. This indicates the importance of enquiring 
about the use of traditional medicines and documenting it in patients' medical record. 
Conversely, except for some patients acknowledging that they sometimes forgot to take their 
OM medication, issues related to adherence to OM medication or the necessity of OM 
medication were not extensively expressed by patients. It is assumed that patients talked 
more about TB compared with OM due to the symptomatic nature of TB disease as compared 
to the silent disease of OM (Murphy & Kinmonth, 1995) and also due to the complex nature of 
TB management that involves DOT. Moreover, the patients were interviewed at the chest 
clinic. 
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Although DOT was perceived to be effective, flexible, provided the opportunity for better care 
and promoted peer support, some reported it to be inconvenient due to the need for daily 
attendance at the chest clinic. However, health care professionals in this study were in favour 
of DOT while some patients preferred self-supervision. Previous study have shown that self-
supervision was the preferred option by most people (Noyes & Po pay, 2007). A review of 
randomised controlled trials, comparing DOT with self administrations of therapy, provides no 
evidence that the routine use of DOT in low and middle income countries improves cure or 
treatment completions in people with TB (Volmink & Garner, 2006). Strategies based on self-
treatment can be strengthened by support and supervision by an identified relative or 
neighbour, or through other social structures. TB control programmes that leave the choice of 
DOT supervisor to the patient have been shown to be successful (Adatu et aI., 2003). As 
suggested by Noyes & Popay (2007), there is a need for patient-centred programmes rather 
than single world-wide intervention like DOT. 
In fact, DOT may not be the gold standard in some conditions. For instance, in this study, a 
physician reported that DOT was not suitable for TB and OM patients who developed severe 
nausea and vomiting as different treatment strategy was recommended and the supervision of 
family members were required. Health care providers in other studies stated that patients 
found DOT to be the most burdensome aspect of the treatment, intrusive and an imposition 
on lifestyle (Hansel, et aI., 2004). Health care professionals in this study acknowledged that 
patients may have the additional burden of attending multiple clinics besides DOT. Similarly, 
DOT was found to be particularly challenging for TB and HIV patients because of physical 
demands and economic constraints; and because further attendance to the clinic for anti-
retroviral treatment were required (Gebremariam, et aI., 2010). Therefore, it was 
recommended that TB and HIV clinics should work in collaboration (Gebremariam, et aI., 
2010). There is an identified need for an integrated management of TB and OM in order to 
reduce the burden of attending mUltiple clinics. 
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It was found that health care professionals from the respiratory department responded 
ambiguously on matters related to the treatment of OM in TB patients. They believed that 
they could handle patients with "simple OM" and the "difficult ones" were left to the OM 
experts. On the other hand, health care professionals from the endocrinology department 
confirmed that they only see TB patients occasionally upon referral. However, they believed 
that TB and OM patients should be receiving similar OM treatment and periodical evaluation 
that are scheduled for OM patients. There were some similarities between the perceptions of 
physicians from the chest and endocrine clinic concerning the poor acceptability of insulin 
injections among patients. However, the physician from the endocrine clinic argued that TB 
and OM patients could be persuaded to use insulin due to the possibility of poor glycaemic 
control. This indicates that TB patients with poorly controlled OM may benefit from insulin 
therapy but might not been receiving insulin due to the lack of confidence among chest 
physicians in managing 'difficult OM'. Furthermore, this issue could be further compounded 
due to the lack of communication between TB and OM care provider with regards to OM 
management in a health care system which is fragmented due to single disease management 
system. 
Poor coordination between health care providers arises because of the common practice of 
single disease management across specialties (Elliott, et aI., 2007; Struijs, Baan, Schelievis, 
Westert, & van de Bos, 2006). To overcome this problem, health care profeSSionals from the 
chest and endocrinology department should work together to coordinate treatment and also 
to help early detection of TB in OM patients or vice versa. It has been recommended that OM 
care programmes should be integrated with other chronic diseases care programme to meet 
the complex health care demand of OM patients with other comorbidites (Struijs, et aI., 2006). 
Some comorbidities such as cardiovascular diseases are known to be associated with OM due 
to their shared pathophysiological nature and therefore, it is incorporated into diabetes 
management programmes and clinical guidelines (Caughey et aI., 2009). However, there are 
limited guidelines to facilitate the care of concomitant non-related diseases in OM patient 
(Caughey, et aI., 2009), as in the case of TB and OM. Comorbidities interfered with patients' 
capacity to manage their medication and adhere to medication regimen (Jowsey, et aI., 2009). 
Ongoing, regular discussion with patients about their medication is required, and for patients 
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with comorbidities, this requires integration and coordination of care across specialties 
(Bayliss, Edwards, Steiner, & Main, 2008; Elliott, et aI., 2007; Gijsen, et aI., 2001; Jowsey, et aI., 
2009; Smith & O'Oowd, 2007). 
The fact that both TB and OM were diagnosed late in most of the patients in this study is a 
huge concern. Patients only presented to the hospitals when they could no longer tolerate 
symptoms, such as severe coughing. Almost all patients knew that something was wrong but 
none of the patients said that they suspected TB. Late treatment seeking behaviour 
corresponded to delayed diagnosis of TB. Some reported that they first sought treatment for 
cough from private clinics and pharmacies which also contributed to the delay in accurate 
diagnosis. This could have a potential impact to public health as TB and OM patients have 
worse clinical presentation as compared to TB only patients. Most of the patients also 
reported that they were diagnosed with OM when they presented to the hospital for some 
other problems and in some patients complications of OM had set in prior to being diagnosed. 
It has also been reported that late treatment seeking behaviour were commonly seen among 
TB (The Star, 2011) and OM patients in Malaysia (Rampal, et aI., 2010). This indicated lack of 
awareness in patients with regards to symptom recognition as well as the importance of 
regular medical check-ups. 
It was also found that some patients in this study associated the diagnosis of TB with risk 
factors such as smoking. Unfortunately, very few patients knew that OM was one of the 
contributing factors for TB infection. Lack of understanding could lead to lack of acceptance of 
the disease. In this study, one patient had put his family at risk by not referring them for TB 
screening. Denial about the illness could also lead to delayed diagnosis of TB. It is not clear 
whether some patients were not aware about the importance of TB treatment or they were 
worried about being stigmatised. The fact that some patients tended to be secretive about T6 
as reported by the nurses could be attributed to stigma. However, none of the patients in this 
study reported any issues about stigma as compared to the nurses. This issue was not 
explored as a main topic in the interviews and that could be one of the reason of why stigma 
was not reported. 
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This study provided an opportunity for pharmacists and other health care professionals to 
discuss their experience in relation to the existing pharmacist-led MTACs. MTACs were found 
to be strategically located and were able to overcome some barriers (e.g. long waiting time) in 
health care services by incorporating features of accessibility and timely delivery of care. 
Having MTAC beside the physician's clinic promoted convenient access to patients and eased 
communication between physicians and pharmacists. Innovations in access to care had been 
cited to be an important component in providing patient-centred care (Berry, Seiders, & 
Wilder, 2003). Pharmacist-led MTACs were well received by the health care professionals and 
pharmacists were able to provide pharmaceutical care services. Pharmacists suggested that 
MTAC could be adapted to provide pharmaceutical care service to TB and OM patients. 
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4.6 Strengths and limitations of the study 
The strengths of this study lies in the unique nature of this investigation as it is the first to 
explore the experiences of both patients and health care professionals in managing TS and 
OM. Furthermore, it is also the first to highlight the views held about pharmacist-led MTAC in 
Malaysia. 
The use of a qualitative methods in this study were also unique with regards to a 
pharmaceutical care study whereby pharmaceutical care needs were indirectly assessed based 
on patients' and providers' experiences. The findings of this study were beneficial in the sense 
that it assisted in developing the next phase of the study. 
The use of focus group discussion with pharmacists allowed group interactions that facilitated 
and generated more discussion that may have not been possible if an interview was 
conducted. My supervisor who is an experienced qualitative researcher moderated the focus 
group. As she was not a local pharmacist, the questions raised were responded in-depth by 
the pharmacists, which may have not been attained if I was the moderator. This could be due 
to the perceived understanding that I already knew about the role of pharmacists in Malaysia. 
As such, it was a good strategy to have my supervisor to conduct the session. However, 
towards the end of the focus group discussion, the pharmacists were interested to find out 
about the role of pharmacists in the UK from my supervisor. As the main issues had been 
discussed, the slight diversion from the topic guide did not impact the data. 
This study is limited by the participation of a small number of the health care professionals 
because they were the only ones involved with the care of the patients where this study was 
conducted. In addition, out of five physicians and five nurses approached, three physicians 
and three nurses participated. Two nurses and two physicians were unable to turn up for their 
interviews due to other work commitment. With regards to pharmacists, four pharmacists 
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who were actively involved in DM, HIV and in-patient management participated in this study. 
Although the number of health care professionals could have been increased by recruiting 
others from different hospitals, it was not done due to time limitation. Nevertheless, health 
care professionals in this study provided a rich description of their opinion which is the most 
important aspect in qualitative research as compared to sample sizes. Furthermore, this study 
provided the basis for the next phase of the study which is the development of a 
pharmaceutical care programme for TB and DM patients in the same hospital. Therefore, it is 
more logical to recruit health care professionals from the same hospital rather than mUltiple 
hospitals. 
Conversely, patients were recruited from four government hospitals (the main hospital where 
the health care professionals were recruited and three other district hospitals) within the 
same state. The reasons for including patients from different locations were due to the 
recommendation by the nurses and the invitation from the chest physicians to participate in 
their weekly district hospital visits. The patient sampling strategy that was dependent on the 
nurses for identification of patients with TB and DM led to a limited number of patients 
identified in the main hospital. The nurses suggested that they knew their patients well and 
will be able to refer them for this study. However, in reflection, some patients may have been 
missed especially if nurses fail to enquire about the presence of OM in TB patients. 
Furthermore, newly diagnosed DM patients may not know that they have OM unless the 
nurses go through each TB patient's medical record to screen for DM from the laboratory 
investigations. Although the strategy of screening patient's medical record was proposed, it 
was considered a waste of time as the nurses informed me that not all patients were on DOT 
at that particular hospital as some patients go the nearest health clinic for DOT. As such, I 
relied upon the nurses to assist me in identifying and recruiting patients for this study. The 
first few interviews were all among older Chinese patients. However I wanted to interview 
patients from other ethnic group as well. According to the nurses, the population near the 
main hospital were predominantly Chinese and that the chances of recruiting Malay and 
Indian patients may be higher in the district hospitals. Therefore, I followed the physicians and 
nurses to those hospitals during their weekly visits and I managed to recruit Malay and Indian 
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patients. Nevertheless, Malay and Indian patients were also recruited from the main hospital 
at the later stages of the study. 
This study may have been limited by the small number of female patients but the experiences 
shared were similar to male patients. On the other hand, patients were also largely middle-
aged, married and teetotal men which could have impacted the generalisability of the findings 
to a certain extent. Although the study started with a purposive sampling strategy, it was 
converted to convenience sampling due to time constraint. Furthermore, it was a challenge to 
recruit patients with a specific cluster of comorbid condition as well as with different 
characteristics within a short period of time. Nevertheless, efforts were taken to include 
patients from different ethnic background as it was important to look at cultural differences in 
medicine-taking behaviour. 
Having understood that there might be a possibility of missing some of the patients with TB 
and OM, the sampling strategy that relied on the nurses to identify patients were not used in 
the next phase ofthe study as I wanted to determine the prevalence of OM in TB patients. 
Instead, individual screening of all TB patients' medical records were performed. 
The participants of the focus group discussion were all actively involved in pharmaceutical care 
activities and as such, they may have held stronger opinions on the subject matter. 
Nevertheless, having recruited a homogenous group of pharmacists allowed in-depth 
exploration with regards to pharmaceutical care issues. 
As this was a cross-sectional study, the views presented were based on the participants' 
memory, knowledge, experience and feelings at that point of time. Whether similar accounts 
can be reproduced if they were to be interviewed again is unknown. 
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This study provided the experiences of patients presenting to government hospitals whereby 
TB and OM treatment were rendered free of charge and therefore the findings cannot be 
generalised to patients presenting to private hospitals or clinics as they may have different 
array of issues and concerns. 
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4.7 Reflection 
Upon personal reflection, I believe that my background as a pharmacist could have impacted 
the way patients and health care professionals responded. Some of these aspects had been 
discussed in section 3.11.1. 
The interviews were conducted in a hospital environment which might have led to more 
socially desirable answers as far as patients are concerned. Interviewing them at home might 
have been a better option, but considering the safety and the infectious nature of TB, this 
decision was not taken. In fact, I wore a mask when I conducted the interviews at the hospital. 
Initially, I felt awkward when I had to wear the mask and interview patients but after 
sometime I realised that patients did not find it as an issue as all health care professionals at 
the clinic were wearing masks. Some patients especially those who were newly diagnosed 
wore their masks while they were being interviewed. In one case, I had to reschedule the 
interview to a later date as the nurses advised me that the patient was highly infectious and it 
would be better to interview him after a month of treatment. 
I had the chance to observe the clinic setting at the district hospital and found that it provided 
better environment for interviewing patients. It was less busy as compared to the main 
hospital and a counselling room was available at the clinic. I used the counselling room to 
conduct my interviews at the district hospitals. However, at the main hospital, I had to use any 
of the empty physician's or nurse's room to conduct the interviews. It was much easier to 
conduct the interviews at the district hospitals as compared to the main hospital. 
None of the patients approached declined to be interviewed. Generally, patients in Malaysia 
have high regards about health care professionals and they might have felt that it was impolite 
to decline. Nevertheless, I gave patients the choice of when they wanted to have their 
interviews. Except for one, all the other patients preferred their interviews to be held on the 
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same day they were approached. In fact, one patient stated that he felt good that he could 
help me by agreeing for the interview. The patient believed that he was doing me a favour by 
participating in the study. 
154 
4.8 Connecting Phase 1 to Phase 2 
Findings from this study were used to develop the research proposal for the following phase. 
It was concluded from this study that there was a need for a pharmaceutical care 
management for patients suffering with both TB and OM. 
The pharmaceutical care needs of TB and OM patients were interpreted based on the patients' 
and health care professionals' experiences of managing TB and OM. The main themes that 
emerged centred on the concerns about medications and the management ofTB and OM. It 
was then construed that there were needs to: 
1. Monitor adverse effects of medications 
2. Help patients manage multiple medications 
3. Address patients' concerns about medications 
4. Motivate and promote adherence to treatment 
5. Advocate the importance of early treatment seeking behaviour 
6. Conduct a thorough medication review and improve documentation of patients' 
medical and medication history 
7. Create opportunities for patient and health providers for communication 
8. Find ways to integrate the management of TB and OM 
9. Enquire about self-management and the use of traditional remedies. 
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Therefore, phase 2 study would need to cover all the nine needs that have been identified. 
Pharmacist-led MTACs can be used as a model for designing a pharmaceutical care 
programme. The following chapter discusses the development of the phase 2 study. 
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CHAPTER 5: METHODOLOGY AND METHODS (PHASE 2) 
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5.1 Introduction 
This chapter describes how the phase 2 study was carried out. It begins with the description 
on the development of the phase 2 study. Then, it presents the research methodology, 
describes the data collection methods, explains how the data was analysed and discusses how 
validity and reliability of the phase 2 findings can be assessed. 
5.2 Objective 
The objective of the phase 2 study was to investigate the feasibility of providing a 
pharmaceutical care service for patients with TB and OM. 
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5.3 Development of Phase 2 study 
5.3.1 Developing the study proposal for Phase 2 
Based on the knowledge gained from the phase 1 study, a proposal for phase 2 was 
developed. The initial plan was to conduct a prospective pretest-posttest single group study. 
Each TB and OM patient would undergo an initial assessment which would include a 
medication use review and a structured interview with a pharmacist. 
The pharmacist would cover all the relevant pharmaceutical care needs that have been 
identified in phase 1. Then an individualised pharmaceutical care plan would be prepared, 
peer-reviewed and then discussed with the clinicians for agreement. Patients would then be 
followed up by the pharmacist for a total of five visits (week 1, week 2, week 4, week 8, week 
12). 
A second assessment would be conducted 12 weeks from the initial interview to examine 
whether the pharmaceutical care issues that were identified had been resolved and to assess 
the outcome measures of the study. The outcome of the study includes the pharmaceutical 
care issues that were identified throughout the study period and the changes in the clinical 
parameters from initial to final assessment. 
The changes in patient's beliefs about medicine would be assessed by using the beliefs about 
medicine questionnaire. Other assessments would include the changes in clinical measures 
such as the HbA1C, sputum conversion, chest-x-ray, blood pressure and total cholesterol. 
159 
5.3.2 Discussion with other health care professionals 
A preliminary discussion regarding the findings of the phase 1 study and the proposal for 
phase 2 was held with a physician from the chest clinic. He suggested that feedback should 
also be obtained from a wider panel of experts, in particular other medical staff from the chest 
clinic, through an oral presentation. 
He said that he would make arrangements to give continuous medical education (CME) pOints 
to the attendees in order to encourage the health care professionals to attend the 
presentation session. In addition to the health care professionals from the chest clinic, the 
pharmacists and the health care professionals from the endocrine clinic who participated in 
the phase 1 study were also invited to attend the session. 
Subsequently, letters of invitation for the presentation were sent to all health care 
professionals who participated in the phase 1 study (see Appendix 9). The physician helped to 
inform the rest of the health care professionals from the chest clinic. The health care 
professionals were informed that the presentation was going to be held at the chest clinic 
during lunch break and that lunch was going to be provided to all the attendees after the 
presentation. A total of 30 health care professionals (physicians, pharmacists, nurses, 
pharmacy PhD students, medical assistants) attended the session but no one from the 
endocrine clinic attended. 
The title of the oral presentation (power point) was 'Exploring the need for pharmaceutical 
care management of T8 and DM: a qualitative study'. The findings of the Phase 1 study and a 
brief explanation on the proposed Phase 2 study were presented. The presentation was half 
an hour long and was followed by a 15 minute 'question and answer' session. Informed 
consent was obtained from all attendees in order to video the presentation and 'question and 
answer' session. 
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Issues highlighted and discussed 
Five main issues were raised and discussed during the 'question and answer session', 
1. OM medications 
• Which antidiabetic drug (gliclazide or metformin) induced vomiting when 
administered concomitantly with TB medications? 
• What was the cost-effectiveness of short-term insulin usage in TB and DM 
patients? 
• Some chest physicians were unsatisfied with hospital guidelines imposed on 
insulin prescription. They reported that they did not have the authority to 
prescribe insulin pens as these were items restricted to prescription only by 
endocrine specialists. They argued for a shared authority in view of higher 
acceptability for insulin pen (versus needles) among patients. 
• Some physicians perceived that patients disliked any form of injections. 
161 
2. Language barriers 
• One physician requested for a pharmacist of Chinese ethnicity to provide the 
pharmaceutical care service. He informed that many patients were from the 
Chinese ethnicity, hence there could be language barrier if only non-Chinese 
speaking pharmacists were available. 
• One pharmacist commented that non-Chinese pharmacists should also learn 
some key words in Chinese language to communicate. 
• The variety of different dialects used among Chinese patients also caused 
difficulties for even the Chinese-speaking pharmacists who did not speak a 
particular dialect. 
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3. Stigma 
• Physicians commented that TB is still a stigmatised disease. One physician 
reported an incident that happened on that day. "A 17-year-old Chinese girl was 
diagnosed with TB. She has to sit for her SPM exams next week. You know about 
the Chinese, the moment they know somebody has TB in school they will not 
send their children to school. So I spoke to the class teacher. I said look here 
there is one student in your class who has TB, the minute you see anybody 
coughing, please refer them to me. I don't want any chaos because I know that 
exams are going on." He emphasised that pharmacist should take note about 
stigma when providing pharmaceutical care. 
• Another physician shared her experience of a lady who started crying when she 
was diagnosed with TB. Apparently, the lady was worried about how her family 
members would react and how she would be treated. She explained that it was 
important to counsel patients and their family members accordingly. 
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4. Involvement of pharmacists 
• One pharmacist reported that the hospital pharmacists may not be able to 
fully participate in the study due to their high workload. Furthermore, 
pharmacists might be reluctant to go through the bureaucracy of securing 
permission from the chief pharmacist to participate in this study. 
• Another physician suggested the researcher to conduct the study instead of 
relying on the hospital pharmacists. 
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5. T8 and OM education 
• One pharmacist suggested that a booklet aimed at providing TB and OM 
education could be designed and distributed to patients. 
• Another physician suggested a video based group education programme where 
TB and OM patients could be invited to view the video. 
The presentation and the 'question and answer' session allowed the researcher to interact 
with the health care professionals and provided an opportunity to discuss the plans for the 
phase 2 study. 
Following the discussion, the protocol of the phase 2 study was refined. The researcher's 
participation in this study was inevitable. Another pharmacist of Chinese ethnicity was invited 
to be involved in the study. 
Issues related to OM medications and stigma was considered during the provision of 
pharmaceutical care. However the recommendation to provide insulin pens was not 
appropriate since physicians in the chest clinic are not authorised to prescribe it. Instead, they 
could make recommendation to admit the patient and initiate insulin in the ward. 
Although it was thought that the booklet and video based education were potentially good 
suggestions, these were not incorporated into the phase 2 study due to financial and time 
constraints. 
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5.4 The methodology of phase 2 study 
Phase 1 study and the discussion held with the health care professionals helped to identify the 
components that need to be embedded in a pharmaceutical care service. However, there 
were other factors that need to be considered in order to determine the feasibility of 
providing the service. Further 'modelling' or fact finding as described in the UK MRC 
framework was required. Therefore, the revised phase 2 study focussed on the processes of 
developing a pharmaceutical care service. 
The following were the research questions for phase 2 study. 
• How can I estimate the number of patients who would require the service? 
• How can I recruit patients with TB and OM? 
• How can I follow-up patients? 
• How can I collaborate with the hospital pharmacists? 
• How can I obtain patients' clinical information? 
• How can I provide the pharmaceutical care service? 
• How can I identify medication-related problems? 
• How can I classify and document medication-related problems? 
• How can I assess adherence to medication? 
• How can I assess whether patients have different sets of beliefs about medications 
with regards to T8 and OM medication? 
• How can I influence changes in patients' behaviour towards medicine-taking? 
• How can I access physicians' response towards pharmacists' recommendation? 
As the research questions take the form of 'How do I understand what I am doing? How do I 
improve it?', and place the emphasis on the researcher's intent to take action for personal and 
social improvement (McNiff & Whitehead, 2006), action research methodology was employed. 
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5.4.1 Action research 
Action research is a style of research rather than a specific method (Meyer, 2000). It provides 
the flexibility needed in research that aimed to bring change (Tanna, 2005) and it has been 
used within pharmaceutical care research (Gilbert, Roughead, Beilby, Mott, & Barratt, 2002; 
Tanna, Pitkin, & Anderson, 2005). For example, Tanna, et. al. (2005) used action research 
methodology to develop the role of specialist menopause pharmacist in the UK. The approach 
allowed reflective practice, enabling the specialist menopause pharmacist to be both the 
service delivery provider (the intervention) and the researcher. 
Action research is conducted in a systematic manner (McNiff & Whitehead, 2006), whereby 
the action plan is to 
• take stock of what is going on 
• identify a concern 
• think of a possible way forward 
• try it out 
• monitor the action by gathering data to show what is happening 
• evaluate progress by establishing procedures for making judgements about what is 
happening 
• test the validity of accounts of learning 
• modify practice in the light of the evaluation. 
Action research implies that the nature of 'knowing' relies on the experience of doing and 
'knowing' is seen to be embedded within the cycles of action and reflection (Ladkin, 2007). 
Knowledge is not derived from one theoretical proposition, but gained from an extended 
epistemology that includes multiple ways of knowing. The epistemology of action research 
include experiential knowledge, practical knowledge and presentational knowledge (Ladkin, 
2007). 
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In short, action research involves the process of 'observe - reflect - act - evaluate - modify-
move in new directions' which is generally known as the action-reflection cycle (McNiff & 
Whitehead, 2006). 
The application of action research methodology in phase 2 study 
The study would begin by taking stock of what was going on at the chest clinic and the 
subsequent process in the action research cycle would follow spontaneously. 
For example, first, this study required the participation of the researcher and the need to 
collaborate with the hospital pharmacist. It was important to assess how the researcher who 
was an 'outsider pharmacist' could collaborate with the hospital pharmacist ('insider 
pharmacist') and other health care professionals to facilitate the provision of a new service. 
The researcher would need to experience 'working' in a new environment, find ways to initiate 
the service and improve service through experiential learning. There was also a need to assess 
the acceptability of pharmacists' recommendations by patients and physicians. 
Second, the researcher would need to find out about other practical issues like patient 
recruitment, follow-up arrangement and the availability of space for patient education and 
counselling at the clinic. For example, it was important to know the prevalence of DM in TB 
patients at the chest clinic in order to make better prediction of the number of patients 
(sample size) who would attend the proposed pharmaceutical care service. This information 
would allow the estimation of additional practice hours required to provide the service. 
Finally, pharmacists would need to address the nine pharmaceutical care needs that were 
identified in phase 1 study. For example, pharmacists would identify and resolve medication-
related problems by assessing patients' adherence to medication, patients' beliefs about 
168 
medication, problems related to prescriptions and by addressing patients' concerns about 
medication. The researcher would then reflect on the process of service delivery and whether 
it was possible to improve the management of TB and DM. 
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5.5 Methods 
5.5.1 Ethical Approval 
This study received ethical approval from the Ministry of Health, Research and Ethics 
Committee, Malaysia (reference number: NMRR-09-463-4064) (See Appendix 10). 
5.5.2 Study setting and duration 
The study was conducted at a tertiary public hospital in the northern region of Peninsular 
Malaysia from November 2009 till February 2010. 
5.5.3 Estimation of sample size 
The sample size for this study was estimated based on the preliminary data (preliminary 
observational study) whereby nearly 23% (n=7) ofTB patients had DM. Almost SO patients 
were newly-diagnosed with TB at the chest clinic every month. Therefore, about 10 patients 
would be most likely to present with OM every month. Since the study was conducted for 3 
months, a sample size of 30 patients was estimated. 
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5.5.4 Source of data 
The source of data varied from medical registers, medical records, observations, interviews, 
questionnaire and informal discussions. Some of the data such as patients' clinical information 
were obtained from medical records prior to the provision of service, whilst other data were 
obtained during the consultation session. 
The research process and procedures are summarised in Figure 5-1. 
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Patient Recruitment Pharmacist Collaboration 
Identification numbers (10) of newly Chief pharmacist were approached and 
diagnosed TB patients were obtained information about the project was 
from TB register informed 
-t J, 
The IDs were written down and passed to A meeting was arranged in order to give 
the staff for the retrieval of patients' further information to the chief 
medical record pharmacist and a senior pharmacist 
-t t All the medical records were screened to 
identify TB patients with OM A pharmacist was seconded by the chief 
pharmacist to assist in the project 
-t t Patients with TB and DM were recruited 
with the nurses' assistance The pharmacist was briefed about the 
project in two meetings 
-t t Patients were informed about the project 
and patients who were interested and The pharmacist agreed to provide 
those who were able to participate were pharmaceutical care service 
recruited. Written informed consent was 
-J 
obtained 
The pharmacist/researcher conducted 
-t V 
medication review and interviewed 
patients for further information. 
The researcher reviewed patients' 
medical records and filled in relevant data ~ ~into data collecting forms and filed them 
in individual patient folders. Then, the Pharmaceutical care 
folder was passed to the pharmacist issues were identified and 
pharmacist intervened 
Ba'eUne .::.::: l\ when necessary (e.g provided education and counselling, referred 
to DM medications The researcher arranged V patients for further were assessed using the patients' follow-up management, made 
the MMAS-8 scale visits dosage modifications) 
and beliefs about 
medications were 
assessed using BMQ 
questionnaire t 
The process and outcome 
of the pharmaceutical 
care interventions were 
documented by the 
pharmacist and the 
researcher 
Figure 5-1 Research Process 
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5.5.5 Patient identification and recruitment 
In order to identify potential patients for this study, all TB medical records from July 2009 till 
February 2010 were screened to identify patients with OM using the list of TB patients 
obtained from the T8 register. The patients' identification number were noted and sent to the 
TB record office. The staff retrieved all the medical records, which were then reviewed to 
confirm eligibility. T8 patients with a previous history or a new diagnosis of OM and who had 
been receiving diabetic medications were eligible to participate. Although the study began in 
November 2009, patients who had started their treatment as early as in July 2009 were 
included because they were still undergoing treatment during the study period hence 
considered eligible to partiCipate. 
After identifying the potential patients, patients were recruited by checking whether the 
patients were having their DOT at the hospital's chest clinic or in other health clinics. If they 
were not having DOT at the clinic, they would be recruited during their next follow-up clinic 
appointments. The follow-up dates were identified from patients' medical records. Patient's 
names were given to the nurses and they assisted the researcher in recruiting the patients. 
Then, the patients were approached by the researcher and were informed about the study. 
Those who were interested to participate were recruited. A patient information leaflet was 
given (see appendix 11) and written informed consent (see appendix 10) was taken. 
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5.5.6 Collaboration with a hospital pharmacist 
The hospital's chief pharmacist was approached and informed about the proposed project. 
Subsequently, Alan (pseudonym) a hospital pharmacist, who is Chinese, was seconded by the 
chief pharmacist to assist with the project. 
Then, Alan was briefed about the project in two meetings that lasted approximately two hours 
each. The pharmaceutical care needs ofTB and OM patients which were identified in the 
previous study were explained. Recent literatures on T8 and DM were provided for his own 
reference. Alan had been providing pharmaceutical care service to chronic obstructive 
pulmonary disease patients and he had pre-established working relationship with other health 
care professionals from the chest clinic. Alan requested the researcher to be present when he 
delivered the service especially during the initial stages of the service. 
The pharmaceutical care project was meant to follow the seven practice steps suggested by 
Hepler and Strand (Hepler & Strand, 1990). The steps are (1) establishment of a pharmacist-
patient relationship; (2) patient data collection, analysis and interpretation; (3) finding out 
medication-related problems; (4) establishing therapy outcomes and goals together with the 
patient; (5) setting possible pharmacotherapy alternatives and selecting the best plan, 
preparing a monitoring plan; (6) implementation of the individual pharmacotherapy regimen 
and monitoring plan; (7) follow-up. 
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5.5.7 Documentation of patients' clinical information 
Upon obtaining patients' consent, the researcher documented all relevant patient information 
from the patients' medical records prior to the patients' appointments with Alan. The data 
was filled in a data collecting form (see Appendix 13). Information filled in the data collecting 
form included treatment centre, demographic data, social history, past medical history, past 
medication history, current medications (including TB treatment regimen), traditional 
medicine/herbal/supplement, current history of TB episode, TB classification, laboratory 
investigations, medication-related problems/pharmaceutical care issues, medication-therapy 
problems to be resolved and the pharmaceutical care plan. 
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5.5.8 Assessment of self reported adherence to medicine-taking 
Patients' self-reported adherence to OM medications (at baseline) was assessed by using the 
translated version of Morisky 8-item medication adherence scale (MMAS-8) (Morisky, Ang, 
Krousel-Wood, & Ward, 2008). This tool was developed through modification of a previously 
validated four-item MMAS (MMAS-4) (Morisky, Green, & levine, 1986) and was found to be 
more reliable and explored additional behavioural features than MMAS-4 (Morisky, et aI., 
2008). The MMAS-8 was used as this questionnaire is commonly used to assess adherence in 
Malaysia. Self-reported questionnaires are thought to give a good estimation of medication 
adherence (Shi et aI., 2010). 
The method for coding the scale is detailed in a copyrighted document which was obtained 
from the scale's developer.2 The first seven items involves a yes or no response. The final 
survey item consists of 5-point Likert Scale. The total summary score ranges from 0-8. Patients 
were considered to be high adherers if the total score is 8, medium adherers if the total score 
is between 6 and less than 8, and low adherers if the total score is less than 6. 
Besides using the translated version of MMAS-8, adherence to medication throughout the 
study period was also assessed through other methods like patient interviews and tablet 
counts (if patients brought their medicines with them). 
Adherence to TB medications was not assessed using the translated MMAS-8 questionnaire as 
adherence could be assessed based on their daily attendance for DOT. 
2 Coding Instructions for the © Morisky Medication Adherence Scale (S-item) was obtained from Prof 
Donald Morisky. 
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5.5.9 Assessment of patients' beliefs about medicines 
Patients' beliefs about the necessity and concerns regarding TB and OM medications were 
measured using the translated version of Beliefs about Medicines questionnaire (BMQ) 
(Horne, Weinman, & Hankins, 1999). This questionnaire has been developed and validated in 
patients with chronic illness, and was found to have good psychometric properties. 
The questionnaire consists of two 5-item scales assessing patients' beliefs about necessity of 
medications and their concerns about the potential outcomes of taking it (Horne & Weinman, 
1999). Response options are provided as a 5-point Likert scale (1=strongly disagree to 5= 
strongly agree). The scores from the individual items within each scale are added to give a 
scale score. The total scores for necessity and concerns scales range from 5-25 points. The 
necessity-concerns differential is derived from deducting the concerns score from the 
necessity scores. The possible scores that can be achieved ranges from -20 to 20. A positive 
score indicates greater necessity or need for the medications, and a negative score indicates 
greater concerns about the medications. This differential can be regarded as a cost-benefit 
analysis. Patients' perceptions of cost (concerns) are weighed against the perceptions of 
benefit (necessity beliefs). 
The BMQ and MMAS-8 were translated into Malay language because most patients did not 
understand written English. The translation was verified by one of my supervisors. In fact, 
there is a validated Malaysian version of the MMAS-8 which was also done in Malay language 
and was tested in Malay, Chinese and Indian patients (AI-Qazaz et aI., 2010). However the 
validated Malaysian version of MMAS was not available for use when this study was 
conducted. Nevertheless, there was not much difference between the translated version of 
MMAS-8 that was used in this study and the validated Malaysian version of MMAS-8. 
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The translated Malay versions of the MMAS and BMQ were not self-administered by patients 
taking part in this study because some of them were not able to read. Therefore, in order to 
maintain consistency in how the tools were administered, the researcher read the items of the 
questionnaires in a face-to-face interview with all patients. This method was also used during 
the validation ofthe translated version of the eight-item MMAS in Malaysia (AI-Qazaz, et aI., 
2010). 
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5.5.10 Provision of pharmaceutical care 
After collecting patients' clinical information, patients' appointments for the pharmaceutical 
care consultation with Alan were arranged. Patients were requested to bring along their 
medications to their first visit with Alan. Alan conducted the initial assessments which include 
medication reviews and interviews. Whenever, Alan was not around due to other important 
obligations, the researcher provided the service. 
The medication-related problems were identified by assessing problems related to the 
prescriptions (e.g. adverse drug reactions, drug interactions), problems related to patient 
factors (e.g. patients' behaviour and attitude towards medications, beliefs and concerns about 
medications) and problems related to procedural/organisational factors (e.g. DOT). Details of 
the observation, assessment and interventions were recorded in the data collection form. 
Following the initial assessment, a pharmaceutical care plan was designed by Alan, reviewed 
by the researcher and suggestions or recommendations were discussed with physicians 
treating these patients when necessary. If there was more than one patient at the same time, 
then the responsibility of providing the service was shared between the researcher and Alan in 
order to reduce the patient's waiting time. 
Patients were educated and counselled on the management of TB and OM during their first 
visit. Some of the medication-related concerns were addressed during the consultation and 
some were communicated to their physicians. Subsequently, some of these patients were 
followed up for a total of four visits, in order to monitor safety and effectiveness of the 
treatment. In some occasions, telephone follow-up calls were made if they did not turn up for 
their follow-up visits. 
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Alan and the researcher met each week during the study period to reflect on the 
pharmaceutical care management of these patients (e.g. lessons learned and the barriers in 
providing optimal care). 
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5.6 Data management and analysis 
Data was analysed using Statistical Packages for Social Sciences (SPSS) version 16.0; SPSS Inc, 
Chicago, IL, USA. Descriptive statistics were used to analyse patients' demographic, clinical 
characteristics and the scores for MMAS-8 and BMQ. Examination of the distributions of the 
necessity, concerns and necessity-concerns differential of total score of MMAS-8 and the BMQ 
revealed the data to be suitable for non-parametric analysis. Frequencies were used for 
categorical variables, while means and standard deviations were calculated for continuous 
variables. Wilcoxon Signed Rank Test was used to examine whether patients' beliefs about TB 
medications were different as compared to beliefs about OM medications. The internal 
consistencies of the scales were assessed using Cronbach's alpha. Some of the data (e.g. 
observational notes) were thematically analysed using the computer software package, NVivo 
qualitative data analysis software; QSR International Pty Ltd. Version 8, 2008. 
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5.7 Validity 
Validity of action research based studies can be judged based on the following criteria: 
• whether the work is participatory 
• whether it is aimed at change 
• whether it involves movement between reflection, action and evaluation 
It is also argued that the inclusion of multiple ways of knowing should be a key criterion for 
validity assessment (Reason & Bradbury, 2001) and one of the most important arbiters of 
action research is the usefulness of the study (Ladkin, 2007). 
Action research should feature both research and practice outcomes and it should give rise to 
theoretical insights as well as health care practice development that could be generalised to 
other settings (Waterman, Tillen, Dickson, & de Koning, 2001). 
As action researchers are intensively involved in the research process at mUltiple levels and in 
multiple roles, it has been suggested that action researchers utilise critical friends (peers or 
colleagues) or a validation team to defend their ongoing findings (Herr & Anderson, 2005). 
Critical friends often encourage researchers to make explicit what they may understand on a 
more tacit level (Herr & Anderson, 2005). Due to the intensity of the research process, critical 
friends can help action researchers to step back in order to understand what they are seeing 
and doing(Herr & Anderson, 2005). 
This strategy has been used in this study as weekly meetings were conducted with Alan 
(hospital pharmacist) to discuss and reflect upon the research activity and the findings. The 
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findings were also presented to the researcher's pharmacy colleagues and the feedback and 
questions posed challenged some of the opinions and allowed the researcher to look at the 
data in a different perspective. 
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5.8 Ethical issues 
5.8.1 Anonymity and confidentiality 
The names of all participants were removed, and pseudonyms were assigned. Due to the small 
number of health care professionals in the chest clinic, they stand a higher chance of being 
recognised. Therefore, the hospital's name is not mentioned in this study. All data were stored 
in a locked cabinet at the researcher's office. 
5.8.2 Informed Consent 
Written informed consent (see Appendix 12) for participating in this study was obtained from 
each patient prior to the start of any research activity. 
The findings and discussion of phase 2 study are presented in Chapter 6. 
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CHAPTER 6: PHARMACEUTICAL CARE SERVICE FOR PATIENTS 
WITH TB AND OM: A FEASIBILITY STUDY (PHASE 2) 
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6.1 Introduction 
This chapter presents the findings and discussions of the phase 2 study. It begins with the 
prevalence of OM in TB patients in the hospital. Subsequently, it describes the patients' clinical 
characteristics followed by the pharmaceutical care issues and interventions. The chapter ends 
with the discussion of the feasibility of providing pharmaceutical care service to TB and OM 
patients. 
6.2 Patient socio-demographic characteristics 
Of the 356 T8 patients' medical records screened, 53 patients were identified to have OM. The 
prevalence of OM among these TB patients was found to be 14.9%. Out of 53 patients 
identified, 35 patients participated in this study. The remaining 18 patients could not 
participate because: 
1) two patients passed away 
2) one patient declined to participate (he was not interested as he had received 
counselling from the diabetic clinic) 
3) one patient had a diagnosis of schizophrenia and was unable to participate 
4) two patients had end-stage renal disease and were admitted in other wards 
5) eight patients failed to turn up for their appointments 
6) four patients were not on OOT (Their TB medication was supplied weekly as they were 
older patients (>80 years) or too ill to come in for daily OOT and their medication was 
collected by a family member) 
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The characteristics of 35 patients with both TB and DM are provided in Table 6-1. The study 
patient's mean age was 52 years (range 29 -73 years) and the feasibility study involved 22 
male and 13 female patients. The majority of the patients were Malays (n=13), followed by 
Chinese (n=l1) and Indians (n==9). There was one patient each from Indonesia and Thailand. 
Twenty-nine patients were married. Out of the 17 patients who had ever smoked, 15 patients 
were current smokers and two patients were ex-smokers. Six patients consumed alcohol 
occasionally (e.g. during festive season). One patient was an intravenous drug abuser. Out of 
those employed, 10 of them did manual jobs (e.g. carpenter, construction worker, farmer). 
The remaining five were a policeman, factory manager, self-employed business man, clerk and 
chef. 
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Table 6-1 Socio-demographics of patients with TB and OM (n=35) 
Patient characteristics Number of patients 
*Range of age, mean ± so 
Gender 
Male 
Female 
Ethnlcity 
Malay 
Chinese 
Indian 
Others 
Social history 
Ever smoked 
Alcohol consumer 
Intravenous drug abuser 
Marital status 
Single 
Married 
Occupational status 
Employed 
Unemployed 
Retired 
29-73years, 52.2 ± 10.6 years 
22 
13 
13 
11 
9 
2 
17 
6 
1 
6 
29 
15 
17 
3 
This is range of age and age (mean and standard deviation) rather than number of patients 
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6.3 Patient clinical characteristics 
Patients' clinical characteristics include the classification ofTB and OM, presence of 
concomitant diseases, past medical or surgical history and complications related to OM as 
detailed in Table 6-2. 
The majority of patients (n=32) were diagnosed with pulmonary TB, of which two had a 
relapse of pulmonary TB and one patient had a recurrence of pulmonary TB due to previous 
history of defaulting TB treatment. The majority of patients had type 2 OM (n=34). In most 
cases, OM preceded TB. Twenty-nine patients had other concomitant diseases besides TB and 
OM. Six patients had undergone cataract surgery. 
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Table 6-2 Clinical characteristics 
Characteristics Number of patients 
Classification of TB 
Pulmonary TB 32 
Extrapulmonary TB 2 
Pulmonary TB and extra pulmonary TB 1 
Classification of OM 
Type 10M 1 
Type 2 OM 34 
Concomitant diseases· 29 
Hypertension 13 
Hyperlipidemia 5 
Ischemic heart disease 3 
Gastritis 2 
Hepatitis C 2 
HIV positive 2 
Chronic active hepatitis 1 
Chronic renal failure 1 
Chronic sinusitis 1 
Deep vein thrombosis 1 
Hyperthyroidism 1 
Primary antiphospholipid syndrome 1 
Relevant past medical/surgical history 
Cataract surgery 6 
Previous pulmonary TB 3 
Amputations due to OM 2 
Stroke 2 
Upper gastrointestinal bleed 1 
Some patients had more than one disease 
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6.4 Patient's TB and OM treatment regimen 
The number and types of medication prescribed for TB and OM are listed in Table 6-3. 
Most patients (n:::26) were treated with the conventional single dose of TB medication. The 
remaining nine patients received fixed-dose combinations of TB medication. OM was mainly 
treated with oral hypoglycaemic agents. In addition, patients were taking an average of three 
medicines for concomitant problems. 
Patients in this study were at risk of potential drug-drug interactions due to the use of multiple 
medicines. For example, rifampicin could reduce the glucose lowering effects of glibendamide 
and glidazide. Other drugs that had a potential to interact with rifampicin were warfarin, 
efavirenz, lovastatin and nifedipine. 
191 
Table 6-3 Number and types of medication 
Medication N 
Number of medication for TB, range (mean ± SO) 
Number of patients on T8 treatment" 
EHRZ 
Akurit (Fixed dose combination therapy) 
HRZ 
SEHRZ 
H & Ofloxacin 
Number of medication for OM, range (mean ± SO) 
Number of patients on OM treatment 
Gliclazide and metformin 
Gliclazide 
Gliclazide, metformin and insulin 
Metformin 
Insulin 
Acarbose, metformin and insulin 
Glibenclamide 
Number of other medication for concomitant diseases, range 
(mean ± SD) 
Number of patients on other medicatlonb 
Lovastatin 
Perindopril 
Aspirin 
Metoprolol 
Frusemide 
Nifedipine 
Efavirenz 
Isosorbide dinitrate 
Lam ivu d i ne!Zidovud i ne (Combivir) 
Ranitidine 
Others' 
"All patients were given pyridoxine 
bSome patients had more than one medication 
2-6(4.1 ± 1.3) 
18 
8 
6 
1 
1 
1-4 (1.7 ± 0.9) 
12 
10 
4 
3 
2 
1 
1 
1-7 (3.4 ± 1.9) 
14 
9 
8 
4 
3 
3 
2 
2 
2 
2 
2 
1 
, Amlodipine, Atenolol, Atorvastatin, Azathioprine, Chlorpheniramine, Clopidogrel, Diclofenac sodium, Enalapril, 
Glycine/aspirin(Cardiprin), Hydrochlorothiazide, l-Thyroxine, Magnesium trisilikat, Pottasium chloride, Prednisolone, 
Telmisartan, Terazosin, Ticlopidine, Tramadol and Warfarin 
E ethambutol, H Isoniazid, R Rifampicin, Z Pyrazinamide, S Streptomycin 
192 
6.5 Pharmaceutical care issues and subsequent interventions by 
pharmacists 
Patients with TB and OM presented with many medication-related problems. Five main issues 
identified were: (1) non-adherence, (2) uncontrolled OM, (3) adverse drug reactions, (4) 
absence of monitoring parameters, and (5) other medication-related problems. The 
information pertaining to the five main issues is summarised in Table 6-4. Although the 
findings are presented separately according to the five main issues, most patients had a 
combination of these issues. 
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Table 6-4 Pharmaceutical care issues 
Medication-related problems* Normal range Mean ± SO N 
Non-adherence 
Non-adherence to TB treatment 
Non-adherence to non-TB treatment 
Uncontrolled OM 
Fasting plasma glucose 
Random blood glucose 
HbA1c 
Adverse drug reactions** 
Itchiness 
Vomiting 
Dizziness 
Peripheral neuropathy 
Gastrointestinal disturbances 
Joint aches/gout 
Vision disturbance 
Nausea 
liver impairment 
Absence of monitoring parameters at 
baseline*** 
HbA1c 
Blood pressure 
Lipid profile 
Hematology test 
Renal function test 
Liver function test 
Other medication-related problems 
3.5-6.7 mmol/I 
4.0-8.0 mmol/I 
4.0-6.0 % 
*Many patients had more than one medication-related problem 
"Some patients experienced more than one reaction 
* "Some patients had a combination of unmonitored parameters 
9.6 ± 3.5 mmol/I 
13.2 ± 4.7 mmol/I 
9.4± 2.7% 
3 
10 
29 
24 
12 
12 
29 
16 
12 
10 
8 
6 
3 
3 
2 
2 
23 
13 
12 
10 
1 
1 
34 
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6.5.1 Non-adherence 
Baseline self-reported adherence to OM medication 
Baseline self-reported medication adherence behaviour of study participants to OM 
medication are presented in Table 6-5. Cronbach's alpha test of internal consistency was 0.794 
for the translated version of MMAS-S. 
Based on the translated version of the MMAS-8 for OM medication, 20 patients were low 
adherers, eight patients were medium adherers, and seven patients were high adherers. 
More than half of the patients (19/35) reported that they sometimes overlooked taking their 
OM medication, and 11 patients reported that they left behind their medication when they 
travelled (see Table 6-5). Fifteen patients reported that they did not take their medication on 
certain days within the last two weeks before the interview. However, 28 patients reported 
that they took their medication the day before the interview. Eleven patients reported 
discontinuing their medication when the treatment led to unwanted or adverse effects. Four 
patients discontinued treatment when they felt that their OM symptoms were under control. 
Twelve patients reported feeling hassled to stick to their treatment plans. 
A study by AI- Qazaz et al. (2010), which had used the similar tool in measuring adherence to 
OM medication showed comparable findings whereby only the minority of OM patients in 
Malaysia were found to be high adherers. Nevertheless, self-reported medication adherence 
tools are not without limitations as it relies on patient's memory and the skills of the 
interviewer in eliciting patient's response. 
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Table 6-5 Self-reported medication adherence behaviour of study participants to OM 
medication as determined by the translated version of MMAS-8 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Number of 
Item patients who 
Do you sometimes forget to take your diabetes medicine? 
People sometimes miss taking their medicines for reasons other 
than forgetting. Thinking over the past two weeks, were there any 
days when you did not take your diabetes medicine? 
Have you ever cut back or stopped taking your diabetic medicine 
without telling your doctor because you felt worse when you took 
it? 
When you travel or leave home, do you sometimes forget to bring 
along your diabetic medicine? 
Did you take all your diabetic medicine yesterday? 
When you feel like your symptoms are under control, do you 
sometimes stop taking your diabetes medicine? 
Taking diabetes medicine everyday is a real inconvenience for 
some people. Do you ever feel hassled about sticking to your 
treatment plan? 
How often do you have difficulty remembering to take all of your 
diabetes medicine? 
a) Never/rarely 
b) Once in a while 
c) Sometimes 
d) Usually 
e) All the time 
answered yes 
(n=35) 
19 
15 
12 
11 
28 
4 
12 
19 
6 
8 
1 
1 
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Since patients were also taking other medication for comorbidities, adherence to those 
medication were assessed through patient interviews and tablet counts (for those who 
brought along their medication) during the consultation sessions. The translated version of 
MMAS-8 was not used to assess adherence for other comorbid condition as it was impractical 
to repeat the questionnaire for all their medication. In fact, patients were more comfortable 
to respond spontaneously in a casual discussion. Furthermore, patients were able to justify 
their reasons for non-adherence. For documentation purposes, patients who were found to be 
non-adherent to OM and other comorbid condition were categorised as non-adherent to non-
TB medication. 
Ten patients stopped taking their treatment for non-TB medication when they had started 
their TB treatment. The most common reason for non-adherence was the experience of 
adverse effects (e.g. giddiness and vomiting). Some patients were worried about consuming 
multiple medicines (e.g. HIV patients and patients with multi-morbidities). Forgetting to take 
medication and self reduction of the number of medication was also reported. 
Below are some examples to illustrate the above. 
• Saranya, a 58-year-old Indian woman asked 'Why should I inject insulin when I am not 
eating?' She highlighted that she had poor appetite and she had stopped taking all her 
medication except for her TB medication after experiencing giddiness. 
• Rahman, a 68-year-old Malay man brought all his non-TB medication which was kept 
in a bag. Similar to Saranya, he also said that he experienced giddiness and therefore 
stopped taking his medicines. None of his non-TB medication was found to be 
consumed. 
• Sivalinggam, a 40-year-old Indian man with multiple medicines believed that he had 
developed allergy (swelling of the face) and adverse effects (severe vomiting and 
headache) which led him to stop all his medication except for his TB medication. 
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None of these patients had informed their physicians that they had stopped taking their 
medication. We (Alan and I) provided education and counselling to address their concerns and 
to promote adherence to treatment. We emphasised the importance of taking all the other 
medication in addition to TB medication. We referred some of the patients to their physicians 
with some recommendations and treatment was modified according to the patients' needs 
(e.g. drug that was perceived to cause allergy was substituted with other drug; patients 
concerned about their giddiness were counselled and some of them who reported not taking 
their breakfast were advised to have their meals after taking their medication). We followed-
up on some of these patients. They informed us that they had begun to take their medication. 
Furthermore, some even discussed problems or adverse effects that they had experienced 
with their medication. 
Non-adherence to TB treatment 
Two patients (Rosa, a 41-year-old Malay woman and Jamil, a 55-year-old Malay man) did not 
adhere to DOT prior to their participation in this study and one patient defaulted TB treatment 
during the study period due to adverse drug reaction. I identified the first two patients from 
their medical records and the nurses informed me that they have defaulted treatment. I 
contacted the patients and persuaded them to come to the clinic. 
• The next day, Rosa came for treatment. She was wheelchair-bound as her toes were 
amputated due to DM complications. She had difficulties coming for daily 
intramuscular streptomycin injections. She explained that she was adherent to TB 
treatment prior to the addition of streptomycin. I informed the physician about Rosa's 
problem. As a result of this conversation with the physician, streptomycin was 
discontinued. She resumed treatment with the HRZ (isoniazid, rifampicin, and 
pyrazinamide) regime. Her medication was packed weekly for her as she was not a 
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suitable candidate for DOT. Changing her treatment from SHRZ (streptomycin, 
isoniazid, rifampicin and pyrazinamide) to HRZ and combined with a weekly supply of 
medication allowed her to continue her treatment. 
• The nurses informed me that Jamil was known to be a frequent defaulter. They said 
that he had the 'couldn't-be-bothered' attitude about his treatment and asked my 
help to counsel him. In 2007, Jamil defaulted treatment after 7 months of TB 
treatment. He had a relapse of TB in 2008 and he defaulted treatment again after 3 
months. During the study period, he was found to be adherent for 3 months and he 
defaulted treatment for 3 days. He also admitted that he forgets to take his DM 
medication. I advised the importance of adherence to both TB and DM treatment and 
explained about the risk of developing MDR-TB given his previous history. He 
promised that he will continue his TB treatment. 
Beliefs about medications 
As adherence to treatment relates to patients' beliefs about medication, patients' beliefs 
about DM medicines and TB medicines were assessed using the translated Malays version of 
BMQ during their first visit. The internal consistency for Beliefs about Medication was tested 
for both beliefs for T8 and DM medication. Cronbach's alpha was 0.566 when the 
questionnaire was tested for TB whilst a higher value was seen when the same questionnaire 
was tested for DM (Cronbach' s alpha = 0.732). Patients' mean scores on the individual item of 
the BMQ with regards to TB and DM are presented in Table 6-6. 
Patients were more worried about taking TB medication as compared to DM medication and 
this was found to be statistically significant using the Wilcoxon signed-rank test (P= 0.01) 
(Table 6-6). Patients expressed more concerns about TB medication compared with DM 
medication and this was confirmed by the Wilcoxon-signed rank test (P= 0.01) (Table 6-7). 
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Necessity-concern differential was higher for OM medication as compared to TB medication 
(Table 6-7). 
Table 6-6 Scores on the Beliefs about Medicine Questionnaire with regards to TB and OM 
medication 
TB OM 
Beliefs about medicine questionnaire _ 
1. My health, at present, depends on my medicines 4.1 ± 0.7 4.1 ± 0.8 
2. Having to take medicines worries me· 3.0 ± 1.2 2.2 ± 1.0 
3. My life would be impossible without my 3.4 ± 1.1 3.4 ± 1.1 
medicines 
4. Without my medicines I would be very ill 3.6 ± 1.0 3.3 ± 1.2 
5. I sometimes worry about long-term effects of my 3.1 ± 1.1 2.9 ± 1.2 
medicines 
6. My medicines are a mystery to me 3.1 ± 1.0 2.7 ± 0.9 
7. My health in the future will depend on my 3.5 ± 1.0 3.5 ± 1.1 
medicines 
8. My medicines disrupts my life 2.6 ± 1.0 2.2 ± 0.9 
9. I sometimes worry about becoming too 2.7 ± 1.0 2.9 ± 0.8 
dependent on my medicines 
10. My medicines protect me from becoming worse 4.1 ± 0.9 4.0 ± 0.8 
·Wilcoxon signed-rank test (P=O.Ol) 
Scores were based on 5-point Likert scale (1= strongly disagree,S = strongly agree) 
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Table 6-7 Necessity, concerns and necessity-concern differential for TB and DM medication 
TB OM 
Scores • 
Necessity 18.6 ± 2.8 18.3 ± 3.9 
Concerns· 14.5 ± 3.6 12.9 ± 3.7 
Necessity-concerns differential 4.1 ± 4.4 5.4 ± 5.2 
·Wilcoxon signed rank test (P=O.Ol) 
Total necessity and concerns scores range from 5 to 25. 
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6.5.2 Uncontrolled OM 
Despite receiving OM treatment, 29 patients had uncontrolled OM. Baseline fasting plasma 
glucose, random blood glucose and glycosylated haemoglobin (HbA1c) levels were all above 
the normal range (Table 6-4). Only 12 patients had baseline HbA1c test results. Not all patients 
had their fasting plasma glucose or random blood glucose test recorded in their medical 
records. 
In order to optimise glycaemic control, the doses of oral hypoglycaemic agents were increased 
by their physicians. We influenced some of the decisions made by physicians which included 
alteration of the type of oral hypoglycaemic agents, dosage modifications of insulin and oral 
hypoglycaemic agents during the study. However, not many patients had regular blood 
glucose tests during their follow-up visits with their physicians at the chest clinic. What 
compounded the challenge in ensuring blood glucose tests were conducted was the 
expectation that this test would be done by anyone of the other care providers involved in the 
treatment of these patients. Other health care providers for OM included practitioners from 
the private and public health clinics. 
Although we made the recommendation to do regular finger-prick monitoring at the TB clinic, 
some physicians were in favour of fasting blood glucose tests. Waiting for fasting blood 
glucose test results led to a delay in making dosage adjustments in one patient and in initiating 
treatment for two newly diagnosed OM patients as these could not be done until a 
subsequent clinic visits. 
Initially, Alan requested the nurses to do a finger-prick monitoring and the nurses did it. It 
helped us to get a quick picture of the patient's OM condition. For example: 
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• We requested a nurse to do a finger-prick monitoring for Malar, a 58-year-old Indian 
woman. The blood glucose level was so high that no reading was shown on the 
glucometer. We referred Malar to the physician immediately. She was then examined 
and was admitted in order to normalise her blood glucose and followed by further 
investigations. 
However, after a couple of weeks the nurses reported that they will only consider doing the 
finger-prick monitoring if they were recommended by the physicians. That caused us some 
difficulties especially when patients who had seen us before had requested for finger-prick 
monitoring during their follow-up visit. For example: 
• A patient's daughter requested for a finger-prick monitoring to check her mother's 
blood glucose. She said that her mother's appetite had increased and she had not 
been compliant to her diet restrictions. I told her to inform the physician so that the 
test can be done. However, her request was denied. She was disappointed and she 
informed me that the physician said "If you want to check blood glucose you have to 
go to the diabetic clinic." This problem was one of the barriers that we encountered in 
this study. Alan was not around at that time and I was not in a position to impose any 
action. I could only observe and take note of what was going on. Later, I discussed the 
matter with Alan. We were both disappointed with the physician's lack of 
consideration and we decided that we will not request for the test anymore but speak 
directly to the physicians if necessary. 
• Zaman, a 52-year-old Malay, man informed me that he had checked his blood glucose 
in his OM clinic recently. He showed me a book and the result of fasting blood glucose 
was 31mmol/1. He did not bring along his medication with him and he did not know 
the name of his medication. However, he said that he was adherent to his treatment. 
Due to his high fasting blood glucose, I informed the staff nurse and suggested that 
this patient should be referred immediately. I followed the patients to the physician's 
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room. The physician's reaction surprised me. She blamed the patient for not being 
adherent to his medication without confirming with the patient whether he took his 
medication or not. She was confused about what to prescribe and she was unsure 
where the patient was being followed-up for OM (health clinic or hospital). In the end, 
she wrote a prescription and she asked me. "Are you the pharmacist managing this 
patient? Can you counsel him? Can you tell him to take his medication gliclazide 80mg 
bd and metformin 500mg bd for one week and then increase the dose of metformin to 
19 bd." The patient and his wife sat quietly throughout this. I was not in a position to 
explain much to the physician as she was a stranger to me and I to her. The clinic was 
busy and there was another physician in the same clinic attending to another patient 
resulting in lack of privacy. I felt there was no proper communication between the 
physician and patient. She requested the nurse to do a finger prick monitoring test 
and the result was 23mmol/1. The nurse thanked me for helping the patient by 
making a timely referral. However, I was unhappy about the whole incident and the 
way the patient was treated. Despite my personal feelings, I explained to the patient 
about the importance of adherence to the medication and diet. 
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6.5.3 Adverse drug reactions 
Twenty-nine patients experienced adverse drug reactions (Table 6-4). Many patients 
experienced a combination of adverse drug reactions. The most common ones were itchiness 
(n=16), vomiting (n=12), dizziness (n=10) and peripheral neuropathy (n=8). Some examples of 
the issues and interventions are presented below. 
• In order to counteract the adverse effects of treatment such as vomiting, one patient 
Mei Ling, a 57-year-old Chinese woman resorted to stopping TB medication on some 
treatment days. She experienced vomiting and she believed that her TB medication 
was causing it. Alan not only counselled her, he also highlighted Mei Ling's problem to 
her physician. The physician advised her to stop metformin and continue with 
gliclazide and insulin. However, 3 days later, Mei Ling was admitted due to severe 
vomiting and she was rechallenged. Alan advised her regarding the process of 
rechallenge. Finally, rifampicin was identified as the culprit and the treatment 
administration time was modified. Ethambutol, isoniazid and pyrazinamide were 
prescribed in the morning and rifampicin was given at night. 
• There was also a general concern that vomiting resulted in wastage of medication 
doses. Another patient Jamaludin, a 62-year-old Malay man said that he wanted to 
stop his TB treatment after two months as he questioned the effectiveness of his 
treatment as he kept on vomiting. I advised him to be patient and I also explained that 
he might end-up getting a relapse if he quits his treatment. 
• Chan, a 35-year-old Chinese man who was a newly diagnosed OM patient reported 
that he felt sick and vomited when he was given metformin. Alan referred Chan to the 
physician with a suggestion to change metformin to gliclazide. The physician agreed to 
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the suggestion and Chan's problem was resolved as he did not complain about 
vomiting during his follow-up visits. 
• Another patient, Mansur, a 49-year-old Malay man reported that he had severe 
episodes of vomiting which could not be controlled. He had tried to overcome it by 
taking breakfast. Mansur believed that he was 'charmed' and he sought help from a 
'bomoh' (traditional Malay healer). He showed me photographs of needles that have 
been removed by the 'bomoh'. He believed that the number of needles that were 
removed reduced after a series of therapies which corresponded to improvement in 
his health. He said that he had gained weight after going to the 'bomoh'. I encouraged 
him to continue his TB treatment regardless of his beliefs. I told him to inform the 
physician regarding the vomiting and he was prescribed metochlopropamide. 
• Eight patients reported symptoms that resembled peripheral neuropathy (pin-pricking 
sensation at the soles of the feet and numbness). Alan recommended increasing the 
dose of pyridoxine to 20mg in some patients and it was agreed by the physicians. 
• Rajan, a 55-year-old Indian man who was on mUltiple medicines complained about 
developing gout after starting TB treatment. He reported blurring of vision and 
experienced swelling of the knee. His uric acid level was elevated. He experienced 
pyrazinamide induced hyperuricemia which contributed to the gouty arthritis. He was 
diagnosed with gouty arthritis after completing two months of EHRZ (ethambutol, 
isoniazid, rifampicin, pyrazinamide) treatment. If the problem was detected earlier, 
pyrazinamide could have been withheld. Rajan could also be experiencing ethambutol 
induced vision disturbances. I advised him to tell his physician regarding the blurring of 
his vision. I wanted to monitor his liver function as he had underlying hepatitis but the 
test was not done by the clinic. 
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6.5.4 Lack of monitoring 
There were many parameters that lacked monitoring (see Table 6-4). Baseline HbA1C, blood 
pressure, lipid profile and haematology tests were absent in many patients' medical records. 
Lack of monitoring especially for OM and other multiple morbidities made it difficult to 
monitor the overall safety and effectiveness of the treatment at the chest clinic. Access to 
monitoring data was a challenge because laboratory investigation tests results were kept in 
different medical records and were not available at the chest clinic. For example, many 
patients were treated for hypertension and hyperlipidemia. However, blood pressure, lipid 
profile and liver function tests were not frequently checked or monitored at the chest clinic 
because the management was focused on TB. These data might be available at the OM or 
cardio clinic but there was no coordinated care between the TB and other health care 
providers. 
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6.5.5 Other medication-related problems 
Besides the first four main issues discussed above, many patients had a myriad of additional 
concerns about medication or medication-related problems that required individualised 
pharmaceutical care management. Examples of issues and interventions are discussed below. 
• Problems associated with the size of fixed-dose combination tablets 
Joanna, a 58-year-old Chinese woman reported that fixed-dose combination tablets 
were too big in size and she had stomach aches after taking them. She preferred to 
take the conventional single dose tablets even though she had to take a total of 13 
tablets. We referred Joanna to the physician and suggested to change her treatment 
to conventional TB treatment. The physician agreed and her prescriptions were 
altered. 
• Concerns about the effectiveness of medication 
Tan, a 51-year-old Chinese man sent me the following text message. 
"Hi, at certain days after taking T8 medicines my urine does not turn as orange as 
compared with other days. Is this normal?" I contacted Tan and discussed his concern 
over the phone. I reassured him that the colour of the urine does not really matter 
and it is not an indicator for treatment success and encouraged him to continue taking 
his medication. He thanked me and informed that the explanation made him feel 
better. 
• Preventing potential adverse drug reactions 
The examination of creatinine clearance revealed that three patients had low 
creatinine clearance. Of these, two were on metformin and we recommended 
reducing the dosage of metformin to prevent unwanted drug effects. 
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• Multiple medical and medication-related problems 
Matthew, a 46-year-old Indian man had DM for 10 years and presented with a relapse 
of pulmonary TB. He had a history of pulmonary TB and had completed his treatment 
in 2009. He had poorly controlled blood sugar and a diabetic foot ulcer. He was 
admitted in the ward in order to normalise his blood glucose. His random blood sugar 
level was very high and ranged from 14.4 to 23.6mmol/l. Insulin was initiated in the 
ward and the doses were increased to normalise his blood glucose. After a few days, 
insulin was stopped and he was prescribed with gliclazide 160mg bd and metformin 
250mg bd. His past medication history showed that he was on glibenclamide 5mg bd 
and metformin 19 bd. He was treated with a fixed-dose combination of anti-TB 
medication combined with streptomycin injections. When Alan visited him for the first 
time, he complained about dizziness and said he was concerned about having 
Streptomycin injections on a daily basis. Alan discussed about the possibility of 
hypoglycaemia and explained what he should do if he experienced dizziness. Alan also 
found out that he had both gibenclamide and glicazide in his possession and he was 
taking both. Alan told him to stop taking glibenclamide. He also reassured him about 
the streptomycin injections by stressing that it would only be administered for two 
months and this treatment is important as he was having a relapse. 
During the second follow-up visit, Alan was not around and I visited Matthew in the 
ward. His wife was present and she complained that her husband was non-compliant 
to diet as well as his DM medication in the past. This had resulted in his diabetic foot 
ulcer. Matthew expressed regret for taking his health for granted and promised that 
he will take his medication accordingly. He said 'I'm worried that I might die'. He also 
complained that he was having abdominal pain, constipation and was unable to lift his 
hand. I advised him about the importance of adherence to diet and DM medication. I 
clarified that he had developed complications due to DM and his relapse could be due 
to poorly controlled DM. Matthew replied that he was not aware that his DM 
condition could have caused a relapse of his TB. I reassured him that TB can be cured 
provided that he takes his TB and DM medication accordingly. As the physician 
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treating Matthew was not at the ward at that time, I informed a nurse regarding his 
complaints. 
Two weeks later, I made a telephone follow-up call and Matthew's wife informed that 
Matthew passed away due to cardiac arrest. Matthew was the only unfortunate 
patient in this study who passed way during the study period. 
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6.6 Discussion 
The prevalence of OM in TB patients was 14.9% (n=53) in this study. A study that was 
conducted in another setting in Malaysia reported a similar prevalence of 14.6% (Nissapatorn, 
et aL, 2005). A systematic review on bi-directional screening for TB and OM revealed that 
many countries had a wide range of OM prevalence in TB patients, ranging from 1.9% to 35% 
(Jeon et al., 2010). The wide range of OM prevalence in TB patients could be due to the varying 
degree of OM prevalence in different countries. One expert from the US Pacific Island reported 
that high prevalence of OM was seen in their setting and OM contributed to 42% of TB cases in 
the Northern Pacific (Brostrom, 2010). Increased prevalence of OM in urban areas in India was 
associated with a 15% greater smear positive TB incidence (Stevenson, et aI., 2007). The 
Malaysian National Health Morbidity Survey III (NHMS III), conducted in 2006 showed that the 
prevalence of OM in the general population was 14.9% in people above the age of 30 and 
more than 20% in people who were between the age of 50 and 79 (Letchuman, et aI., 2010). 
The survey indicated that the prevalence of OM in Malaysia almost doubled compared to its 
prevalence in 1996 which was at 8.6% in people above the age of 30. The increasing trend of 
OM prevalence in the general population could have a negative impact in TB control in 
Malaysia and a higher prevalence of OM in TB patients could be expected. 
The mean age of TB and OM patients in this study was 52 ± 10 years and in terms of gender, 
male patients predominated. Another study from Malaysia also reported similar findings with 
regards to age and gender (Nissapatorn, et aL, 2005). The present study did not compare the 
socio-demographic differences between TB patients with OM and those without. However, 
Nissapatorn et aL (2005) reported that TB and OM patients were older than TB patients 
without OM. 
One of the key findings of this study was to highlight the change in medication taking 
behaviour with regards to consuming non-TB medication on commencing TB treatment. The 
fact that more than half of the patients did not adhere to their OM medication after starting 
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TB treatment suggests that patients may be giving priority to one class of medication over 
another. In a qualitative exploration of multiple medicines beliefs of patients with comorbid 
DM and cardiovascular disease showed that patients undervalued their cardiovascular 
medications as compared to DM medications (Stack, Elliott, Noyce, & Bundy, 2008). 
Conversely, the findings in this study showed that patients had prioritised their TB medication 
when compared with non-TB medication. These findings also suggest that when a patient 
presents with comorbidities, practitioners need to understand which group of medicines is 
likely to be omitted by the patient and once this has been identified extra vigilance and 
support for adherence is needed. 
The fact that patients held different sets of beliefs for different diseases with the necessity-
concern differential for DM medication being higher compared to TB medications indicate that 
patients' adherence level differs. It has been postulated that medication adherence is 
influenced by necessity-concern differential in which beliefs about the necessity of prescribed 
medication are weighed against concerns about the negative effects of taking it (Horne & 
Weinman, 1999). Based on this hypothesis, it could be assumed that patients might be low 
adherers to TB medication when compared with DM medication as they have more concerns 
about TB medication. However, this was not true in this study because patients were found to 
be low adherers to DM medication as compared to TB. One plausible explanation for this is 
that the majority of TB patients were treated through DOT whereby adherence was enforced. 
Alternatively, in agreement with the hypothesis, it could be interpreted that these patients 
might be low adherers to TB treatment if they were to be allowed for self-supervision. In fact, 
some of the patients in this study were allowed for self-supervision and of these, one patient 
was found to have defaulted TB treatment due to vomiting. This indicates that patients weigh 
the risk and benefit of taking their medication and decide whether to adhere to their 
treatment or not. As such, DOT is still important to ensure adherence and to monitor adverse 
effects of medication but alone, it may not be sufficient. It has been recommended that 
supplementing DOT with other strategies like patient education, individualised patient care 
and follow-up, effective communication, adherence aids, educational materials and incentives 
could strengthen DOT programmes (Cohen, 1997; Grange & Zumla, 1997; Morisky et aI., 1990; 
Ormerod, 1999; WHO., 2003). likewise, pharmacists in the present study helped to promote 
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adherence to TB treatment by addressing patients' concerns and persuaded patients who 
defaulted TB treatment to continue treatment. 
Adverse drug reactions either experienced or perceived were one of the reasons for non-
adherence to treatment. This study not only identified patients who did not adhere to their 
treatment regimen but it also provided an opportunity to understand the reasons for non-
adherence. Furthermore, pharmacists managed to help patients cope with their treatment by 
making timely recommendations and addressing their concerns. Problems that bothered 
patients were the experience of vomiting, itching and other sensations that resembled 
peripheral neuropathy. Regular telephone follow-up calls made by pharmacists allowed 
patients to communicate their problems and some of these were resolved by referring them 
to their physicians as soon as possible without the need to wait for their next follow-up visit. 
Other studies have also shown that pharmacists were able to reduce non-adherence in 
patients with chronic conditions and meet patients' needs for information and advice on 
medicines through telephone follow-up calls (Clifford, Barber, Elliott, Hartley, & Horne, 2006; 
Clifford, Garfield, Eliasson, & Barber, 2010; Elliott, Barber, Clifford, Horne, & Hartley, 2008; 
Kassam et aI., 2001). 
Uncontrolled OM was a concern in this study as tight glycaemic control is important to fight 
any infectious condition including TB. Besides non-adherence to treatment, drug-drug 
interactions, drug-induced hyperglycaemia and stress due TB could all contribute to poorly 
controlled OM. The majority of patients in this study were treated with oral hypoglycaemic 
agents. Despite the increase in the doses of OM medication in some of the patients, it was 
difficult to achieve the targeted blood glucose level. Even those who were on insulin had their 
doses increased by pharmacists in this study in order to optimise their blood glucose level. 
Concurring with this finding, a study from Turkey reported that 11.4% of the first-time TB 
patients and 27.5% of MDR-TB patients had poorly controlled OM and pharmacist's 
intervention resulted in the correction of hyperglycaemia in some patients (Clark, et aI., 2007). 
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It is unclear whether the current measures that were taken to optimise blood sugar level were 
sufficient or insulin should have been given to all TB and OM patients. Although pharmacists 
felt that it was important to initiate insulin in patients with poorly controlled OM, chest 
phYSicians believed that patients would less likely to adhere to insulin (versus to oral 
medication) treatment especially in an out-patient setting. Moreover, hospital policy 
restricted chest physicians from prescribing insulin pens due to financial constraints. As such, 
pharmacists were reluctant to suggest the conversion from OHAs to insulin in this study 
despite some evidence supporting the use of insulin. It has been suggested that insulin might 
be beneficial to achieve tight glycaemic control in TB patients with OM (The Francis J. Curry 
National Tuberculosis Center, 2009). More research is being conducted in the area of TB and 
OM and more recommendations will be expected in the near future (World Diabetes 
Foundation, 2010, 2011). So far, the Brazilian Thoracic Association has considered replacing 
oral hypoglycaemic agents with insulin during TB treatment to keep fasting blood glucose 
below 160mg/dl (8.89 mmol/I) (Conde, et aI., 2009). 
The fact that patients' concerns were addressed and communicated using various means such 
as face-to-face verbal interactions, follow-up calls and text messages via mobile phone 
reinforces the importance of individualiSing patient care and using methods accessible to the 
patient. It has been recommended that health care professionals should utilise the frequent 
DOT visits with TB patients to help manage OM by encouraging lifestyle changes at every 
patient encounter and consider concurrent administration of both OM and TB medications, via 
DOT, for TB patients with OM (Brostrom, 2011; The Francis J. Curry National Tuberculosis 
Center, 2009). Piette & Kerr (2006) suggested that pharmacists can assist patients with 
comorbid conditions by managing patients' complex medication regimen. Based on the 
number of pharmaceutical interventions presented so far, it is evident that pharmacists could 
playa role in integrating TB and OM management by addressing medication-related concerns 
and by making relevant recommendations to patients and physicians. Besides, pharmacists 
also played a role in educating patients about the risk factors of TB such as adviSing patients to 
quit smoking as it is one of the risk factors that worsen TB infection. Furthermore, helping 
patients to understand the importance of adherence to OM medication by explaining the link 
between TB and OM was well appreciated by patients. For example, many patients in this 
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study reported that they did not know that DM is a risk factor for TB and therefore, did not 
recognise the importance of tight glycaemic control. 
Another important observation suggests that patients' carers also played an important role by 
reporting patients' problems during follow-up visits or calls. During the counselling sessions, 
pharmacists provided relevant information to patients' carers. In fact, it has been 
recommended that families and carers should also have the opportunity to be involved in 
decisions concerning patients' treatment and care (Lewis & Newell, 2009; Nunes et aI., 2009). 
Another important finding is the absence of a comprehensive documentation of medical and 
medication history in TB patients' medical record. This finding was also found in the phasel 
study. It was observed that physicians filled up a specific TB documentation form when 
patients were diagnosed with TB. The form has a number of prelisted medical problems that 
could be ticked as past or concurrent medical problems. Physicians may have overlooked the 
possibilities of enquiring about other medical problems not listed in that particular form or 
patients may not inform them about their problems if they were not asked specifically about 
it. Pharmacists identified a number of concurrent medical problems and past medical histories 
(e.g. chronic sinusitis, gastritis, history of cataract surgery) as well as past medication histories 
that were not documented in the patients' medical records. At times, pharmacists requested 
the patients to bring along all their medication during their next follow-up visits because most 
patients were unable to name their medication. This assisted in identifying other medical 
problems. 
Despite being able to provide the pharmaceutical care service, there were some logistic 
barriers that need to be addressed. These barriers existed due to the inherent organisation of 
the health care system that was not adequately designed to accommodate patients with 
multiple disease profiles. Furthermore, the unavailability of shared electronic medical records 
restricted the access to obtain the results of the laboratory tests (e.g. HbAlc test, lipid profile 
test) that were done in other clinics. Lack of regular monitoring of certain clinical and 
215 
laboratory parameters (e.g. finger-prick blood glucose monitoring test, liver function test, 
renal function test) at the chest clinic was another barrier encountered. It has been 
recommended that monthly liver function test should be conducted as patients with TB and 
OM carry the risk of developing hepatotoxicity (The Francis J. Curry National Tuberculosis 
Center, 2009). Besides isoniazid, pyrazinamide and rifampicin, many patients in this study 
were on lovastatin which could increase the risk of developing hepatotoxicity and therefore 
needed to be monitored carefully (The Francis J. Curry National Tuberculosis Center, 2009). 
However, in the present study, there was a dilemma of whether to recommend certain 
monitoring tests or to wait and see whether a particular test was ordered by the physician or 
not. At times it was only feasible to take note of what was done and what was not. For 
example, despite the suggestion for finger prick monitoring of blood glucose, reluctance to 
conduct finger-prick monitoring by the nurses were observed in some occasions. It has been 
recommended that a glucometer should be available in every TB clinic and glucose should be 
checked at least weekly for the first four weeks of TB treatment and then less frequently 
thereafter if OM is well controlled (Brostrom, 2011). 
Weekly meetings were held with Alan (hospital pharmacist) to reflect on the issues related to 
the provision of pharmaceutical care, to discuss the barriers encountered, and to come up 
with an action plan to improve the service. For example, one of the barriers encountered in 
this study was lack of space to provide counselling. Lack of privacy limited the depth of 
consultations with some patients. Nevertheless, action was taken to remedy the problem by 
using one of the nurse's rooms at the clinic. It was found that patients communicated better 
when they had more privacy. 
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6.7 Strengths and limitations 
The action research methodology was the main strength of this study. It provided the 
flexibility that is needed to research a 'real world' environment by using multiple research 
methods. It allowed the researcher to participate, understand the local context and develop 
practical knowledge based on the experiences gained. 
Nevertheless, this study has several limitations. The study was conducted in one public 
hospital in Malaysia which may restrict the generalisation of the findings. It was carried out in 
a relatively short period of time and only 15 patients were followed-up for a total of four visits. 
Nonetheless, recruitment of patients continued until the end of the study in order to have a 
larger sample size and the reason was to identify as many different problems as possible that 
were unique to patients with T8 and OM. 
Older bed-ridden patients above the age of 80 and those who were severely ill due to other 
complications did not participate in this study and as such the findings do not reflect the 
problems of those patients. 
The prevalence of OM in T8 patients in this study could have been underestimated as there 
was no standard strategy employed in screening for OM patients. The first step in the 
identification of OM was based on patients' self-report of OM. Secondly, baseline laboratory 
investigations which include fasting or random blood glucose were done and based on the 
results, some patients were newly-diagnosed with OM. In some instances, physicians repeated 
fasting blood glucose test to confirm the diagnosis of OM. However, a delay in diagnOSis of OM 
in two patients was observed in this study as physicians waited for their next follow-up to 
initiate OM treatment. Screening of OM in T8 patients with regards to when and how the 
screening should be performed is a current research agenda that has been put forward by the 
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experts (Harries, et aI., 2010; Jeon, et aI., 2010). Active screening may lead to the detection of 
more OM cases in TB patients and vice versa (Jeon, et aI., 2010). 
This study compared beliefs of two different diseases in the same patient. The translated 
Malays version of BMQ was tested for beliefs of TB and OM medication. With regards to the 
term used in the translated Malay version of BMa, many patients reported that they could not 
understand the word 'mystery' in question 6 (My medicines are a mystery to me) in BMQ. 
Mystery is also known as 'mister;' in Malay language. It seemed that the concept of mystery 
was not easily captured. Moreover, there were differences in the internal consistencies of the 
BMQ scale with regards to TB and OM. It is unclear whether the differences could be 
attributed to the different degree of beliefs on TB and OM medication respectively. BMQ 
questions were repeated twice, first for TB medication and subsequently for OM medication. It 
is not known whether repeated questioning could impact the way patients responded to the 
individual items of the questionnaire. Previous research has recommended the need to 
examine the impact of repeated questioning on the validity and reliability of responses to 
questionnaire items (Stack et aI., 2010). Both the translated version of BMQ and MMAS-8 was 
not a validated instrument. Validation of a translated instrument is a huge project by itself and 
it was beyond the scope of this study. Although, the current availability of the validated 
Malaysian version of the MMAS can be used in future studies (AI-Qazaz, et aI., 2010), this 
study signalled the need for the translated BMQ to be validated in Malaysia. 
Feedback from the patients and health care professionals regarding the provision of 
pharmaceutical care service was not obtained. Their feedback would have helped to improve 
the service. With regards to the physicians, there were many physicians that managed patients 
and the researcher did not work with any particular physician. Therefore, it was not feasible to 
get the feedback from physicians. Furthermore, not all patients completed their follow-ups 
and therefore feedback was not attained. Nonetheless, feedback from the hospital pharmacist 
(Alan) was obtained (see appendix 15). Except for lack of space, language barriers (different 
dialects) and time limitation, Alan provided positive feedback and would like to continue 
providing the service. 
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6.8 Reflection 
Reflection is an inseparable component in action research (Waterman, et aI., 2001). The 
reflexivity in research includes reflection on self, the process, and representation. It is equally 
important to evaluate the power relations and the politics in the research process as well as 
the researcher's accountability in data collection and interpretation (Dickson-Swift, James, 
Kippen, & liamputtong, 2006; Silverman, 2005; Thomas, 2008). 
As compared to Phase 1 study, I was emotionally attached and felt responsible for the patients 
in Phase 2 study. The sense of responsibility was felt when I became part of the health care 
team and started to provide the service together with Alan. Coming from the clinical pharmacy 
background, I used to identify medication-related problems mainly through patient's medical 
record with limited interactions with patients and the problems were usually solved based on 
clinical knowledge. I provided recommendations according to evidence-based practice and I 
spent more time reviewing the literature to identify the best approach in managing a 
particular case. However, in this study, the way I approached patients changed from 'I know 
what is best for you' to 'I know that you can help me understand how best to solve your 
medication-related problems'. The approach taken was more patient-centred. The prospective 
nature of this study allowed me to provide a continuous service and follow-up on some of the 
patients. Although I wished that I had completed the follow-ups for all patients, action 
research is time consuming and I had to stop at a particular point for the purpose of 
completing this PhD study within the allocated time period. 
The way I felt at the beginning changed when I compared with how I felt at the end of the 
research process. Initially, I was very theoretical in the sense that I believed that there was a 
standard way of managing a particular pharmaceutical care issue. However, as the study 
progressed, I scrutinised my own ability to execute the pharmaceutical care plan. I was able to 
appreciate the intricacies involved due to the complex nature of the intervention and how 
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different it would have been if I was just an observer. As an observer I would have been less 
attached to the patients and I would not have had the burden of deciding what I should do in a 
given situation. It would have been easier for me to say that 'Pharmacist A did a, b, c and not 
x, y, z'. But when I provided the service, I understood why such decisions were made. 
The execution of a pharmaceutical care plan was not the same or identical in every patient 
even when there were similarities with regards to the pharmaceutical care issues. One of the 
reasons was related to the ease of communication between the physician treating the patients 
and me. For example, I was comfortable in communicating with the physicians that I have 
known when compared to those that I do not know. I had a pleasant experience working with 
physicians that I have known and my recommendations were usually acted upon. On the other 
hand, it was difficult for me to intrude a busy clinic and explain about the research and my role 
to a new physician. Besides, there were other issues like nurses who were initially cooperative 
in fulfilling our request in doing a finger-prick blood glucose monitoring, who later exhibited 
reluctance to do so. It was learnt that one of the nurses was ticked off by a physician who felt 
that the finger prick test should only be conducted after a physician's order was obtained. 
Such issues subconsciously affected me from making certain recommendations to physicians 
that I have not encountered before. As such, I limited my interactions with those physicians 
that I do not know. However, it was not a problem for Alan as he provided pharmaceutical 
care service for patients with chronic obstructive pulmonary disease at the same clinic and it 
was easier for him to provide recommendations and to communicate with the physicians and 
the nurses since a long term working relationship had already been established, compared to 
me who was new at the setting. Although, I had presented my research proposal to the 
medical audience prior to the start of the research and managed to develop rapport with 
some of the physicians, there were many new faces at the clinic when I started the study. I 
realised that there were many senior and junior house officers involved in managing TB and 
some of them were in rotation and were not permanent staff of the clinic. Lack of time to 
develop rapport with all the physicians created barriers in communication. 
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I observed Alan hesitating in writing the pharmaceutical care issues and plan in the patients' 
medical record despite having the permission for doing so. He felt that it was better to speak 
directly to the physicians if there were to be any recommendations. Although, it is better to 
communicate directly, documentation of such recommendations could serve as a reminder to 
other physicians during the next follow-up. Furthermore, documentation helped to 
acknowledge the contribution of a pharmacist to patient care. Reflecting on this issue, I 
understood that Alan found it simpler to communicate and solve the problem immediately but 
the hesitation to write could be due to the lack of practice or confidence. I did not write in the 
patients' medical record as I was not the hospital pharmacist. 
In summary, action research allowed me to understand various pharmaceutical care issues of 
TB and OM patients and the organisational component that needed to be factored in when 
designing a pharmaceutical care service. 
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CHAPTER 7: THESIS DISCUSSION 
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7.1 Introduction 
This chapter aims to collate the key findings from the phase 1 and phase 2 studies to discuss 
how successful this research was in meeting its aim and objectives. Subsequently, it provides 
and overall discussion. Finally, it presents the implications ofthe findings for policy, practice 
and future research. 
7.2 Summary of key findings 
Firstly, a qualitative enquiry (phase 1) was carried out in order to explore the pharmaceutical 
care needs of TB and OM patients. The phase 1 study provided a snap shot of patients' and 
health care professionals' experiences in managing TB and OM. In addition, it also explored 
the health care professionals' perspectives on MTACs and the potential role of pharmaCists in 
the management of TB and OM. 
Concerns about medication and issues related to the management of TB and OM were the two 
main themes that emerged. Concerns about medication include the negative consequences of 
medicine taking (adverse effects of medication, burden of multiple medication, drug 
interactions and medication confusion) and the perceived positive effect of medication which 
were expressed in terms of necessity and efficacy of medication. Therefore, the 
pharmaceutical care needs of TB and OM patients include the need to monitor adverse effects 
of medication, help patients manage multiple medicines and address patients' concerns about 
medication. Issues related to the management of TB and OM patients include longer duration 
of TB treatment in OM patients, delayed initiation of TB and OM treatment, poor record 
keeping, communication barriers between patients and physicians, the ambiguity of OM 
management in TB patients, OOT and the burden of attending multiple clinics, and self-
management and incorporation of traditional remedies. As such, the pharmaceutical care 
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aspects include the need to motivate and promote adherence to treatment, advocate the 
importance of early treatment seeking behaviour, conduct a thorough medication review and 
improve documentation of patients' medical and medication history, create opportunities to 
communicate with patients, find ways to integrate the management of TB and OM, and 
enquire about self-management and the use of traditional remedies. 
Health care professionals believed that pharmacist-led MTAC programmes allowed the 
provision of pharmaceutical care, enhanced pharmacist-patient communication and 
encouraged pharmacist-physician interactions. Health care professionals proposed that 
pharmacists could play an important role in educating and counselling patients with TB and 
OM and that the MTAC model could be expanded to include management of patients with TB 
and OM. 
Secondly, the findings of the phase 1 study and the proposed phase 2 study was presented to 
health care professionals at the chest clinic in order to incorporate their feedback into 
consideration. Then, the revised phase 2 study was conducted to determine the feasibility of 
providing a pharmaceutical care service. Phase 2 revealed more complex issues with regards 
to pharmaceutical care management of TB and OM. Oue to the prospective nature of phase 2 
and the study design that employed action research methodology, a variety of 'real-life' 
experiences were captured. 
In spite of the need to address logistic barriers and the need for more collaborative practices 
between pharmacists and physicians, the provision of the pharmaceutical care service for TB 
and OM patients was a feasible conclusion. Pharmacists played an important role in managing 
OM in TB patients by: raising the awareness that OM is a risk factor for T8; emphasising the 
importance of adherence to OM medication as well as to dietary recommendations; 
advocating the importance of regular monitoring of blood sugar level; addressing patients' 
concerns about their medication; and referring patients to physicians and recommending 
treatment modifications. Nevertheless, there were other issues which could be regarded as 
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barriers to pharmaceutical care management such as communication barriers; delays in 
initiating OM treatment in newly-diagnosed OM patients; infrequent monitoring of blood 
glucose level; absence of certain clinical and laboratory data; and nurses' reluctance to 
conduct finger-prick blood glucose monitoring if it was not a physician's order at the chest 
clinic. 
This study revealed the complex nature of pharmaceutical care interventions and provided 
various insights and experience that could be used for further development work prior to 
conducting a ReT to evaluate the effectiveness of the service. 
The next section provides an overall discussion of findings. 
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7.3 Overall discussion 
It has been reported that there is a need for quality research designs and a clear description of 
the pharmaceutical care process to evaluate the impact of pharmaceutical care (Kassam, et aI., 
2001; Kennie, et aI., 1998; Roughead, Semple, & Vitry, 2005). Studies have also fshown that 
pharmaceutical care is a complex intervention and research in this area should reveal its 
complexity (Tulip & Campbell, 2001). In line with the pharmaceutical care theory, the present 
study has shown that pharmaceutical care interventions were indeed complex as it was not 
just about identifying, preventing and resolving medication- related problems in TB and DM 
patients but it also involved the need to establish a therapeutic relationship with the patients 
and their caregivers, develop a collaborative practice with other health care providers and 
follow-up the patients. The identification of these factors was possible with the application of 
the MRC framework for complex interventions which emphasised the importance of 
conducting qualitative and feasibility studies to identify the components of a particular 
intervention prior to developing a definitive trial. 
Interest in using qualitative methodologies to investigate pharmaceutical care has been 
growing (Dupotey & de Oliveria, 2009; van Mil, et aI., 2004). This study adds to the body of 
knowledge by demonstrating that qualitative methodologies are indeed valuable to assess the 
pharmaceutical care needs or issues from the patients' and providers' perspectives. Action 
research has also been suggested to be used in pharmaceutical care research (Tanna, 2005; 
Tulip & Campbell, 2001). The use of action research in the phase 2 study was helpful in 
identifying the intricacies of pharmaceutical care interventions by using multiple strategies of 
inquiries such as observation, interviews, medical chart/record reviews and participation of 
the researcher. The researcher played a dual role (researcher/practitioner) in the phase 2 
study and this allowed the researcher to acquire experiential knowledge. Furthermore, action 
research allowed the researcher to identify various areas that needed to be strengthened 
prior to developing a full-fledged service such as the need for: more commitment and 
collaborative effort among health care professionals, access to medical records for comorbid 
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conditions and strategies to integrate or improve communication between different care 
providers/specialties. 
Several studies that have been conducted in patients with multiple diseases had identified 
numerous medication-related problems (Elliott, et aI., 2007; Krska et aI., 2001; Townsend, et 
aI., 2003). However, identification of pharmaceutical care issues of patients with specific 
comorbid conditions was difficult due to heterogenous sampling of patients in those studies. 
In contrast, this study identified medication-related problems of a homogenous group of 
patients. As such, some common medication-related problems associated with TB and DM had 
been identified. Nevertheless, many of these patients had other comorbidities besides TB and 
DM which shows that despite some similarities among the patients, each individual was 
unique and had their own concerns about medication that requires individualised 
pharmaceutical care management. Hence, despite the need for 'specialised knowledge' on 
pharmaceutical care issues in a specific comorbid condition, there is also a need to have 
'generalised knowledge' in order to provide individualised or holistic pharmaceutical care 
management. Therefore, it can be implied that pharmacist could playa generalist role by 
bridging the care for TB, DM and other comorbid conditions which is currently separated due 
to the single disease management system. Although there have been calls to move from single 
disease management system to a more integrated disease management system, radical 
changes are unlikely to happen overnight. However, integrating pharmacists into a 
multidisciplinary health care team might be a feasible option. 
Harries et al. (2010) reported that there is a need for research in four key priority areas in TB 
and DM management which include: 1) the need to screen DM in TB patients and vice versa, 
2) the impact of DM on TB treatment outcome, 3) the implementation of the TB DOTS strategy 
for managing and monitoring DM, and 4) the development of diagnostic and monitoring test 
including HbAIC for OM patients. Interestingly, the findings of the present study were in 
agreement with the key research area that has been put forward by Harries, et. al. (2010) and 
could be considered as preliminary evidence. Firstly, this study has shown that there is a need 
for thorough screening of DM in TB patients as the prevalence of DM in TB patients could have 
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been underestimated in this study due to lack of standard screening mechanisms. Secondly, 
poorly controlled OM and non-adherence to OM medications may have a detrimental effect to 
TB treatment outcome although it has to be further investigated in a longitudinal study. 
Thirdly, it is possible to implement the TB DOTS strategy to incorporate OM monitoring 
through finger-prick monitoring test at the chest clinic, although lack of support from the 
other health care professionals with regards to finger-prick monitoring was observed in this 
study. This indicates the lack of awareness on the importance of monitoring OM at the chest 
clinic. Fourthly, there was either lack of monitoring of HbAlc at the chest clinic or lack of 
amalgamation of this data into TB patients' medical records if the HbAlc test had been carried 
out at the OM clinic. Therefore, it is important to improve communication between TB and OM 
care providers with regards to access to monitoring data. 
Some of the findings in this study (e.g. pharmaceutical care issues, barriers to provision of 
service) might be transferable to other public health care settings in Malaysia. As with other 
qualitative research, the degree of generalisability or transferability to other settings could 
only be determined by the reader as it is context specific. The researcher has provided a thick 
description about the setting and it is up to the reader to decide on the components that are 
relevant to their setting. This study could be taken as an example for investigating the role of 
pharmacists in other clusters of comorbid conditions. Despite the fact that each patient may 
have different pharmaceutical care needs, it might be worthwhile to investigate the 
pharmaceutical care issues in other specific clusters of comorbid conditions because general 
problems pertinent to those conditions could be unveiled. 
The following three sections provide the implications of the findings in relation to policy, 
practice and future research. 
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7.4 Policy implications 
Based on a myriad of pharmaceutical issues identified and intervened, this study has 
established evidence that pharmacists have a role to play in integrating the management of T8 
and OM. Although this study targeted TB patients with comorbid OM, it was found that other 
non-OM comorbid conditions also required individualised pharmaceutical care management. 
Based on this finding, it can be argued that pharmacist's service is not only relevant to T8 and 
OM patients per se but could be extended to all TB patients. As such, it is recommended that 
pharmacists should become one of the participating health professionals for the National TB 
programme. In order to have an impact on practice, it is imperative to first have a policy that 
supports the integration of pharmacist in the National TB programme. Having such policies in 
place may ensure the integration of pharmacist in the management of TB at a larger scale. 
Recently, the WHO and FIP have signed a joint statement at the World Pharmacy Congress in 
Hyderabad in September 2011 on the role of pharmacists in the management of TB (FIP, 
2011b) and this may bring positive changes in many National TB programmes in the near 
future. The present study could provide good political support for pharmacists to be part of 
the National TB programme. 
It was observed that there was an association between non-adherence to OM medication and 
suboptimal blood glucose control. As it is important to maintain tight glycaemic control while 
on TB treatment, this finding indicates a need for policies to support co-management of T8 
and OM. At the moment, TB and OM patients receive treatment from various care providers 
and there is a lack of coordination between TB and OM care providers. It is suggested that 
health care professionals at the chest clinic integrate the management of TB and OM by 
utilising the opportunity of meeting patients during DOT to provide OM education. It might be 
the most ideal if OM medications can be dispensed at the same time in order to reduce the 
need to attend multiple clinics. There is a lack of effective communication between both TB 
and OM care providers. Innovative approaches such as using shared electronic medical 
records or any other means of communication should also be considered. Development of 
guidelines with regards to the management of TB and OM will be beneficial to health care 
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providers. Lately, the WHO have published a collaborative framework for care and control of 
TB and DM (WHO, 2011) and some of its recommendations are in agreement with the 
proposed suggestions derived from this study. 
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7.5 Practice implications 
Factors that could have affected the pharmaceutical care service in this study include logistic 
barriers, communication barriers due to lack of inter-professional relationships and 
pharmacist's hesitation in documenting pharmaceutical care plans in a patient's medical 
record. In order to enhance practice in the future, it is suggested to: 
a) Enhance collaboration between pharmacists, physicians and nurses 
b) Access to patients' other medical records for comorbid conditions 
c) Provide patient education and counselling in a separate consultation space 
d) Encourage pharmacists to document pharmaceutical care plans in patients' medical 
records 
The following is a summary of recommendations that were drawn from the experience of 
providing the pharmaceutical care service. These recommendations could be used as a guide 
to enhance practice. 
• Communicate with patients and patients' carers 
It is important to listen, empathise, develop rapport and communicate with patients in a 
private consultation area. Therefore, health care professionals should encourage patients to 
voice their concerns and provide assurance that TB can be cured. Patients' carers play an 
important role in supporting patients' treatment. As such, health care professionals should 
also communicate with patients' carers. 
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• Monitor 
Firstly, patients need to be informed about the potential adverse drug reactions of their 
medication and how they should respond if adverse drug reactions occur. Patients need to be 
monitored for adverse effects like vomiting, itching, joint pain, visual disturbances, 
hypoglycaemia and sensations that resembled peripheral neuropathy. Parameters that need 
to be monitored for adverse drug reactions include liver enzymes, serum creatinine, uric acid 
and visual acuity. Patients might have additional risk of developing liver impairment especially 
when lovastatin is added. Regular monitoring (e.g. monthly monitoring of liver and renal 
function test) should be recommended. It is suggested that health care professionals should 
also ask patients whether they have cataract or have a history of cataract surgery as 
ethambutol may not be suitable for these patients or they may need to have their visual acuity 
assessed prior to the administration of the drug. Similarly, patients should also be asked about 
history of gout as their uric acid level will require monitoring. 
Secondly, adherence to both TB and OM treatment need to be assessed and monitored. It is 
also important to encourage patients to adhere to all the other medications that have been 
prescribed for comorbidities. Patients may need to be provided with strategies to cope with 
multiple medicines and at the same time monitored for polypharmacy. Patients who have 
other comorbidities like hypertension will need blood pressure monitoring. Due to the 
consumption of multiple medicines as well as the use of traditional and herbal remedies, drug-
drug interactions and drug-herb interactions need to be checked. Some patients in this study 
also highlighted that they had difficulties in consuming medication on an empty stomach. In 
such cases, patients should be advised to take their medication with light food. 
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• Optimise blood glucose level 
It is very important to keep blood sugar level within the targeted range. Fasting blood sugar 
should be checked monthly and HbAlc should be checked every three months. Health care 
professionals should take note of blood glucose levels and advocate regular finger-prick 
monitoring. Nurses should conduct regular finger prick monitoring at the chest clinic. Nurses 
have plenty of opportunity to reinforce OM education due to their frequent contact with 
patients during DOT. Health care professionals should explain to patients that DM is a risk 
factor for TB and that it is important to keep their blood glucose under control. Health care 
professionals should look out for drugs that could induce hyperglycaemia (e.g. prednisolone, 
atypical antipsychotics). It is important to check whether patients adhere to OM treatment 
and whether they are being followed-up. Health care professionals at the chest clinic may 
have to contact the OM care provider if there is a need for further information. Patients with 
poorly controlled DM may benefit from insulin therapy. 
• Educate, counsel and address patients' concerns 
It was found that patients had various concerns about medication, misconceptions, and 
knowledge gaps which required individualised pharmaceutical care management. Pharmacists 
could play an important role in providing drug information, communicating patients' problems 
to their physicians, making timely referrals and recommending early initiation of treatment for 
adverse effects (e.g. antihistamines for itchiness and metoclopramide for vomiting). Educating 
and helping patients understand the link between TB and OM may encourage adherence to 
treatment. 
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• Empower patients 
In order to optimise medication use, health care professionals should empower patients to 
make decisions about goals, therapeutic options, self-care behaviors and to assume 
responsibility for TB and DM care in order to help patients care for themselves. Although 
health care professionals are experts in disease management, this study showed that patients 
are the experts on their own lives and that they have their own strategies to manage their 
medicines. As such, knowing about the disease is not the same as knowing about a patient's 
life, beliefs, culture and medicine-taking behavior. Therefore, patients are the primary 
decision-makers with regards to their daily self-management of their diseases. Health care 
professionals should help patients assume responsibility for their care and encourage patients 
to participate actively during consultations. 
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7.6 Implications for patients 
Patients will benefit from a pharmaceutical care service because it provides an opportunity for 
them to discuss their concerns about medication and receive education and counselling for 
both T6 and OM. They will have an opportunity to have their medication reviewed by the 
pharmacists before they see their physicians and at the same time their waiting time will be 
utilised effectively. Furthermore, they may not have to wait for their next appointment at their 
OM clinic to monitor their blood glucose or to optimise the dosage of their medication since 
their daily attendance for DOT can also be utilised for OM management. Pharmacists will be 
able to make a timely referral as well as recommendations to physicians should there be any 
medication-related problems. 
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7.7 Research implications and future work 
• Lack of time to develop rapport with other health care professionals was a barrier in 
the phase 2 study. Future work should consider the involvement of a multidisciplinary 
research team. A collaborative agreement should be made prior to the start of the 
study so that the research team members are aware of their responsibility and their 
expected contribution to the study. Regular meetings should be held with health care 
professionals participating in the study and their feedback should be obtained. 
Researchers could also discuss and have an agreement with physicians on the 
following: 
o issues related to monitoring parameters for TB and OM 
o access to medical records 
o the role of nurses in supporting patient care activities such as conducting 
regular finger-prick monitoring. 
• The present study showed that patient's beliefs about medications and adherence can 
be assessed by using the BMQ and MMAS-S. However, there is a need to validate the 
translated Malay version of the BMQ in a larger sample in Malaysia. 
• As there is a need for more evidence for the use of insulin in the management of OM 
in TB patients, future research should investigate the benefit and cost effectiveness of 
intensifying OM treatment with insulin therapy to control blood glucose in TB and OM 
patients through a RCT. 
• The phase 2 study demonstrated that it was relatively feasible to provide 
pharmaceutical care to TB and OM patients. However, future research should 
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evaluate the effectiveness of the pharmaceutical care service using a prospective, 
longitudinal study design. Based on the findings, a RCT could be designed to evaluate 
the clinical, humanistic and economic outcomes of the pharmaceutical care study. A 
qualitative study should also be conducted to examine patients' and health care 
professionals' perceptions with regards to the provision of service. 
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7.8 Thesis conclusion 
This study applied the first three phases of the MRC framework for complex intervention as a 
theoretical guide to develop a pharmaceutical care service for TB and OM patients in a public 
hospital in Malaysia. The use of qualitative approaches in phase 1 and action research in phase 
2 helped to identify various medication-related problems in patients with TB and OM. Despite 
the need to address the barriers encountered during the provision of pharmaceutical care, this 
study demonstrated that pharmacists could playa generalist role by integrating care for TB 
and OM in a health care system which is fragmented due to the single disease management 
system. In short, this study has laid the foundation for future work to be carried out in 
improving the current pharmaceutical care service through thorough analysis of the challenges 
faced in the developmental phase prior to evaluating its effectiveness in a RCT. 
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Literature review search terms and strategy 
The initial literature search was conducted in 2007-2008. The search was updated during data 
analysis in 2010-20ll.The search used the terms below. 
Search term 
Comorbidity (comorbid, co-morbid, comorbidities) 
Complex intervention (Complex intervention AND Pharmaceutical care) 
Diabetes (Type 2 diabetes, Diabetes mellitus, OM) 
Directly observed therapy (Directly observed treatment, DOT, DOTS) 
Malaysia (T8 AND Malaysia, Diabetes AND Malaysia) 
Pharmaceutical care (Pharmaceutical care AND diabetes, Pharmaceutical care AND 
tuberculosis) 
Pharmacist (Pharmacist AND tuberculosis, Pharmacist AND diabetes, Pharmacist AND 
Malaysia) 
Qualitative (Qualitative AND T8, Qualitative AND diabetes, Qualitative AND comorbidities) 
Tuberculosis (T8, Tuberculosis AND diabetes) 
Databases used 
Medline, Embase, Ovid, Pubmed, Google Scholar, Scopus. 
A hand search of the references cited in some of the key journals on TB and OM was also 
conducted. 
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The University of 
Nottingham 
The need for pharmaceutical care in the management of tuberculosis 
and diabetes mellitus: an exploratory study (Phasel ) 
PATIENT INFORMATION SHEET 
You are invited to take part in a research study. However, before you decide whether you want 
to be involved in the study, it is important that you understand what the study is about and 
what taking part will mean to you. Please take time to read the information carefully. 
The information is presented in two parts. Part 1 explains the purpose of the study and 
describes what will happen to you if you agree to participate in the study. After you have 
finished reading part 1, and you feel that this study is of interest to you and you are thinking of 
taking part then continue to read part 2. Part 2 provides you with additional information about 
how the project will be managed. 
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PART 1 
What is the purpose of the study? 
This study aims to understand patients' experiences of living with tuberculosis and diabetes 
mellitus. We are interested to learn how you manage your medicines. We are also interested 
to find out what things make it easier or harder for you to follow your treatment. 
Do I have to take part In this study? 
Taking part in this study is entirely your choice. Only make a decision once you have had the 
chance to read the information provided and have asked us any questions you might have. 
Whatever your decision is, please contact Shubashini Gnanasan at 012·2877774 or email 
paxsg2@nottingham.ac.uk . If you have decided to take part in the study, we will ask you to 
sign an informed consent form to show your agreement. You will be given a copy of the signed 
informed consent form to keep for your records. 
Will my decision affect the care I receive? 
Please be assured that the standard of care you to receive will not be affected in anyway. 
Can I change my mind once I have signed the consent form? 
If you agreed to take part in the study, and for whatever reason you are unable to, that is 
absolutely fine. If you have initially decided not to take part and would now like to be involved, 
that is fine too. All you need to do is contact us. This will not affect the standard of care you 
receive 
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What will happen to me if I take part in the study? 
You will be invited to take part in an interview. We will ask you about your experiences of 
managing tuberculosis and diabetes mellitus. The interview will take place in the hospital and 
it will be expected to last between 30 to 45 minutes. You will be contacted for an interview 
appointment. If you are unable to make your interview appointment for whatever reason, 
don't worry. Please contact us and we will have this arranged for a more suitable time. 
What are the risks of taking part in the study? 
As this project involves you in an interview, we believe that the risks of taking part in this 
project are minimal. 
What are the benefits of taking part in the study? 
This project is not expected to directly benefit you. However, the information you provide us 
may help in the future development of services designed to help patients affected with both 
tuberculosis and diabetes mellitus. 
What happens If something goes wrong? 
Any complaint you have resulting from taking part in the study will be addressed accordingly. 
For more details, see Part 2. 
Will the Information provided be kept confidential? 
Confidentiality will be maintained at all times. For more details, see Part 2. 
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If the information in Part 1 has been of interest and you are considering taking part in the 
study, please read the additional information given in Part 2 before you make a decision. 
PART 2 
If you have any complaints or concerns regarding an aspect of this study, please contact me 
(Ms. Shubashini Gnanasan) at 012-2877774 or e-mail paxsg2@nottingham.ac.uk and I will try 
to resolve any issues to the best of my ability. 
You may also contact the academic supervisors of this project. 
Academic Supervisors Email Contact number 
Professor Claire Anderson Claire.Anderson@nottingham.ac.uk 0115 951 5389 
Dr. Ting Kang Nee Kang-Nee.Ting@nottingham.edu.my 03-89248209 
Assoc. Prof. Dr. Salmiah Mohd I drsalmiah@salam.uitm.edu.my 03-55442761 
Will the Information I give be kept confidential? 
Any information you provide will be kept strictly confidential. However, if you tell us 
information that indicates that you or your health might be endangered we might need to 
inform somebody else. However, we will discuss this with you first and ask you permission to 
do so. 
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Will you be contacting my doctor? 
If you agree to take part in the study, we will inform your doctor. However, we will NOT 
discuss anything you tell us, without your permission. What you tell us is confidential and will 
not be repeated back to your doctor. Please feel free to talk to your doctor about taking part in 
this study. 
Will the information I give be handled and stored safely? 
The overall responsibility for handling any information you provide during the course of the 
study lies with Shubashini Gnanasan. The information you provide us will be held on secure 
protected computers and/or in a locked and secure drawer or filing cabinet. 
Who will have the access to the data collected during the study? 
Only the research team involved in this project will have access to the data collected. The data 
collected will be stored at the University of Nottingham for 5 years following the completion of 
the study. 
What will happen to the results of the study? 
We will share the information with you if you wish. We can send you a short communication 
about our findings. We will also present results at conference and write journal articles so that 
other people can learn from our study. None will have any of you personal information. 
Nobody will know that the results are yours. 
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Who is organising this research? 
This study is being organised by Shubashini Gnanasan as a part of a requirement for the 
completion of an educational qualification (PhD). This research study is conducted under the 
supervision of Professor Claire Anderson and Dr. Ting Kang Nee from University of Nottingham 
as well as Dr. Salmiah Mohd Ali from Universiti Teknologi MARA. 
Who has reviewed the study? 
Before any research project is allowed to go ahead, it has to be checked by a Medical Research 
Ethics Committee. They make sure that the research is fair and pose minimal risks to study 
participants. This project has been registered in the National Medical Research Register 
(Research 10: 1165). 
Whom should I contact for further information? 
If you need further information on this study, please feel free to contact me on the details 
provided below: 
Ms. Shubashini Gnanasan, BPharm (Hons), MPharm (Clinical) 
PhD research student 
University of Nottingham. 
Tel. number: 012-2877774 
Email address:paxsg2@nottingham.ac.uk 
Thank you for reading this document. 
Please ask any questions if you need to. 
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The University of 
Nottingham 
INFORMED CONSENT FORM 
Title of Project: The need for pharmaceutical care in the management of tuberculosis 
and diabetes: an exploratory study 
Name of Investigator: Shubashini Gnanasan 
Please initial the box at the end of each statement: 
1. I confirm that I have read and understood the information sheet for the above study. I D 
have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any D 
time, without giving any reason, without my legal rights being affected. 
3. I understand that relevant data collected during the study, may be looked at by D 
responsible individuals from The University of Nottingham and Universiti Teknologi 
MARA. I give permission for these individuals to have access to this data. 
4. I give my informed consent for the audio-taping of the interview. D 
5. I give my informed consent for anonymised direct quotes to be used in reports and D 
publications. 
6. I agree to take part in the above study. D 
Name of Participant: Date: Signature: 
Investigator: Date: Signature: 
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Interview Schedule 
The need for pharmaceutical care in patients with tuberculosis and diabetes: an 
exploratory study (Phase 1) 
General Themes: 
1. Experiences of managing TBDM and issues related to medication 
2. Health-system barriers 
3. Potential role of pharmacists in a multidisciplinary team 
4. DOTS 
Patients: 
Medication issues 
1. What medication are you currently taking? 
2. How long have you been on this medication for? 
3. How do you take your medication? 
4. How many medicines do you have to take? 
5. Has your medication changed over time? 
6. Are you taking any supplements or traditional medicines? If yes, what do you 
take? 
7. Are there times when you feel you need to take more or less of your 
medication? 
8. Do you experience any side effects from your medication? 
9. What are your concerns about your medication? 
10. How do you feel about DOTS? 
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Patient understanding of TBOM and experiences 
1. Can you share your experiences when you found out that you had TB and OM? 
2. What do you think caused you to get TB and OM? 
3. What effect has your disease had on your life? Has having TB and OM changed 
your life? 
4. How do you cope when you have more than one illness? 
5. What kind of support do you receive from your family? 
Health system 
1. Since your diagnosis, whom within the hospital have you seen? 
2. When did you see them? 
3. What information and advice have you received? 
4. What other sorts of support have you had or want? 
5. Would you like to see a pharmacist? 
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Doctors (Chest clinic): 
1. Can you share with me how TBOM patients are managed? 
2. How do patients prioritize treatment and self management when faced with 
multiple, complex diseases/conditions? 
3. How does that affect their medication-taking behavior? 
4. What measures do you take to improve glycemic control in TBOM patients? 
5. How do the health systems create barriers to patient care? 
6. What are the common drug-related problems that occur in TBOM patients? 
7. How can collaborative practice improve TBOM care? 
8. What kind of contribution will you expect from a pharmacist? 
9. What is your opinion on patient-centered care? 
10. What is your opinion on DOTS? 
Doctors (Endocrine clinic): 
1. How do you manage diabetes patients in your clinic? 
2. How do you manage diabetes patients with comorbidities? 
3. Do you manage the co-morbid condition of the diabetic patients as well or do 
you refer them to other specialties? 
4. Have you encountered TBOM patients in your practice? For ego Patient coming 
in with chronic cough? 
5. Can you share with me how TBOM patients are being managed? 
6. How will you treat TBOM patients? 
7. What are the common drug related problems that occur in TBOM patients? 
8. Would you prescribe Insulin for TBOM patients? 
9. Do TBOM patients get the same treatment as the other OM patients? 
10. How do the health systems create barriers to patient care? 
11. How can collaborative practice improve TBOM care? 
272 
12. How do you feel about the MTAC run by the pharmacist? 
Nurses (Chest clinic): 
1. Can you share your experiences of caring for TBOM patients? 
2. What measures do you take to improve glycemic control in TBDM patients? 
3. What are your experiences of working in a multi-disciplinary team? 
4. What are the common drug-related problems that occur in TBDM patients? 
5. How do the health systems create barriers to patient care? 
6. How can collaborative practice improve TBDM care? 
7. What kind of contribution will you expect from a pharmacist? 
8. What is your opinion on patient-centered care? 
9. What are the usual complaints of TBDM patients? 
10. What is your opinion on DOTS? 
Nurses (Endocrine clinic): 
1. How do you manage diabetes patients in your clinic? 
2. How do you manage diabetes patients with comorbidities? 
3. Can you share your experiences of caring for OM patients with comorbidities? 
4. Have you encountered TBDM patients in your practice? 
S. Can you share with me how TBOM patients are being managed? 
6. What are the common drug related problems that occur in TBDM patients? 
7. How do the health systems create barriers to patient care? 
8. How can collaborative practice improve TBDM care? 
9. What is your opinion on patient-centered care? 
10. What kind of contribution will you expect from a pharmacist? 
11. How do you feel about the MTAC run by the pharmacist? 
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Focus group schedule 
The need for pharmaceutical care in patients with tuberculosis and diabetes: an 
exploratory study (Phase 1) 
Pharmacists: 
1. Can you share your experiences of providing pharmaceutical care? 
2. How do you assist patients with comorbidities? 
3. What are the common drug-related problems that occur in patients with 
comorbidities? 
4. What are your experiences in managing TBDM patients? 
5. What kind of service will you be able to provide to TBDM patients? 
6. What are your experiences of working in a multi-disciplinary team? 
7. How can a pharmacist provide pharmaceutical care services by collaborating 
with other health care professionals? 
8. What is your opinion on DOTS? 
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DATA COLLECTING FORM-PHASE 1 
The need for pharmaceutical care In patients with tuberculosis and diabetes: an 
exploratory study (Phase 1) 
A. Demographic Data 
I Patient'. Name 
Race Marital Status 
Malay/ChlnesenndlaniOthers SlnglelMarrled 
I Contact Number I Occupation 
B. Medical History 
Past medical history of OM Newly diagnosed OM 
FPGlRBS 
HbA1c 
I Other past medical history 
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Past medication history 
A. TB Classification 
Pulmonary tuberculosis Ves No 
Extrapulmonary tuberculosis Ves No 
Pulmonary with extrapulmonary 
tuberculosis Ves No 
If extrapulmonary 
Tuberculous Meningitis Ves No 
Miliary TB Ves No 
Others 
B. Participation 
Patient willing to participate In the study Ves/No 
Patient's command of English language Good! Moderate/Poor 
Patient's command of Malay language Good! Moderate/Poor 
Interview Date 
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Background information of patients 
Patient's name Age Sex Ethnicity Duration of Other Tobacco Alcohol use Occupation Language 
(pseudonym) (years) DM comorbidities/ use used 
complications 
Rl:Yong 50 Male Chinese 
Newly 
Nil Nil Nil Carpenter Malay diagnosed 
R2: Yuenc 64 Male Chinese 5 years Nil Nil Nil Carpenter Malay 
R3: Ooi·,b 63 Male Chinese 30 years Nil Nil 
Regular 
Ex-lorry driver Malay 
consumption 
R4: Mydeen 72 Male Indian 16 years Nil Nil Nil 
Retired government 
Tamil 
officer 
RS: Imran' 69 Male Malay 9 years Hypertens i on Ex-smoker Nil Ex-driving instructor Malay 
R6: Najib 54 Male Malay 8 years Nil Smoker Nil Ex- factory worker Malay 
R7: Pavithran 49 Male Indian 1 year Gout Nil Nil School lab assistant E n g l i ~ h h
R8: Badrul 55 Male Malay 5 years Cholelithiasis Nil Nil Medical assistant Malay 
R9:Zaman 50 Male Malay 12 years Nil Ex-smoker Nil Policeman Malay 
R10: Ellass 64 Male Malay 18 years Nil Nil Nil Retired postman Malay 
Rll: Tlm"c 78 Male Chinese 20 years Hypertension Ex-smoker Nil Retired businessman Malay 
R12: longC 63 Male Chinese 10 years 
Hypertens i on/ Smoker Nil Retl red busi npssman Malay Osteoarthritis 
R13: Veeramuthu 50 Male Indian 7 years 
Hypertension/ 
Ex-smoker Nil Ex-security guard Tamil Heart disease 
R14: Sharon 42 FemaleChinese 1 year Nil Nil Nil Ex-nursery worker Malay 
R1S: Ramamany 56 Female Indian 2 years Nil Nil Nil Ex-factory worker Tamil 
R16: Jeyaraj 52 Male Indian Newly diagnosed 
Di a beti c foot! 
Pneumonia 
Nil Nil Ex-factory worker Tamil 
R17: Hakim 55 Male Malay 10 years 
Hyper-
Ex-smoker Nil Ret! red enforcement Malay cholesterolemia officer 
R18:Goh 51 Male Chinese 4 years Nil Nil Nil Ex-restaurant worker Malay 
R19:Chooc 53 Male Chinese 15 years Gout Nil 
Regular 
Salesman Malay consumption 
R20:Nusa c 53 Male Malay 8 years Nil Smoker Nil 
Ex-quarry factory 
worker Malay 
~ e s e e patients had a relapse of TB 
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Example of invitation letter for Phase 1 research presentation 
Dato' Dr. Haji Abdul Razak Mutallif 
Head of Respiratory Department 
1 June 2009 
Dear Dato' 
Inyltatlon to a research presentation and discussion 
We are glad to inform that we have successfully conducted the first phase of our research 
which aimed to explore the pharmaceutical care need of tuberculosis patients' with co-morbid 
diabetes mellitus (TBDM). Hence, we would like to present the findings of our research. We 
take this opportunity to thank all healthcare professionals who participated in the interviews 
and focus group discussion which was held last year. We would like to cordially invite you to 
attend a presentation and discussion followed by lunch. 
Title: Managing tuberculosis with co-morbid diabetes mellitus (TBDM) 
Venue: Chest Clinic, Hospital Pulau Pinang 
Date: 29th June 2009 
Time: 1.00 pm 
Thank you. 
Yours sincerely, 
Shubashini Gnanasan 
PhD Research Student 
Division of Social Research of Medicine and Health 
School of Pharmacy, University of Nottingham 
Email: paxsg2@nottingham.ac.uk 
Tel: 012-2877774 
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PEJABAT TIM BALAN KETUA PENGARAH KESIHATAN 
OFFICE OF THE DEPUTY DIRECTOR·GENERAL OF HEAL TH 
(PENYELIDIKAN & SOKONGAN TEKNIKAL) 
(RESEARCH & TECHNICAL SUPPORT) 
KEMENTERIAN KESIHA T AN MALAYSIA 
MINISTRY OF HEAL TH MALA YSIA 
Aras 12 Biok E7. Parsel E. Presmt 1 
Level 12 Block £7 Parcel E Precinct 1 
Pusat Pentadbtran Kerajaan Persekutuan 
Federa l GovemmeJJl AdmmlslratlVe Cenll e 
62590 PUTRAJAYA 
Te l 03 8883254:! 
Faks 03 68S 5 ..\ 
JAWATANKUASA ETiKA & PENYELIDIKAN 
PERUBATAN 
Ruj Kami (2) KKM/NIHSEC/08/0604/P09·31 3 
KEMENTERIAN KESIHATAN MALAYSIA 
dla Institut Pengurusan Kesihatan 
Jalan Rumah Sakit, Bangsar 
59000 Kuala Lumpur 
Ms Shubashinl Gnanasan 
DIVision of Social Research In Medictnes and Health 
School of Pharmacy 
University No ingham 
Puan, 
NM RR-09-463-4064 
Tarikh 1 September 2009 
Pharmaceutical care management for patients w ith tuberculosis and diabetes mellitus a 
feasibility study 
Lokasi projek : Hospital Pulau Pinang 
Dengan hormatnya perkara dl atas adalah dlrujuk. 
2 Jawatankuasa Etika 8. Penyelidikan Perubatan (JEPP), Kementerian Kesihatan MalaYSia (KKM) 
mengambil maklum bahawa projek tersebut merupakan syarat akademik program Falsafah Kedoktoran 
dan lelah diluluskan oleh the University Nottingham 
3 Sehubungan dengan ini, dimaklumkan juga bahawa pihak JEPP KKM tiada halangan, d ri segl 
elika, ke atas pelaksanaan projek tersebut. JEPP mengambil maklum bahawa projek tersebut tldak 
melibatkan intervensi klinikal dan hanya melibatkan pengumpulan data kajian melalui temuramah dan 
pemerhalian ke alas plan farmaseulikal subjek kajian. Segala rekod dan data subjek adalah SULIT dan 
hanya digunakan un uk ujuan kajian dan semua isu serta prosedur mengenai data confident,ality e II 
dipaluhl. Kebenaran daripad3 Pengarah hospita l di mana kajian akan dijalankan mesti d lperolehl 
lerlebih sebelum kaJian dlmulakan. Puan perlu akur dengan keputusan yang diberikan 
4 Laporan tama! kajian dan sebarang penerbitan dan kajlan ,ni hendaklah dikemu akan k pad a 
Jawa!ankuasa Etika 8. Penyelidlkan Perubalan selepas lamatnya kaJlan Inl 
S S ~ d a n n lerima kaslh. 
DATO' DR CHANG KlAN MENG 
Pengerusl 
Jawatankuasa Etika & Penyelidikan Perubatan 
Kementerian Kesihatan MalaYSia 
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The University of 
Nottingham 
Patient Information Sheet 
Pharmaceutical Care Management for Patients with Tuberculosis and Diabetes Mellitus 
(T8DM): A Feasibility Study 
Oear Sir/Madam, 
This letter is to inquire whether you would be willing to participate in a pharmaceutical care 
project for patients with T80M. The study is being conducted to evaluate the impact and 
feasibility of having a pharmacist to run a pharmaceutical care programme for TBOM patients. 
This study will be useful to enhance the current health management of TBOM patients. We 
hope to identify and resolve medication related problems in TBOM patients. 
We are asking if you would allow the pharmacists to interview you; ask specific questions 
regarding your medications; conduct a thorough medication used review and provide health 
education and counselling. Upon the first meeting with the pharmacist, subsequent 
appointments for the next visits will be given. You will only be seeing the pharmacist when you 
come to the clinic for your TB treatment. No additional trip to the hospital will be required. 
The pharmacist will be seeing you while you wait to see your doctor or while you wait to take 
your medications. You will be followed up for five visits which will take a total of 3 months to 
complete. Each visit will take about 15 minutes and will only be conducted after your consent. 
Even if you agree to participate in this project, you may stop your involvement at any time 
during the study if you wish. 
Your privacy will be maintained and your details will be held in the strictest of confidence. 
Your name and any other identifying information will not be revealed. 
The outcome of the study will help us to understand the benefits of having a pharmacist in a 
multi-disciplinary health care team in enhancing the current management of TBOM patients. 
The results will be provided to the government and published in relevant journals to show the 
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impact and the feasibility to provide pharmaceutical care to TBDM patients. If you are willing 
to participate in this pharmaceutical care project, please sign the consent form and return it to 
the researcher. 
Thank you for considering this request to participate in this study. 
Sincerely, 
Shubashini Gnanasan 
PhD Research Student 
Division of Social Research in Medicines and Health 
School of Pharmacy, University of Nottingham, United Kingdom. 
Note: 
1. If you have any complaints or concerns regarding an aspect of this study, please contact me 
(Ms. Shubashini Gnanasan) at 012-2877774 or e-mail paxsg2@nottingham.ac.uk and I will try 
to resolve any issues to the best of my ability. You may also contact the academic supervisors 
of this project. 
Academic Supervisors Email Contact 
number 
Professor Claire Anderson Claire.Anderson@nottingham.ac.uk 01159515389 
Dr. Ting Kang Nee Kang-Nee.Ting@nottingham.edu.my 03-89248209 
Assoc. Prof. Dr. Salmiah Mohd drsalmiah@salam.uitm.edu.my 03-55442761 
Ali 
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2. This study has been reviewed and approved by the Medical Research & Ethics Committee, 
Ministry of Health Malaysia. This committee is responsible for reviewing and approving any 
research project that involves patients or public. 
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The University of 
Nottingham 
Patient Consent Form 
Consent to Participate in a Pharmaceutical Care Management Project for Patients with 
Tuberculosis and Diabetes Mellitus (TBDM) 
I have been asked to take part in a pharmaceutical care project for patients with Tuberculosis 
and Diabetes Mellitus (TBDM). I have read the informed consent document for this project. I 
have received an explanation of the nature, purpose and duration of this 
project. My questions have been answered satisfactorily. 
I, ______________________ (name of participant) 
hereby consent to participate in the pharmaceutical care project. 
I understand that: 
a. My participation is voluntary. I can stop participating in this project at any time and I 
am free to not answer any particular question(s). 
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b. While information gained in this study may be used in a conference presentation, and 
may also be published in a journal article, I will not be identified. Information 
concerning me will remain strictly confidential. 
c. I can ask the investigator, at any time for any additional information. 
Investigator's name: Participant's name: 
Date: __________ _ Date: __________ _ 
Investigator's signatu re: Participant's signature: 
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Pharmaceutical Care Management for Patients with Tuberculosis and Diabetes 
Mellitus (TBDM): A feasibility study 
(Phase 2) 
A. Treatment Centre 
Treatment Treatment Treatment Start Dally DOTS! Admitted in 
date TBward 
Initiation Centre Continuation Weekly packing 
Centre 
B. Demographic Data 
Patient's Name IC RIN Contact Age Gender Race Marital 
number Status 
MIF Malayl Single! 
Chinese! Married 
Indian! 
Others 
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Tobacco Alcohol Occupation 
Use Use 
C. Past Medical History D. Past Medication History 
E. Current medication history 
Drug Dosage Regimen 
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Non-prescribed drugs (TradltionaVHerbaIlSupplements) 
F. Laboratory Test 
Sputum AFB Other Specimen 
Posltlve/Negative PosltlveINegative 
G. Chest X-Ray 
Date 
X-ray 
presentation 
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F. Current History of TB episode 
Main symptoms: 
Tick 
Cough more than 2 weeks 
Cough with blood stained sputum 
Loss of weight 
Loss of appetite 
Fever 
Night sweats 
Others 
G. TB Classification 
Pulmonary tuberculosis Yes No 
Extrapulmonary tuberculosis Yes No 
Pulmonary with extrapulmonary 
tuberculosis Yes No 
If extrapulmonary 
Tuberculous Meningitis Yes No 
Miliary TB Yes No 
Others 
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J. TB treatment regimen 
Initial Body Weight 
Treatment 
Treatment Start Date Change Date Tick 
Dosage Change of Dosage 
Intensive Phase Reglmen(1f Reason for 
Regimen there Is) Change 
Streptomycin Streptomycin Resistant TB 
Isoniazid Isoniazid ADR 
Rifampicin Rifampicin OTHERS: 
Pyrazinamide Pyrazinamide 
Ethambutol Ethambutol 
AKURIT4 
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Body Weight at 
Continuation Phase 
Treatment 
Treatment Start Date Change Date Tick 
Dosage Change of Dosage Reason 
Maintenance Phase Reglmen(if for 
Regimen there Is) Change 
Resistant 
Streptomycin Streptomycin TB 
Isoniazid Isoniazid ADR 
Rifampicin Rifampicin OTHERS: 
Pyrazinamide Pyrazinamide 
Ethambutol Ethambutol 
K. LABORATORY INVESTIGATION 
Normal 
Range Baseline 
Random blood >5.5-
glucose doFBG 
Fasting blood 
glucose 3.5-6.7 
HbA1C 4.0-6.0 
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LIVER FUNCTION Normal 
TEST Range Baseline 
Total Protein 66-87 giL 
Albumin 35-50 giL 
Globulin 20-36 gil 
AlG Ratio 0.9 -1.8 
3- 21 
Total Bilirubin tJmoVL 
Alanine Transaminase 0-55 ~ L L
4 O - 1 5 0 ~ ~
(>15yrs) 
<500 
Alkaline Phosphatase (1-12 yrs) 
RENAL PROFILE Normal Range Baseline 
Sodium 136-145 mmoliL 
Pottaslum 3.5 -5.0 mmollL 
3.5-7.2 (>50yrs) 
Urea mmoVL 
Creatinine 53-115 ~ m o V L L
Chloride 98-107 mmoVL 
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Normal 
ESR Range Baseline 
ESR (Men) 3-10mmlhr 
ESR (Women) 4-15mmlhr 
Normal 
HEMATOLOGY Range Baseline 
WBC 5.2-12.4 
RBC 4.2-5.4 
HGB 12.0-16.0 
HCT 37-47 
MCV 81-99 
MCH 27-31 
MCHC 33-37 
RDW-CV 11.5-14.5 
PLT 130-400 
NE% 40-74 
LY% 19-48 
MO% 3.4-9.0 
EO% 0.0-7.0 
BAO/o 0.0-1.5 
NE# 1.5-8.0 
LY# 0.9-5.2 
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MO# 0.16-1.00 
EO# 0.0-0.8 
BA# 0.0-0.2 
FASTING LIPID PROFILE Normal Range Baseline 
<5.2 desirable 
5.2-6.2 borderline 
>6.2 
Total Cholesterol high 
<1.7 normal 
1.7-2.3 borderline high 
Trlglcerldes >2.3-5.6 high 
3.3-4.9 
<3.3 low risk 
LDL Cholesterol > 4.9 high risk 
> 1 negative risk factor 
HDL Cholesterol <1 major risk factor 
15-25 low risk 
% HDL Cholesterol <15 high risk 
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Visual acuity for patient on 
ethambutol 
L. DRUG RELATED PROBLEMS 
a) (I) Adverse drug reaction related to TB drugs (Symptom based approach) 
Minor side- effects 
Tick Side- effects Drug(s) probably Tick Recommended WHO 
responsible Management 
Anorexia Pyrazinamide, Give drugs with small 
Rifampicin meals or last thing at night 
Nausea Pyrazinamide, Give drugs with small 
Rifampicin meals or last thing at night 
Abdominal pain Pyrazinamide, Give drugs with small 
Rifampicin meals or last thing at night 
Joint pains Pyrazinamide Aspirin 
Burning sensation Isoniazid Pyridoxin 100 mg dally 
In the feet 
Orange/red urine Rifampicin Reassurance 
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Major Side-effects 
Tick Side- effects Drug(s) Tick Recommended WHO 
probably Management 
responsible 
Itching, skin rash S,H,R,Z Stop antl-T8 drugs 
Deafness Streptomycin Stop streptomycin, Use 
ethambutol 
Dlzzlness(vertlgo and Streptomycin Stop streptomycin, Use 
nystagmus) ethambutol 
Jaundice Isoniazid Stop anti -T8 drugs 
Pyrazinamide 
Rifampicin 
Hepatitis Isoniazid Stop anti -T8 drugs 
Pyrazinamide 
Rifampicin 
Confusion Most antl-T8 Stop antl-T8 drugs. 
drugs 
(suspect drug-Induced Urgent liver function 
acute liver failure If tests and prothrombin 
Jaundice present) time 
Visual Impairment Ethambutol Stop ethambutol 
Shock Rifampicin Stop rifampicin 
Purpura Rifampicin Stop rifampicin 
Acute renal failure Rifampicin Stop rifampicin 
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II) Adverse drug reaction to non-TB drugs 
ADR Offending Drug 
b) Drug Interactions 
Isoniazid Rifampicin I Streptomycin Others I 
Phenytoin Cyclosporine Am inoglycoside Aminoglycoside 
Carbamazepine Corticosteroids Amphotericin B Amphotericin B 
Aluminium Protease Inhibitors Cephalosporine Cephalosporine 
Hydroxide 
Oral Contraceptive Ethacrynic acid Ethacrynic acid 
pill 
Oral hypoglycaemic Cyclosporine 
agents 
Oral anticoagulants Frusemide 
Phenytoin Cisplatin 
Cimetidine Vancomycin 
Theophylline 
Digoxin 
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Follow-up progress notes 
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Medical condition and drug INDICATION 
therapy involved 
Unnecessary Drug Therapy 
----- No medical indication 
----- Duplicate therapy 
----- Non drug therapy indicated 
----- Treating avoidable ADR 
----- Addictive / recreational 
'" Needs Additional Drug Therapy :e
&AI 
~ ~
lID 
0 
----- Untreated condition ac 
a. 
~ ~
----- Preventive/prophylactic ~ ~
&AI 
:I: 
... 
----- Synergistic/potentiating 
'" ::) ac 
c 
Medical condition and drug EFFECTIVENESS 
therapy Involved 
Needs different drug product 
----- More effective drug available 
----- Condition refractory to drug 
----- Dosage form inappropriate 
----- Not effective for condition 
Dosage Too Low 
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----- Wrong dose 
----- Frequency inappropriate 
----- Drug interaction 
----- Duration inappropriate 
Medical condition and drug SAFETY 
therapy involved 
Adllerse Drug Reactian 
----- Undesirable effect 
----- Unsafe drug for patient 
----- Drug interaction 
----- Duration inappropriate 
Dosage Too High 
----- Wrong dose 
----- Frequency inappropriate 
----- Duration inappropriate 
----- Drug Interaction 
----- Incorrect administration 
Medical condition and drug COMPLIANCE 
therapy Involved 
Noncompliance 
----- Directions not understood 
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----- Patient prefers not to take 
----- Patient forgets to take 
----- Patient cannot afford 
----- Cannot swallow/administer 
----- Drug product not available 
DRUG THERAPY PROBLEMS TO BE RESOLVED 
----------- No Drug Therapy Problem(s) at this time 
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PHARMACEUTICAL CARE PLAN 
Indication; 
(Description and history of the present illness or medical condition including previous approaches to treatment and 
responses) 
Goals of Therapy (improvement or normalisation of signs /symptoms/laboratory tests or reduction of risk) 
1. 
2. 
Drug Therapy Problems- to be resolved 
None at this time 
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Therapeutic Alternatives (to resolve the drug therapy problem) 
1. 
2. 
Pharmacotherapy plan (Includes current drug therapies and changes) 
Medications Dosage Instructions 
(Drug products) (Dose, Route, Frequency, Duration) 
Other intervention to optimize drug therapy: 
Note Changes 
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Schedule for next follow-up evaluation: 
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Appendix 14: Follow-up schedules 
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Follow-up schedule 
Patients 1st visit 2nd visit/call 3rd 4th 
visit/call visit/call 
Pl V V V V 
P2 V V V V 
P3 V V V V 
P4 V V V V 
P5 V V V V 
P6 V V V V 
P7 V V V V 
P8 V V 
" " P9 
" " " " P10 
" 
V 
" " Pll 
" " " " P12 
" 
V 
" " P13 
" " " " P14 
" " " " P15 
" 
V 
" " Passed 
P16 
" " 
away 
P17 
" " " couldn't 
P1S V contact 
P19 
" " P20 
" " P21 
" " P22 
" " P23 
" " P24 
" P25 
" P26 
" P27 
" P28 
" P29 
" P30 
" P31 
" P32 
" P33 
" P34 
" P35 
" 
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Follow-up dates 
Patients Treatment start 1st visit date 2nd visit/call 3rd viSit/cali 4th viSit/cali date date date date 
PI 03/11/2009 04/11/2009 19/11/2009 23/11/2009 03/12/2009 
P2 08/10/2009 05/11/2009 19/11/2009 03/12/2009 31/12/2009 
P3 20/10/2009 05/11/2009 19/11/2009 14/12/2009 18/01/2010 
P4 23/10/2009 05/11/2009 19/11/2009 31/12/2009 25/02/2010 
P5 03/11/2009 09/11/2009 23/11/2009 07/12/2009 31/12/2009 
P6 26/10/2009 09/11/2009 23/11/2009 07/12/2009 27/01/2010 
P7 16/10/2009 16/11/2009 19/11/2009 10/12/2009 11/02/2010 
P8 05/11/2009 16/11/2009 30/11/2009 14/12/2009 26/01/2009 
P9 19/08/2009 16/11/2009 30/11/2009 14/12/2009 12/01/2010 
P10 04/11/2009 16/11/2009 19/11/2009 31/12/2009 21/01/2010 
PH 05/11/2009 19/11/2009 03/12/2009 31/12/2009 28/01/2010 
P12 24/09/2009 19/11/2009 03/12/2009 17/12/2009 12/01/2010 
P13 18/11/2009 30/11/2009 14/12/2009 28/12/2009 25/01/2010 
P14 11/11/2009 30/11/2009 14/12/2009 28/12/2009 07/01/2010 
PIS 23/09/2009 03/12/2009 21/12/2009 09/02/2010 22/02/2010 
P16 30/11/2009 08/12/2009 22/12/2009 15/01/2010 
P17 30/09/2009 10/12/2009 26/11/2009 21/01/2010 
P18 04/08/2009 24/12/2009 
P19 13/07/2009 31/12/2009 09/02/2010 25/02/2010 
P20 10/07/2009 07/01/2010 09/02/2010 
P21 27/08/2009 11/01/2010 21/01/2010 
P22 05/10/2009 11/01/2010 09/02/2010 
P23 10/11/2009 14/01/2010 09/02/2010 
P24 10/12/2009 14/01/2010 
P25 14/06/2009 28/01/2010 
P26 12/10/2009 28/01/2010 
P27 14/08/2009 08/02/2010 
P28 06/07/2009 11/02/2010 
P29 19/11/2009 11/02/2010 
P30 27/08/2009 11/02/2010 
P31 13/01/2009 11/02/2010 
P32 20/08/2009 22/02/2010 
P33 17/07/2009 22/02/2010 
P34 15/10/2009 25/02/2010 
P35 26/01/2010 25/02/2010 
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Appendix 15: Pharmacist's feedback 
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The following was the hospital pharmacist's (Alan)feedback regarding the provision of 
pharmaceutical care service for TB and OM patients that I received via email on the 30 
October 2010. 
1. Practicality of the project 
Can be done and pharmacist have a role in helping patients to identifying drug- related 
problems in patients as patients are having lots of medications due to different disease 
condition 
2. Barriers 
Space (no proper place to counsel patient and no privacy) 
Time (have several work commitments) 
Language (dialect) 
3. Physicians and pharmacist collaboration 
Definitely will improve patient's benefit (increase understanding abaut their condition, 
medication and compliance) 
Enhance understanding and collaboration between pharmacist and doctors 
Physician's implementation of therapy recommended by pharmacist will increase 
pharmacist's confidence and satisfaction 
4. Continue with the service? 
Yes, it is very satisfying to see patients condition improving and to build patient-
pharmacist rappon 
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Appendix 16: Research publication 
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